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Summary 
With numerous small recombinant proteins being developed for treatment of various 
diseases, half-life extension strategies are becoming increasingly vital for the 
creation of long lasting and efficient biotherapeutics. Because of their small size, 
these proteins are rapidly cleared from plasma circulation and lose a lot of their 
potential as therapeutic. Using immunoglobulin-binding domains (IgBD), in particular 
domain C3 from Streptococcus protein G (SpGC3), can substantially increase the 
half-life by forming transient complexes with endogenous IgG molecules. This 
complex formation needs to occur at neutral pH to prevent rapid renal clearance, but 
also under acidic conditions, facilitating the salvage from lysosomal degradation via 
the neonatal Fc receptor (FcRn). In order to enable FcRn recycling, the major binding 
site of SpGC3 to the IgG-Fc part was eliminated, since it is overlapping with the FcRn 
binding site, generating the CH1 specific domain SpGC3Fab. Affinity maturation 
towards the Fab fragment resulted in domains SpGC3FabRR and SpGC3FabRR,E15V 
showing significantly increased terminal half-lives as scDb-IgBD fusion proteins.  
Since the IgBDs originate from bacterial proteins, they might provoke immunogenic 
reactions and the production of anti-drug antibodies. For deimmunization, possible 
T-cell epitopes were identified by sequence and structure-based analysis and 
eliminated by combination of single amino acid substitutions. This resulted in 
deimmunized IgBDs that were able to strongly increase the terminal half-life as scDb 
fusion proteins. 
The application of SpGC3FabRR to recombinant human erythropoietin (huEPO) 
resulted in a roughly 5-fold increased terminal half-life compared to the unmodified 
huEPO that also translated into increased hemoglobin concentration after one single 
intravenous injection.  
Furthermore, a comparative study of various Fc fusion proteins revealed that a 
multitude of factors is jointly responsible for the long half-life of full-length IgG 
molecules. Although possessing an identical huIgG1 Fc part and affinity to the 
moFcRn, neither an scFv-Fc nor an scDb-Fc or a single-chain version of the IgG 
molecule (scFv-scCLCH1-Fc) could reach the pharmacokinetic properties of the IgG 
molecule, not fully explainable by factors like size, isoelectric point and stability.  
All in all, the utilization of immunoglobulins and FcRn-mediated salvage via IgBDs 
and Fc fusion proteins is a powerful tool for the generation of recombinant fusion 
proteins with favorable pharmacokinetic properties.  
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Zusammenfassung 
Angesichts der Entwicklung einer Vielzahl kleiner rekombinanter Proteine, die für die 
Behandlung verschiedenster Krankheiten eingesetzt werden, nimmt das Interesse an 
Strategien zur Halbwertszeitverlängerung zu, um lang zirkulierende und effiziente 
Biotherapeutika zu entwerfen. Aufgrund ihrer geringen Größe werden diese Proteine 
schnell aus dem Blutkreislauf eliminiert und verlieren einen Großteil ihrer 
therapeutischen Wirksamkeit. Die Verwendung von Immunglobulin-bindenden 
Domänen (IgBD), insbesondere Domäne C3 von Protein G aus Streptococcus 
(SpGC3), führt zu einer deutlichen Erhöhung der Halbwertszeit rekombinanter 
Proteine, indem sie transiente Komplexe mit körpereigenen IgG Molekülen bildet. 
Diese Komplexbildung muss sowohl bei neutralem als auch saurem pH im Endosom 
auftreten und kann eine schnelle Ausscheidung in der Niere sowie den lysosomalen 
Abbau durch Recycling über den neonatalen Fc Rezeptor (FcRn) verhindern. Da die 
Bindestelle von SpGC3 und FcRn am IgG-Fc Teil überlappen, wurde diese bei der 
IgBD beseitigt und die CH1 spezifische Domäne SpGC3Fab generiert, um besseres 
FcRn Recycling zu ermöglichen. Die Domänen SpGC3FabRR und SpGC3FabRR,E15V, 
die durch CH1-gerichtete Affinitätsreifungen entstanden, zeigten signifikant erhöhte 
terminale Halbwertszeiten als scDb-IgBD Fusionsproteine.  
Da die IgBDs aus bakteriellen Proteinen hervorgingen, ist das Einsetzen einer 
Immunantwort und die damit verbundene Produktion von Antikörpern gegen das 
Medikament möglich. Für eine Deimmunisierung wurden daher mögliche T-Zell 
Epitope mittels sequenz- und strukturbasierter Untersuchung identifiziert und durch 
eine Kombination einzelner Aminosäureaustausche beseitigt. Die so entstandenen 
deimmunisierten IgBDs konnten die terminale Halbwertszeit als scDb 
Fusionsproteine deutlich steigern.  
Die Fusion von SpGC3FabRR mit rekombinantem humanem Erythropoietin (huEPO) 
erhöhte dessen Halbwertszeit ungefähr 5-fach, verglichen mit nicht modifiziertem 
huEPO. Diese verbesserte Pharmakokinetik spiegelte sich auch in einer erhöhten 
Hämoglobin Konzentration nach einmaliger intravenöser Gabe wieder.  
Außerdem zeigte eine vergleichende Studie verschiedener Fc Fusionsproteine, dass 
eine Vielzahl von Faktoren für die lange Halbwertszeit von ganzen IgG Molekülen 
mitverantwortlich ist. Obwohl alle Fusionsproteine einen identischen huIgG1 Fc Teil 
mit gleicher Affinität zum FcRn besaßen, konnten weder ein scFv-Fc, noch ein 
scDb-Fc oder eine einzelkettige Version des IgG Moleküls (scFv-scCLCH1-Fc) die 
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pharmakokinetischen Eigenschaften des IgG Moleküls erreichen. Faktoren wie 
Größe, isoelektischer Punkt und Stabilität sind nicht in der Lage dies hinreichend zu 
erklären. 
Zusammenfassend kann gesagt werden, dass die Verwendung von Immunglobulinen 
und FcRn-abhängigem Recycling durch IgBDs und Fc Fusionsproteine rekombinante 
Fusionsproteine mit vorteilhaften pharmakokinetischen Eigenschaften schaffen kann.  
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Abbreviations 
 
ABD Albumin-binding domain kcps Kilo counts per second 
ADA Anti-drug antibody kDa Kilo Dalton 
ADCC Antibody dependent cellular cytotoxicity MFI Mean fluorescence intensity  
APC Antigen presenting cell MHC Major histocompatibility complex 
AUC Area under the curve mo Mouse 
BiTE Bispecific T-cell engager MW Molecular weight 
CD Cluster of differentiation  n.d. Not determined 
CDR Complementarity determining region NTA Nitrilotriacetic acid 
CEA Carcinoembryonic antigen OD Optical density 
CH Constant region of the heavy chain PAA Polyacrylamide 
CL Constant region of the light chain PBMC Peripheral blood mononuclear cell 
CTLA-4 Cytotoxic T lymphocyte associated molecule-4 PBS Phosphate buffered saline 
DMSO  Dimethyl sulfoxide PCR Polymerase chain reaction 
DNA Desoxyribonucleic acid PDB Protein data bank 
dNTP Desoxy nucleotide triphosphate PE Phycoerythrin 
EC50 Half maximal effective concentration pI Isoelectric point 
EDTA Ethylendiamtetraacetic acid Sr Stokes radius 
ELISA Enzyme linked immunosorbent assay sc Single-chain 
EpCAM Epithelial cell adhesion molecule scDb Single-chain diabody 
EPO Erythropoietin scFv Single-chain variable fragment 
Fab Fragment antigen binding SDS Sodium dodecylsulfate 
FAP Fibroblast activation protein SEC Size exclusion chromatography 
FACS Fluorescence activated cell sorting SpAB Staphylococcal protein A domain B  
Fc Fragment crystallizable SpGC3 Streptococcal protein G domain C3 
FcRn Neonatal Fc receptor t1/2α Initial half-life 
FCS Fetal calf serum t1/2β Terminal half-life time 
HEK Human embryonic kidney TAE Tris-acetate EDTA 
His6 Hexahistidyl-tag TCR T-cell receptor 
HLA Human leukocyte antigen TEMED Tetramethylethylenediamine 
HPLC High pressure liquid chromatography TMB 3,3’,5,5’-Tetramethylbenzidine 
HRP Horse radish peroxidase TNF Tumor necrosis factor 
hu Human v/v Volume per volume 
IFN Interferon VH Variable part of the heavy chain 
IgBD Immunoglobulin-binding domain VL Variable part of the light chain 
IgG Immunoglobulin G w/v Weight per volume 
IL Interleukin w/w Weight per weight 
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1 Introduction 
A prognosis for protein-based pharmaceuticals in 2020 projects a worldwide sale of 
more than $300 billion (Baeuerle and Murry 2014). A huge part thereof will be 
derived from monoclonal antibodies or other Fc constructs, but growing interest is 
placed into small recombinant fusion proteins. Although many of these proteins 
exhibit an extraordinary potential, most suffer from a rapid elimination, which requires 
frequent applications or even infusions to maintain a therapeutically effective 
concentration (Enever et al. 2009; Melder et al. 2005; Szlachcic, Zakrzewska, and 
Otlewski 2011). Therefore, half-life extension strategies gain an increasing interest to 
improve pharmacokinetic and pharmacodynamic properties.  
1.1 Small therapeutic proteins with poor pharmacokinetics  
Proteins broadly used for human therapies include hormones, growth factors, 
chemokines, coagulation factors, antibody fragments and many others (Kontermann 
2012) (Table 1-1). The majority of them have a short half-life in common, ranging 
from several hours down to just a few minutes. In order to maintain a therapeutically 
effective dose over a prolonged period of time, frequent injections or even infusions 
are necessary (Kontermann 2011). For instance, the recently approved BiTE 
molecule Blinatumomab requires repeated continuous infusion with mini-pimps over 
several weeks (Topp et al. 2015), denoting a high burden for the patients. Differing 
from IgG molecules and Fc fusion proteins, many of these proteins possess a 
molecular mass below 50 - 60,000 Dalton and do not interact with the neonatal Fc 
receptor.  
 
Table 1-1: Half-life of therapeutic proteins 
 
Protein Indication M [kDa] Terminal half-life 
Insulin Diabetes 6     4 – 6 min 
Erythropoietin Anemia 34   2 – 13 h 
IFNα  Hepatitis C (and B) 20 2 – 3 h 
IFNβ  Multiple sclerosis 23   5 – 10 h 
IL-2 Renal cell carcinoma 16     5 – 7 min 
Factor VIIa Hemophilia 50 2 – 3 h 
Tissue plasminogen activator Myocardial infarction 65       2 – 12 min 
IgG Various 150     Days to weeks 
TNFR2-Fc Rheumatoid arthritis 150  3 – 6 d 
Fab Age-related macular degeneration 50  30 min 
BiTE Non-Hodgkin’s lymphoma 55   Few hours * 
Data adapted from (Kontermann 2012); * from (Baeuerle 2009); M: molecular mass 
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The single-chain diabody (scDb) and the single-chain fragment variable (scFv) used 
in this study fit well into this set of small recombinant proteins with a molecular mass 
of 28 and 53 kDa, respectively. Due to their size and missing salvage from lysosomal 
degradation via the FcRn, they exhibit terminal half-lives of only 0.6 and 1.3 h, 
representing good properties to be exploited as model molecules for half-life 
extension (Hutt et al. 2012).  
 
One of the main elimination routes from the bloodstream is the filtration of small 
proteins in the glomeruli of the kidney. Luminal fenestrations of about 4 - 5 nm 
diameter decorated with negatively charged extracellular matrix proteins function as 
a filter for proteins with a molecular mass below 60 kDa (Haraldsson and Sörensson 
2004; Tryggvason and Wartiovaara 2005) (Figure 1-1). Proteins that exhibit 
hydrodynamic radii above that threshold are less subject to renal clearance and 
therefore continue to circulate in the blood for a longer period of time. Due to 
electrostatic repulsion, proteins with negative net charge, like serum albumin, are 
also retained, although their size would just allow them to pass through the vessel 
walls (Kontos and Hubbell 2012). Changes in net charge might possibly result in 
longer half-life, but can also cause lower tissue distribution, and are therefore 
application dependent measures (Boswell et al. 2010). The second central route of 
protein elimination is the degradation of endocytosed plasma proteins in the 
lysosome. In contrast to most other serum proteins, immunoglobulins of the γ class 
and albumin undergo less lysosomal degradation, since they are salvaged by the 
neonatal Fc receptor. Via nonspecific fluid phase endocytosis serum proteins are 
internalized into endosomes that get gradually acidified. Due to conformational 
changes and the formation of salt bridges with protonated histidine residues upon 
acidification, IgG molecules can bind to the FcRn via the interface of their CH2 and 
CH3 domains (Martin et al. 2001). On the other side, the interaction of the FcRn with 
albumin at acidic pH is independent from IgG binding and requires the elaboration of 
hydrophobic pockets and the stabilization of loops (Chaudhury et al. 2003, 2006; 
Schmidt et al. 2013). From the acidified endosome FcRn and its bound cargo are 
sorted into recycling endosomes and further back to the cell surface, where the cargo 
is released at physiological pH (Lencer and Blumberg 2005; Roopenian and Akilesh 
2007; Weflen et al. 2013). FcRn is expressed on the surface of endothelial, epithelial 
and hematopoietic cells including organs such as skin, muscle, kidney, liver, spleen 
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and placenta. Although expressing FcRn, liver and spleen are the major sites of IgG 
catabolism in rodents on a tissue mass-normalized basis, whereas the skin and 
muscle are actually more important since they comprise a greater percentage of 
body weight (Yip et al. 2014). 
1.2 Strategies for half-life extension 
In order to overcome the limitation of a short half-life and low bioavailability, many 
approaches have been successfully established, focusing on the increase of the 
hydrodynamic radius. Di- or multimerization of recombinant fusion proteins enlarge 
the hydrodynamic radius and can therefore prevent rapid renal clearance. Apart from 
half-life extension, in particular antibody fusion proteins can benefit from higher 
valency, due to an increased avidity effect (Seifert et al. 2014). One of the most 
approved methods for half-life elongation is the attachment of highly flexible, 
hydrophilic polymers via chemical conjugation or genetic fusion. Polyethylene glycol 
is a synthetic polymer consisting of repeating units of ethylene glycol that are 
attached to proteins for example via a maleimide group that interacts with the free 
thiol group of a cysteine or via succinimide to form bonds to primary amines (Kang, 
Deluca, and Lee 2009). Besides the increase in hydrodynamic radius followed by 
lower renal clearance and longer half-life, PEGylation can also reduce 
immunogenicity and increase solubility and stability of the biotherapeutic. Several 
small recombinant proteins conjugated to PEG chains are used as therapeutic, 
including IFNα2b, human growth hormone and erythropoietin (Ezan 2013). An 
alternative to the synthetic PEG is the recombinant addition of a hydrophilic 
polypeptide chain to the biotherapeutic. Issues of cost and intrinsic heterogeneity of 
the PEG, as well as possible vacuolation in the renal tubules or the formation of PEG 
hydrates in the kidney can therefore be avoided (Schellenberger et al. 2009; 
Schlapschy et al. 2013). Furthermore, chemical conjugation of biodegradable 
hydroxyethyl starch (HES) as well as the coupling of polysialic acid can prolong the 
terminal half-life, depending on size and structure (Gregoriadis et al. 2005; Liebner et 
al. 2014). Likewise, posttranslational modifications leading to additional glycosylation 
can improve the pharmacokinetic performance, either by adding a glycosylated tail 
(Stork, Müller, and Kontermann 2007) or by mutating different residues within the 
sequence of the therapeutic protein, which has been successfully employed to 
human erythropoietin (Powell and Gurk-Turner 2002).  
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Figure 1-1: Half-life extension 
A) Small uncharged serum proteins can float freely across the glomerular filter in the kidney, whereas 
bigger and negatively charged molecules are retained in the blood. B) FcRn expressing endothelial 
cells internalize proteins from plasma. Only proteins with affinity towards FcRn at acidic conditions 
(IgG and albumin) are sorted into a recycling endosome and transferred back to the cell surface, 
where they are released back to the blood. Other proteins are degraded in the lysosome. C) Half-life 
extension strategies are based on increased hydrodynamic radius and on FcRn mediated recycling. 
Various half-life extension modules can be chemically coupled or genetically fused to the therapeutic 
protein.  
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A straightforward approach for half-life extension is the fusion of therapeutic proteins 
with long circulating serum proteins. Since albumin and IgG are the longest lasting 
serum proteins, much effort has been placed in the understanding of their long 
half-life as well as the generation of therapeutics (Kontermann 2009). The benefit of 
the salvage from lysosomal degradation via the FcRn is the key factor for the long 
half-life and success of recombinant antibodies. However, not only antibodies utilize 
FcRn-mediated recycling, but also albumin. Thus, fusion of albumin or the Fc part of 
long-lasting IgGs is a suitable measure to improve pharmacokinetics, since 
supplementary to the recycling the size of the fusion proteins is augmented above 
the threshold for renal clearance. Direct fusion to albumin has been applied to a 
variety of therapeutic proteins, including IFNα2b, insulin, factor VIIa, scFvs and 
others and strongly increased their pharmacokinetic performance, leading to several 
biotherapeutics in clinical tests (Sleep, Cameron, and Evans 2013). On the other side, 
fusion to an Fc part can protect from lysosomal degradation, but also leads to a 
homodimerization, which can be advantageous in terms of affinity and avidity. 
However, for distinct applications monomeric interactions are necessary in order to 
prevent a crosslinked network in plasma or unwanted agonist activity (Berger et al. 
2013; Ishino et al. 2013). Many therapeutic fusion proteins comprising an Fc part 
have been successfully generated, including fusions to TNFR2, CTLA-4, EPO, 
factor VIII and also recombinant antibody fragments (Kontermann 2009). A further 
advantage of albumin and IgG molecules is the enhanced permeability and retention 
effect that occurs in solid tumors and inflamed tissue. These macromolecules 
accumulate in the modified tissues due to their unique vascular characteristics, 
resulting in higher concentration and possibly also higher treatment benefit 
(Matsumura and Maeda 1986). 
 
As an alternative to direct fusion of serum proteins to the therapeutic protein, several 
strategies have been employed to take advantage of the long half-life of IgG and 
albumin by transient and reversible binding. Using transient binding instead of fusion 
or conjugation to increase the hydrodynamic radius of recombinant therapeutics is 
often advantageous, since dissociation of the molecules facilitates tissue penetration 
(Stork et al. 2009). The natural function of albumin is that of a carrier protein for 
various molecules, including long-chain fatty acids. Therefore, the fusion of for 
example myristic acid to insulin (Insulin detemir) can lead to a substantial increase in 
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albumin affinity and improvement in pharmacokinetics (Havelund et al. 2004). 
Likewise, peptides that have been selected to bind to albumin also represent small 
fusion partners that are able to augment the circulation time of biotherapeutics. 
Hereby, the affinity of the peptides correlates clearly with the half-life extension 
properties, meaning that further improvement in affinity should translate into better 
pharmacokinetics (Nguyen et al. 2006). Besides albumin cargos and peptides, there 
are naturally occurring albumin binding proteins, namely streptococcal Protein G. 
Protein G contains three homologous albumin binding domains and in particular the 
46 amino acid long domain 3 has been extensively studied for half-life elongation 
(Andersen et al. 2011; Stork, Müller, and Kontermann 2007). Recycling by the FcRn 
was investigated in a comparative study with FcRn wild-type and FcRn heavy chain 
knockout mice demonstrating that the bound ABD does not interfere with FcRn 
binding of albumin (Stork et al. 2009). Affinity improvement of the ABD towards 
serum albumin did only result in a moderate augmentation of terminal half-life when 
fused to an scDb molecule (Hopp et al. 2010). Furthermore, other albumin-binding 
proteins like nanobodies, single-domain antibodies and alternative scaffolds have 
been used for half-life extension (Kontermann 2011). Strategies to transiently bind to 
IgG molecules have also been investigated, revealing an Fc binding peptide that is 
able to substantially elongate the plasma half-life of a recombinant fusion protein 
(Sockolosky, Kivimäe, and Szoka 2014). Similar to albumin, there are also other 
proteins that have been used as a fusion partner in order to target endogenous IgG 
for a pharmacokinetic purpose. By generation of a bispecific diabody targeting IgG 
molecules, the terminal half-life experienced a 5-fold increase (Holliger et al. 1997). 
Analogous to the albumin-binding domain, there are several bacterial proteins that 
possess affinity towards immunoglobulins. The immunoglobulin-binding domains 
(IgBD) from Protein A, Protein G and Protein L have demonstrated to enhance the 
circulation time as fusion partners to an scFv or scDb (Hutt et al. 2012; Unverdorben 
et al. 2012).  
1.3 Immunoglobulin-binding domains 
The rationale in using immunoglobulin-binding domains instead of albumin-binding 
domains is that the terminal half-life of IgG with up to 23 days in humans is even 
higher than the 19 days of albumin (Kontermann 2009). Even more important is the 
recycling effect mediated by the neonatal Fc receptor. The efficiency in recycling for 
IgG is better than for albumin because of a higher FcRn saturation of albumin, owing 
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to its higher plasma concentration and the 1 to 2 stoichiometry of IgG to the FcRn 
(Kim et al. 2007). Upon knock-out of the functional FcRn, the terminal half-life of IgG 
decreases from 95 h to only 19 h, whereas the half-life of albumin is less shortened 
from 39 h to about 25 h in C57BL/6J mice (Chaudhury et al. 2003). In a recent study 
the potential of various IgBDs for half-life extension was demonstrated by binding to 
different parts of IgG molecules (Hutt et al. 2012). These IgBDs are composed of 
50 – 60 amino acids and form either 3 α-helix bundles or structures of 4 β-sheets 
packed against a central α-helix (Tashiro and Montelione 1995). As a fusion partner 
to an scDb or scFv, the 56 amino acid long domain C3 from Streptococcus Protein G 
(SpGC3) showed the highest potential in enhancing the circulation time (Hutt et al. 
2012). SpGC3, comprised of 4 β-sheets and one α-helix, is able to bind to IgG 
molecules at two distinct binding sites, the interface of CH2 and CH3 domain on the 
Fc part and the CH1 domain on the Fab arm (Figure 1-2). Its primary binding site is 
located at the Fc part, overlapping with the interaction site of the FcRn (Burmeister, 
Huber, and Bjorkman 1994; Sauer-Eriksson et al. 1995). In contrast to other IgBDs, 
SpGC3 was able to maintain binding under physiological and acidic conditions, 
meaning that stable complexes during circulation in the blood as well as during FcRn 
recycling can be formed. However, the overlapping binding site of SpGC3 and the 
FcRn might cause interference in an acidified lysosome, possibly hampering the 
recycling. The terminal half-life of roughly one day that was reached with 
immunoglobulin-binding domains so far is distant from the pharmacokinetic 
properties of the endogenous mouse IgG with up to 8 days (Vieira and Rajewsky 
1988) indicating the interference with FcRn at the Fc part and leaving space for 
further improvements.  
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Figure 1-2: Interactions of IgG 
A) The binding site of serum albumin towards the neonatal Fc receptor at acidic pH is distinct from the 
IgG binding site. FcRn binds to an immunoglobulin at the interface of CH2 and CH3 on its Fc part. B) 
SpGC3 has two separate binding sites on an IgG molecule, one located on the Fc part at the interface 
of CH2 and CH3, the other on at the CH1 domain. The binding of FcRn and SpGC3 is only depicted on 
one IgG heavy chain, but since IgGs are symmetrical molecules, similar binding could occur at the 
second heavy chain. Albumin: green; FcRn heavy chain: blue; β2-microglobulin: yellow; SpGC3: red; 
IgG heavy chain: violet; IgG light chain: grey; PDB entries: 4N0U (Oganesyan et al. 2014), 1IGC 
(Derrick and Wigley 1994), 1FCC (Sauer-Eriksson et al. 1995). 
  
1.4 Deimmunization 
Over the last decade the use of biopharmaceuticals has immensely increased, using 
the high binding specificity of antibodies, the catalytic efficiency and specificity of 
enzymes or the strong ligand receptor interaction that can lead to proliferation or cell 
death, depending on the drug. All these macromolecules exhibit a remarkable 
potential, but even fully human biopharmaceuticals can cause an immune response 
and the generation of anti-drug antibodies (ADA) (Baker et al. 2010). These ADAs 
will have severe influence on pharmacokinetic and pharmacodynamic properties of 
the drug, with effects like increased clearance, neutralization or even allergic 
responses (Barbosa and Celis 2007; Chirmule, Jawa, and Meibohm 2012). Anti-drug 
antibodies can form immune complexes triggering rapid elimination of the therapeutic 
protein. An example for the effect on pharmacokinetic properties was seen during 
treatment of chronic inflammatory bowel disease with infliximab. In patients 
developing anti-drug antibodies against infliximab, the clearance was 2.7 times 
higher and terminal half-life was 34 % lower (Ternant et al. 2008). However, 
immunogenicity can not only have consequences for the therapeutic, but also to 
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endogenous proteins, which was seen during an immunologic reaction to a treatment 
of renal dysfunction with recombinant human erythropoietin. The formation of 
anti-drug antibodies against the recombinant therapeutic protein resulted in the 
recognition of endogenous EPO, causing red-cell aplasia in several patients 
(Casadevall et al. 2002). 
 
The most easily explained mechanism is a ‘vaccine-like’ response to foreign proteins, 
involving T-cells, B-cells and the innate immune system (De Groot and Scott 2007). 
In order to induce naïve B-cells to produce antibodies against a therapeutic protein, 
an activated T-helper cell is necessary. First, the protein is nonspecifically 
internalized and processed by professional antigen presenting cells (APC), mostly 
dendritic cells. Upon cleavage of the biotherapeutic, an immunogenic peptide can 
bind to the antigen-binding groove in the major histocompatibility complex class II 
molecule (MHCII) and is subsequently transported to the surface of the cell (Figure 
1-3). In the lymph nodes, the MHCII with bound peptide is presented to naïve T-cells, 
together with a costimulatory signal, like CD80 or CD86. When a CD4 positive T-cell 
is able to recognize the bound peptide and receives the additional costimulatory 
signal via CD28, it will get fully activated and can activate reactive B-cells to expand, 
perform immunoglobulin class switch and differentiate (Alberts et al. 2002; Sauerborn 
et al. 2010). Besides this T-cell dependent mechanism, there are other ways to 
provoke immunogenicity reaction, like low-level contamination with bacterial DNA, 
lipids or endotoxins, posttranslational protein modification (alternative glycosylation) 
or chemical decomposition (e.g. oxidation) that can contribute to immunologic 
responses (Hermeling et al. 2004). Additionally, aggregation of the therapeutic 
protein can strongly induce immunogenicity (Prümmer 1997). Therefore, reducing the 
total number of doses, minimizing aggregates, diminishing T-cell activation and 
avoiding delivery vehicles that have adjuvant effects are rational strategies for 
reducing immunogenicity (De Groot and Scott 2007). A subsequent strategy to 
overcome immunologic reactions is the deimmunization of therapeutic proteins. 
Varying with the allelic distribution of the human leukocyte antigens (HLA) of class II, 
only certain peptides will fit into the antigen-binding groove. This is dependent on the 
amino acids (size, charge, hydrophobicity) of the peptide, whether their side chains fit 
into the pocket of the HLA molecule and can be presented to the T-cells (Scott and 
De Groot 2010). 
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Figure 1-3: First signal in activation of CD4 T-cells by antigen presenting cells 
A) CD4 T-cells recognize peptides that are presented via the MHC class II molecules of antigen 
presenting cells with their T-cell receptor (TCR). B) Model of the TCR (green) recognizing a peptide 
(red) in the peptide-binding groove of mouse MHC class II molecule (blue). C) Top view to the 
antigen-binding groove of MHCII molecule with immunodominant hen egg lysozyme 11-27 peptide; 
PBD entry: 3MBE (Yoshida et al. 2010) 
 
 
Peptides that bind into the pocket of MHC class II molecules usually range from 
anywhere between 12 and 25 amino acids. For HLA-DR1 (and probably other 
HLA-DR molecules), the groove-anchored stretch of peptides is (in most cases) 
exactly nine amino acids long with anchoring sites specific for the allelic distribution 
(Rammensee 1995). This nonamer of amino acids that binds specifically to a MHC 
class II molecule will subsequently be referred to as T-cell epitope. In order to 
prevent an immunologic reaction to a therapeutic protein, its sequence ought to 
possess as little T-cell epitopes as achievable. From a protein engineer’s point of 
view, this can be achieved by deimmunization of the sequence. First, possible T-cell 
epitopes have to be identified, for example by in silico analysis involving large 
artificial neural networks that include data of confirmed MHC binders as well as 
known non-binders. Additionally, force field analysis based on structural information 
and prediction of cleavage site and transport can help to recognize potential epitopes 
(Brinks et al. 2013). Once identified, these epitopes can be deleted using 
computational approaches that induce point mutations to minimize the occurrence of 
predicted T-cell epitopes, while maintaining therapeutic activity (Parker et al. 2010). A 
special focus is placed on the removal of promiscuous epitopes that will fit into a 
number of different HLA pockets, meaning that they could be immunogenic in the 
general population (Scott and De Groot 2010). In the end, a complete lack of T-cell 
epitopes would prevent APCs from presenting peptides from the biotherapeutic to 
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T-helper cells, resulting in missing activation of reactive B-cells and their subsequent 
apoptosis (De Groot and Scott 2007).  
1.5 Recombinant human erythropoietin 
Small recombinant proteins have a very broad field of possible applications, but an 
obstacle for the creation of an efficient therapeutic is often their rapid elimination from 
the body (Kontermann 2011). One of those proteins exhibiting such a short 
circulation time in the blood is erythropoietin with a terminal half-life of just 6 to 8 
hours in humans (Macdougall 2008). Much effort has been placed in the prolongation 
of serum persistence resulting in products like CERA and Aranesp. These products 
have a strongly improved terminal half-life, but due to their modification also a 
decreased EPO receptor affinity (Jelkmann 2007). Instead of using posttranslational 
modifications or chemical coupling mechanisms to increase the hydrodynamic radius, 
the use of Immunoglobulin-binding domains can also prevent lysosomal degradation 
via the neonatal Fc receptor. Therefore, a set of human EPO fusion proteins with 
IgBDs was generated to increase the serum half-life via transient binding to long 
lasting IgG molecules. 
 
With an increased concentration of erythropoietin, a variety of cells can be stimulated 
during the maturation process of red blood cells. The first steps during hematopoiesis 
take place in the bone marrow where pluripotent stem cells can differentiate through 
the erythrocyte lineage depending on different cytokines, including EPO (Figure 1-4). 
The earliest cell to express the erythropoietin receptor and to respond to EPO 
stimulation is the burst forming unit-erythroid. All subsequent cell types are 
dependent on EPO in their development until the stage of erythroblasts (Jones, 
Anderson, and Longmore 2005; Sinclair 2013). Colony forming unit-erythroids begin 
synthesis of hemoglobin and differentiate into erythroblasts. Erythroblasts enucleate 
forming reticulocytes that migrate to the peripheral blood for the final step of 
hematopoiesis, where they differentiate into erythrocytes (Elliott and Sinclair 2012).  
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Figure 1-4: Erythropoiesis 
This schematic illustration shows the erythropoiesis in the bone marrow and blood. The earliest cell to 
depend on EPO presence is the BFU-E (burst forming unit-erythroid). The EPO receptor is expressed 
until the stage of erythroblasts. CFU-GEMM: colony forming unit-granulocyte, erythroid, macrophage, 
megakaryocyte; CFU-E: colony forming unit-erythroid 
 
Recombinant human erythropoietin has been used as treatment for anemia for over 
two decades, but due to the low terminal half-life of huEPO two to three intravenous 
applications per week are required for an effective therapy (Egrie et al. 2003). 
Therefore, huEPO presents a therapeutically relevant target molecule to half-life 
extension strategies. Furthermore, functional activity can be assayed rather easily, 
since EPO retains its activity across most species (Koury 2005). Various strategies to 
extend the serum half-life were applied to human EPO, like hyperglycosylation to 
increase the hydrodynamic radius together with the addition of negatively charged 
sialic acids. This resulted in second and third-generation erythropoietins Darbepoietin 
alfa (Aranesp) and CERA (pegylated epoietin β), respectively (Kang, Deluca, and 
Lee 2009). The hyperglycosylated variant Aranesp exhibits a terminal half-life that is 
roughly 3-fold elongated compared to huEPO (Macdougall et al. 1999), but it also 
displays a lower in vitro activity, determined in an EPO dependent cell line (Sinclair 
2013). Increasing the glycosylation lowers the affinity towards the EPO receptor and 
thus also the in vitro activity. Both, slower association and faster dissociation rate 
contribute to the decreased affinity (Gross and Lodish 2006). More precisely, the 
sialic acid content of the EPO isotype is responsible for decreased receptor binding 
and lower proliferation rate, but it also reflects in longer half-life (Egrie and Browne 
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2001). Despite its reduction in activity, but also because of the lower affinity and 
degradation of Aranesp, only 1/200 of dosage is needed to achieve the same clinical 
effect as withunmodified recombinant human EPO (Gross and Lodish 2006; Hörl 
2013). 
1.6 IgG derivates 
With about 350 immunoglobulin-based therapeutics approved for clinical therapy or 
in the commercial pipeline and development, these recombinant proteins represent 
the most important class of biotherapeutics (Rath et al. 2013). Their advantage is 
dependent on the fusion to an Fc part that mediates dimerization and can therefore 
contribute to higher bioactivity. This dimerization can provoke an avidity effect that is 
beneficial when targeting cells with an IgG or scFv-Fc, but the effect of a therapeutic 
fusion partner can also be augmented (Gieffers et al. 2013). More important, the Fc 
part increases the size of the recombinant fusion protein to prevent rapid renal 
clearance and it is responsible for the salvage from lysosomal degradation via FcRn 
recycling (Figure 1-1). Additionally, fusion to an Fc part often results in improved 
stability and solubility, as well as expression or secretion. The cost-effective 
purification via Protein A affinity chromatography further favors IgG based 
therapeutics (Carter 2011). If desired, the Fc part is able to mediate effector functions, 
such as antibody dependent cellular cytotoxicity or complement dependent 
cytotoxicity by specifically recognizing Fcγ receptors or complement proteins, 
dependent on the subclass (Kapur, Einarsdottir, and Vidarsson 2014). The human 
IgG1 Fc part is glycosylated at the asparagine residue 297. This glycosylation is 
necessary for proper effector functions, but can be tailored to show better binding to 
activating or inhibiting Fcγ receptors (Czajkowsky et al. 2012). Besides full length 
monoclonal antibodies, 9 other Fc fusion proteins are clinically approved, including 
etanercept (Enbrel), which consists of the extracellular domain of TNF receptor II 
fused N-terminally to an IgG1 Fc part, abatacept (Orencia) and belatacept (Nulojix) 
comprising CTLA-4 and romiplostim (Nplate) containing peptide thrombopoietin 
(TPO) mimetic fused to the C-terminus of aglycosylated human IgG1 Fc (Beck and 
Reichert 2011; Levin et al. 2014). Other peptides or therapeutic fusion proteins like 
huEPO, factor VIII or VEGF receptor have been fused to either the C-terminus or the 
N-terminus of the Fc part (Kontermann 2012; Way et al. 2005) (Figure 1-5). Also the 
combination of a targeting moiety, like an scFv directed against CD30 or targeting 
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EpCAM, combined with a therapeutic molecule, like IL-2 or IL-12, is under close 
investigation (Gillies et al. 2002; Hombach, Heuser, and Abken 2005).  
 
 
Figure 1-5: Fc fusion proteins 
Various therapeutic proteins, targeting moieties or peptides can be genetically fused to a human Fc 
part in order to generate dimeric, long-lasting fusion proteins. The fusion partners can be added to the 
N- and/or C-terminus of an Fc part with the possibility of additional bispecificity. Modifications in 
protein sequence or the glycosylation of the Fc part can mediate half-life extension and enhancement 
or deactivation of Fc effector functions.  
 
Fusion of an scFv to a human IgG1 Fc part increases its molecular weight and 
hydrodynamic radius above the renal threshold and the Fc part enables 
FcRn-mediated salvage from lysosomal degradation. These measures result in a 
considerably extended terminal half-life in a mouse model (Kenanova et al. 2005). 
However, it has been demonstrated that full-length immunoglobulins with the same 
specificity and identical Fc part still exhibited a longer circulation time than an 
scFv-Fc (Hopp et al. 2010). Differences in binding affinity to the FcRn have 
previously been identified as plausible reason for shorter retention time of Fc fusion 
proteins, possibly caused by altered conformation of the CH2-CH3 domain interface or 
steric hindrance (Suzuki et al. 2010). The affinity relation between pH6 and pH7.4 
has also been investigated, claiming that low affinity under physiological conditions is 
crucial for low clearance and long serum persistence (Borrok et al. 2014). A recent 
study revealed a contribution of the Fab fragment to FcRn recycling, showing 
unknown FcRn interaction sites in the Fab region or possible conformational links 
between IgG Fc and Fab regions upon FcRn binding (Jensen et al. 2015). However, 
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other studies could not detect an association between FcRn affinity and the plasma 
circulation time of antibodies in mouse models (Gurbaxani et al. 2006).  
1.7 Goal of this study 
The aim of this study was to advance the half-life extension strategy of the 
immunoglobulin-binding domains. Hitherto, domain C3 from Streptococcus Protein G 
(SpGC3) exhibited the most favorable properties in improving the pharmacokinetics of 
small recombinant antibody fusion proteins (Hutt et al. 2012). In order to generate 
long-lasting fusion proteins with IgBDs, some criteria have to be fulfilled. Stable 
formation of complexes with IgG under physiological conditions, but also at acidic pH, 
is necessary to guarantee reduced renal clearance as well as salvage from 
lysosomal degradation via FcRn-mediated recycling. Furthermore, an interference or 
competition with the FcRn during endosomal recycling has to be avoided. Deletion of 
the Fc binding site of SpGC3 and simultaneous improvement of the CH1 binding 
properties are possibilities to enhance the performance of the IgBDs. After having 
determined affinities to immunoglobulins and fragments, the most promising 
candidates are subject for pharmacokinetic analysis as scDb-IgBD fusion protein. 
Decreasing the impact on functionality of the fusion proteins is also a key 
requirement for new IgBDs, since previous domains demonstrated reduced activity or 
altered binding in the presence of IgG (Hutt et al. 2012; Unverdorben et al. 2012).  
 
Since the immunoglobulin-binding domains are derived from bacterial proteins, there 
might be possible concerns with immunogenicity and the generation of anti-drug 
antibodies as answer to a treatment with IgBD fusion proteins. In order to solve this 
issue, a deimmunization strategy can be applied to the sequence of the previously 
improved IgBDs. First, possible T-cell epitopes have to be identified by sequence- 
and structure-based analysis. Knowing the number and location of these epitopes, a 
combination of amino acid substitutions is needed that is able to eliminate as many 
epitopes as possible without impeding the functionality of the IgBD. These properties 
have to be determined by in vitro characterization, especially the affinity towards IgG, 
as well as the in vivo half-life extension of selected deimmunized IgBDs. 
 
Having determined the in vitro bioactivity and pharmacokinetic parameters of IgBDs 
as scDb fusion proteins, their benefit for another therapeutic molecule has to be 
verified. For this purpose, recombinant human erythropoietin was selected. The IgBD 
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fusion proteins have to prove their in vitro proliferative effect on an EPO-dependent 
cell line prior to determining the pharmacokinetic parameters. Finally, the ability to act 
as therapeutic drug and increase the hemoglobin level in a mouse model has to 
confirm the potential of the IgBDs to improve the efficacy of biotherapeutics as 
half-life extension modules.  
 
Furthermore, the pharmacokinetics and the biochemical properties of various 
IgG-based fusion proteins are compared. These fusion proteins all contain the same 
human IgG1 Fc part, but they differ in the N-terminal fusion moiety. This study 
includes a full-length IgG, as well as an scFv-Fc, an scDb-Fc and a single chain 
version of IgG, where an scFv is fused to a single-chain version of the constant 
domains of the Fab fragment (scFv-scCLCH1-Fc). Combination of thermal and 
serum stability as well as FcRn binding affinities, size and isoelectric point are 
investigated to explain possible differences in half-life. An scDb-CH2 fusion protein is 
incorporated, since the CH2 domain is jointly responsible for FcRn recycling.  
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2 Materials and methods 
2.1 Materials 
2.1.1 Instruments 
Balances Feinwaage Basic (Sartorius AG, Göttingen, Germany)  
440-39N and 443-33N (Kern, Balingen, Germany) 
Cell counting chamber Counting chamber Neubauer improved (Plan Optik, Elsoff, 
Germany) 
Centrifuges Avanti J-30I and J2-MC with rotors JA10, JA14, JA20, JA30.5 
Optima TL with rotor TLA 100.3 (all: Beckman Coulter, Krefeld, 
Germany) 
Eppendorf 5804R (Eppendorf, Hamburg, Germany) 
Electrophoresis system Mini-Protean 3 Cell Electrophoresis System  
Ready Agarose Precast Gel Electrophoresis  
Power Pac Basic and HC (all: Bio-Rad, Munich, Germany) 
Electroporation  Gene Pulser Xcell Electroporation System (BioRad, Munich, 
Germany) 
ELISA reader  Infinite M200 (Tecan, Crailsheim, Germany) 
Flow cytometer MACSquant Analyzer 10 (Milteny, Bergisch Gladbach, 
Germany) 
Gel documentation Transilluminator, Gel documentation system Felix (Biostep, 
Jahnsdorf, Germany) 
HPLC system   Waters HPLC-System (Millipore, Billerica, USA) 
Yarra SEC-2000 column (Phenomenex, Aschaffenburg, 
Germany) 
Incubator for bacteria  Infors HT Multitron 2 (Infors Ag, Basel, Switzerland) 
Incubator for cell culture  CO2 Incubator 2424-2 (Zapf, Sarstedt, Germany) 
Laminar flow cabinet  Variolab Mobilien W90, (Waldner-Laboreinrichtungen, Wangen, 
Germany) 
PCR cycler    Robocycler 96 (Stratagene, La Jolla, USA) 
Quartz crystal microbalance Attana Cell A200 with C-fast system (Attana AB, Stockholm, 
Sweden) 
Spectrophotometer  NanoDrop ND-1000 (Thermo Fisher Scientific, Darmstadt, 
Germany) 
ZetaSizer    ZetaSizer Nano ZS  
12 mm square glass cell for 90 sizing (Malvern Instruments, 
Herrenberg, Germany) 
2.1.2 Implements 
All cell culture and other plastic material was derived from Greiner Bio-One (Frickenhausen, 
Germany), if not stated otherwise. 
 
Attana sensor chips  Low nonspecific binding-carboxyl chips  
    Biotin sensor chip (Attana AB, Stockholm, Sweden) 
Dialysis membranes  ZelluTrans MWCO 6000 (Roth, Karlsruhe, Germany) 
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Dynabeads Dynabeads M-280 Streptavidin  
Dynabeads MPC-S (Magnetic Particle Concentrator) (Thermo 
Fisher Scientific, Darmstadt, Germany) 
Electroporation cuvettes Gene Pulser electroporation cuvettes 1 mm (BioRad, Munich, 
Germany) 
IMAC beads   Protino Ni-NTA agarose (Macherey-Nagel, Düren, Germany)  
Immunotubes  5 ml immunotubes Nunc MaxiSorp (Thermo Fisher Scientific, 
Darmstadt, Germany) 
Microhematocrit tubes  Heparinized (Thermo Fisher Scientific, Darmstadt, Germany) 
Protein A beads TOYOPEARL AF rProtein A-650F (Tosoh Bioscience, Stuttgart, 
Germany)  
2.1.3 Chemicals 
All chemicals were purchased from Roth (Karlsruhe, Germany), Merck (Darmstadt, 
Germany), Roche (Basel, Switzerland) and Sigma-Aldrich (Taufkirchen, Germany), if not 
stated otherwise. 
2.1.4 Bacterial culture and phage display 
All media are prepared as aqueous solution. 
 
Ampicillin 100 mg/ml as 1000 x stock solution 
IPTG 1 M isopropyl β-D-1-thiogalactopyranoside as 1000 x stock 
Kanamycin 30 mg/ml as 1000 x stock solution 
LBAmp,Glc agar plates LB-medium, 2.0 % (w/v) agar, after autoclaving adding of 
ampicillin to 100 μg/ml and 1 % (w/v) glucose  
LB medium   1 % (w/v) peptone, 0.5 % (w/v) yeast extract, 0.5 % (w/v) NaCl 
Minimal plates 1.5 % (w/v) agar, 0.2 % (w/v) glucose, 1 mM MgSO4, 2 μg/ml 
vitamine B1, 1 x M9 stock solution 
10 x M9 stock solution 0.5 M Na2HPO4, 0.22 M KH2PO4, 5 % (w/v) NaCl, 
10 % (w/v) NH4Cl, pH7.2 
SOB medium 0.5 % (w/v) yeast extract, 2 % (w/v) peptone, 10 mM NaCl, 
2.5 mM KCl, 10 mM MgSO4, 10 mM MgCl2 
SOC medium   SOB medium, 20 mM glucose 
TY medium 1.6 % (w/v) peptone, 1 % (w/v) yeast extract, 0.5 % (w/v) NaCl 
2.1.5 Cell culture  
All media and supplements were purchased from Thermo Fisher Scientific (Darmstadt, 
Germany), if not stated otherwise. 
 
Eosin solution   0.4 % (w/v) eosin G, 0.02 % (w/v) NaN3 in sterile PBS pH7.4 
EPO    Recombinant human EPO (Sigma-Aldrich, St. Louis, USA) 
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2.1.6 Solutions 
All solutions prepared contained water as solvent, if not stated otherwise. 
 
Bradford reagent  BioRad protein assay (BioRad, Munich, Germany) 
Coomassie staining solution 0.008 % (w/v) Coomassie Brilliant Blue G-250, 35 mM HCl 
DNA loading buffer (5 x) 25 % (v/v) glycerol, 0.02 % (w/v) bromphenol blue in 
5 x TAE buffer  
ELISA blocking/MPBS 2 % (w/v) non-fat dry milk powder in 1 x PBS 
ELISA developing 100 mM Na-acetate (NaOAc) pH6, 0.1 mg/ml 
3,3’,5,5’-tetramethylbenzidine, 0.006 % (v/v) H2O2 
ELISA stopping  1 M H2SO4 
ELISA washing  0.05 % (v/v) Tween 20 in 1 x PBS 
Ficoll    LSM 1077 Lymphocyte Separation Medium (PAA Laboratories, 
Pasching, Austria) 
Freezing solution  10 % (v/v) dimethyl sulfoxide in FCS 
Glycogen   20 mg/ml (Thermo Fisher Scientific, Darmstadt, Germany) 
IMAC elution buffer  250 mM imidazole in 1x sodium phosphate buffer 
IMAC wash buffer  30 mM imidazole in 1x sodium phosphate buffer 
Laemmli buffer (5 x) Non-reducing: 10 % (w/v) SDS, 25 % (v/v) glycerin, 
0.05 % (w/v) bromphenol blue in 312.5 mM Tris-HCl pH6.8 
 Reducing: non-reducing buffer, 25 % (v/v) β-mercatoethanol 
MTT    0.5 % (w/v) thiazol blue tetrazolium bromide 
MTT lysis buffer 15 % (w/v) SDS in Dimethylformamide/H2O (1:1) with 
80 % acetic acid pH4-5 
PBA    2 % (v/v) FCS, 0.02 % (w/v) NaN3 in 1 x PBS  
Periplasmic preparation  30 mM Tris-HCl pH8, 1 mM ethylenediaminetetraacetic acid 
buffer    (EDTA), 20 % (w/v) sucrose 
Phage precipitation buffer 20 % (w/v) PEG6000, 2.5 M NaCl (autoclaving essential) 
PBS (10 x) 80.6 mM Na2HPO4, 14.7 mM KH2PO4, 1.37 M NaCl, 26.7 mM 
KCl; used as 1x PBS diluted in dH2O  
PBST (0.1 %) PBS with 0.1 % (v/v) Tween 20 
Protein A elution  100 mM glycine-HCl pH3  
Protein A neutralization 1 M Tris-HCl pH7 
SDS running (10 x)  1.92 M glycine, 0.25 M Tris, 1 % (w/v) SDS, pH8.3  
Sodium phosphate (5 x) 210 mM Na2HPO4, 40 mM NaH2PO4, 1.25 M NaCl, pH7.5 
TAE (50 x)   2 M Tris, 1 M glacial acetic acid, 50 mM EDTA, pH8 
2.1.7 Enzymes 
Lysozyme  Roche Diagnostics (Mannheim, Germany) 
N-Glycosidase F Roche Diagnostics (Mannheim, Germany) 
O-Glycosidase  Roche Diagnostics (Mannheim, Germany) 
Neuraminidase Roche Diagnostics (Mannheim, Germany) 
 
The following enzymes for cloning were all purchased from Thermo Fisher Scientific 
(Darmstadt, Germany): AgeI, BamHI, BstWI, EcoRI, Fast alkaline phosphatase, NcoI, NotI, 
SalI, SfiI, T4 DNA ligase, Taq polymerase (recombinant), XbaI 
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2.1.8 Antibodies and immobilized proteins 
Table 2-1: Antibodies and immobilized proteins 
 
Protein Source Concentration 
Anti-His-tag antibody-HRP Santa Cruz Biotech (Santa Cruz, USA) 1:2000 (ELISA) 
Anti-His-tag antibody-PE Miltenyi Biotec (Bergisch Gladbach, 
Germany)  
1:150 (FACS) 
Anti-human IgG-HRP (Fc 
specific) Sigma-Aldrich (St.Louis, USA) 1:5000 (ELISA) 
CEA Antikörper-online.de (Aachen, Germany) 3 µg/ml (ELISA) 
Human serum IgG Sigma-Aldrich (St.Louis, USA) 100 µg/ml (ELISA, FACS, IL-2 release) 
Human serum IgG Fab 
fragment EMELCA (Breda, Netherlands) QCM 
Human serum IgG Fc fragment EMELCA (Breda, Netherlands) QCM 
Mouse FcRn (biotinylated) Novimmune (Geneva, Switzerland) QCM 
Mouse serum IgG Sigma-Aldrich (St.Louis, USA) QCM 
Mouse serum IgG Fab fragment EMELCA (Breda, Netherlands) QCM 
Mouse serum IgG Fc fragment EMELCA (Breda, Netherlands) QCM 
Protein L-HRP Genscript (Piscataway, USA) 1:5000 (ELISA) 
 
2.1.9 Kits and markers 
Amine coupling kit (EDC + sNHS)  (Attana AB, Stockholm, Sweden) 
Biotin-Streptavidin coupling kit  (Attana AB, Stockholm, Sweden) 
EZ-Link Sulfo-NHS-Biotin (Thermo Fisher Scientific, Darmstadt, Germany) 
GeneMorph II Random Mutagenesis kit  (Agilent, Waldbronn, Germany) 
Hemoglobin assay kit    (Sigma-Aldrich, St. Louis, USA) 
Interleukin-2 Sandwich ELISA   (R&D Systems, Abingdon, UK) 
NucleoBond Xtra Midi    (Macherey-Nagel, Düren, Germany) 
NucleoBond Gel and PCR Clean-up  (Macherey-Nagel, Düren, Germany) 
NucleoBond Plasmid    (Macherey-Nagel, Düren, Germany) 
GeneRuler DNA ladder mix    (Thermo Fisher Scientific, Darmstadt, Germany) 
PageRuler prestained protein ladder  (Thermo Fisher Scientific, Darmstadt, Germany) 
 
2.1.10  Bacteria and phages 
Escherichia coli TG1  Genotype: supE thi-1 Δ(lac-proAB) Δ(mcrB-hsdSM)5 (rK– mK–) 
[F´ traD36 proAB lacIqZΔM15] (Stratagene,La Jolla, USA) 
Phage VCS M13   Interference-resistant helper phage (Stratagene, La Jolla, USA) 
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2.1.11  Cell lines 
Eucaryotic cells were cultivated at 37 °C in a humidified incubator in 5 % CO2 atmosphere.  
 
Table 2-2: Cell lines 
 
Cell line Origin Culture medium 
CHO-K1 Chinese hamster ovary RPMI 1640 + 5 % FCS 
HEK293 Human embryonic kidney RPMI 1640 + 5 % FCS 
LS174T Colon carcinoma RPMI 1640 + 5 % FCS 
PBMCs Buffy coat from healthy donors RPMI 1640 + 10 % FCS 
UT-7/EPO Human leukemic EPO dependent IMDM + 10 % FCS + 1 U/ml EPO 
 
2.1.12  Plasmids 
pAB1 Vector for prokaryotic expression in periplasm of E.coli TG1 (Müller et 
al. 2007) 
pEE14.4 Glutamine sythetase encoding eukaryotic expression vector (Lonza 
Biologics, Berkshire, UK) 
pHEN3  Phagemid vector (based on pHENIX, with additional His-tag (Finnern 
et al. 1997) 
pSecTagA  Eukaryotic expression vector (Thermo Fisher Scientific, Darmstadt, 
Germany) 
pSecTagAL1 Modified pSecTagA with additional AgeI restriction site (K. Zettlitz) 
 
2.1.13  Primers 
All primers were synthesized by Sigma-Aldrich (St. Louis, USA) and dissolved in 
water to a final concentration of 50 µM.  
 
Table 2-3: Primer for sequencing 
 
Name Target Sequence (5' – 3') 
pET-Seq1 pSecTagA (forward) TAA TAC GAC TCA CTA TAG GG  
pSec-Seq2 pSecTagA (reverse) TAG AAG GCA CAG TCG AGG  
LMB4 pAB1 (reverse) GCA AGG CGA TTA AGT TGG 
LMB3 pHEN3 (forward) CAG GAA ACA GCT ATG ACC 
fd-SEQ1 pHEN3 (reverse) GAA TTT TCT GTA TGA GG 
VLCEA-back VL scFvCEA (forward) GAG GCT GAA GAT GCT GCC 
Fc fusions CH2 domain (reverse) TGG GGG GAA GAG GAA GAC 
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Table 2-4: Primer for cloning of IgBD fusion proteins 
 
Name Sequence (5' – 3') 
NotI-Linker-SpGC3Fab-back A TTT GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC GTG 
EcoRI-Stop-His-SpGC3-for 
G ATC GAA TTC TCA TCA GTG GTG ATG GTG GTG GTG GGA TCC GCC CTC GGT 
CAC GGT GAA GGT 
SpGC3FabT1A,E15Q-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA GCA ACA TAC AAG CTC GTG ATC 
AAC GGC AAG ACC CTG AAG GGC CAG ACA ACC ACC AAA GCC G 
SpGC3FabK50Q-for 
GAT CGA ATT CTC ATC AGT GGT GAT GGT GGT GGT GGG ATC CGC CCT CGG 
TCA CGG TGA AGG TCT GGG TGG CGT CGT CGT AGG 
SpGC3FabK4E-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC GAG CTC GTG ATC 
AAC GGC AAG 
SpGC3FabL5A-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG GCC GTG ATC 
AAC GGC AAG ACC 
SpGC3FabV6A-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC GCG ATC 
AAC GGC AAG ACC CTG 
SpGC3FabI7E-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC GTG GAA 
AAC GGC AAG ACC CTG AAG 
SpGC3FabI7L-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC GTG CTC 
AAC GGC AAG ACC CTG AAG 
SpGC3FabN8D-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC GTG ATC 
GAC GGC AAG ACC CTG AAG GGC 
SpGC3FabK10E-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC GTG ATC 
AAC GGC GAG ACC CTG AAG GGC GAG ACA 
SpGC3FabL12A-back 
A TTT GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC GTG ATC 
AAC GGC AAG ACC GCG TCT GGC GAG ACA ACC ACC 
SpGC3FabT44S-for 
G ATC GGA TCC GCC TTC GGT CAC GGT GAA GGT CTT GGT GGC GTC GTC GTA 
GGA CCA CAC GCC GTC CAC GCC 
SpGC3FabA48G-for 
G ATC GGA TCC GCC TTC GGT CAC GGT GAA GGT CTT GGT GCC GTC GTC GTA 
GGT CCA CAC 
SpGC3FabDI1-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC GAG CTC GCG ATC 
AAC GGC CAG ACC CTG AAG GGC GAG ACA 
SpGC3FabDI2-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG GTC GCG ATC 
AAC GGC CAG ACC CTG AAG GGC GAG ACA 
SpGC3FabDI3-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC ACG ATC 
GAC GGC AAG ACC CTG AAG GGC 
SpGC3FabDI4-back 
G ATC GCG GCC GCA GGC GGA TCT GGC GGA ACA ACA TAC AAG CTC ACG ATC 
AAC GGC GAG ACC CTG AAG GGC GAG ACA 
SpGC3FabY33A-back 
G ATC GTC GAC GCC GAA ACA GCC GCC GCT GCC TTT GCC CAG GCT GCC AGG 
AGG AAT GGC GTG 
SpGC3FabY33T-back 
G ATC GTC GAC GCC GAA ACA GCC GCC GCT GCC TTT GCC CAG ACT GCC AGG 
AGG AAT GGC GTG 
 
Table 2-5: Primer for phage display 
 
Name Sequence (5' – 3') 
NcoI-SpGC3Fab-back C ATG CCA TGG CCA CAA CAT ACA AGC TCG TGA TCA ACG 
NotI-SpGC3Fab-for ATT TGC GGC CGC CTC GGT CAC GGT GAA GGT 
NcoI-SpGC3FabΔN-back CAT GCC ATG GCC TGA CCA AAG CCG TCG ACG 
SalI-SpGC3FabΔN-back T CGA GTC GAC AGT ACG CCA ACG ATA ATG GCG 
SpGC3Fab Library1-back 
CCG GCC ATG GCC ACA ACA TAC NNK CTC GTG ATC AAC GGC AAG ACC CTG 
AAG GGC NNK NNK NNK ACC AAA GCC GTC GAC GCC GAA ACA 
SpGC3Fab Library2-back 
CCG GCC ATG GCC ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG NNK NNK 
NNK NNK GAG ACA ACC ACC AAA GCC GTC GAC 
SpGC3Fab Library3-back 
T CGA GTC GAC GCC GAA ACA GCC GCC GCT GCC TTT GCC CAG NNK GCC NNK 
NNK NNK GGC GTG GAC GGC GTG TGG ACC 
NNK triplets were used at the sites that encode for amino acids binding to the CH1 domain. 
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Table 2-6: Primer for Fc fusion proteins 
 
Name Sequence (5' – 3') 
BsiWI-scFv-for G ATC CGT ACG TTT CAG CTC CAG CTT GGT GCC 
BsiWI-CLkappa-back G ATC CGT ACG GTG GCA GCG CCA TCT GTC TTC ATC 
BamHI-CLkappa-for G ATC GGA TCC ACC GCC CCC TGA CCC ACC GCC TCC ACA CTC TCC CCT GTT GAA 
BamHI-CH1-back G ATC GGA TCC GGG GGA GGC GGT TCA GGA GGC GGT GGG AGT GCC TCC ACC AAG GGC CCA 
NotI-CH1-for GAT CGC GGC CGC ACA AGA TTT GGG CTC AAC 
NotI-CH2-back G ATC GCG GCC GCA GGC GGA TCT GGC GGC GCA CCT GAA CTC CTG GGG 
BamHI-CH2-for G ATC GGA TCC TCC TTT GGC TTT GGA GAT GGT 
 
2.1.14  Programs and online tools 
Attana evaluation software 3.3.4 Attana AB (Stockholm, Sweden) 
C-Fast Software   Attana AB (Stockholm, Sweden) 
ExPASY Prot Param   http://web.expasy.org/protparam/ 
FlowJo 8.8.6   http://www.flowjo.com/ 
GraphPad Prism 5.01  GraphPad software (La Jolla, USA) 
Microsoft Excel and Add-Ins  Microsoft Corporation 
MacPYMOLEdu   http://pymol.org/educational/ 
RCSB protein databank  http://www.rcsb.org/pdb/home/home.do 
Serial Cloner 2.6.1   http://serialbasics.free.fr/Serial_Cloner.html 
TraceDrawer 1.6   Attana AB (Stockholm, Sweden) 
 
2.2 Cloning 
2.2.1 Cloning of antibody fragment-IgBD fusion proteins 
The DNA sequences encoding for SpGC3Fab, SpGC3Fc and SpGC2 were synthesized 
from Geneart (Regensburg, Germany) including the linker between the antibody 
fragment and the IgBD as well as the C-terminal His-tag followed by a Stop codon. 
These sequences were ligated into the eukaryotic expression vector pSecTagA, 
either containing an scDb or scFv (Hutt et al. 2012). The identical modular system 
with NotI and EcoRI as restriction sites was used for the generation of the prokaryotic 
expression vector pAB1 scFv-IgBDs (Hopp et al. 2010). Analogously, all 
affinity-maturated variants have been introduced into the expression vectors by PCR 
using the primers NotI-Linker-SpGC3Fab-back and EcoRI-Stop-His-SpGC3-for and the 
pHEN3 vector of the selected clone as template (Table 2-4). Only 
SpGC3FabT1A,E15Q and SpGC3FabK50Q needed other primers 
(SpGC3FabT1A,E15Q-for, SpGC3FabK50Q-back), since their mutations were at the 
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beginning or the end of the transferred sequence, respectively. In order to introduce 
the deimmunized variants into the expression vectors, the same strategy was applied, 
using the primers with the corresponding mutations and pSecTagA-SpGC3Fab as 
template for PCR.  
2.2.2 Cloning of huEPO-IgBD fusion proteins 
The DNA for the huEPO-IgBD fusion proteins was synthesized by Geneart 
(Regensburg, Germany), including a hexahistidyl tag, with flanking AgeI and XbaI 
restriction sites for cloning into pSecTagAL1. Additionally, a NotI site was included 
prior to the His-tag in order to insert the IgBD sequences via NotI and XbaI from the 
pSecTagA vectors used above.  
2.2.3 Cloning strategy for phage display 
For the generation of the phage display libraries 1, 2 and 4, an acceptor vector had to 
be created, comprising a 5’ terminally truncated version of SpGC3Fab in the phagemid 
vector pHEN3 (pHEN3 SpGC3FabΔN) that was cloned using NcoI-SpGC3FabΔN-back 
(forward) and NotI-SpGC3Fab-for (reverse) as primers for the SpGC3Fab sequence from 
pSecTagA. For library 3, the SalI and NotI restriction sites were necessary. Therefore, 
another acceptor vector was created via the alternative forward primer 
SalI-SpGC3FabΔN-back. The PCR product from the degenerate primers (Table 2-5) as 
forward primers and NotI-SpGC3Fab-for as reverse primer was digested with NcoI 
(Libraries 1, 2 and 4) or SalI (Library 4) and NotI for subsequent ligation to the 
corresponding acceptor vector.  
2.2.4 Cloning of Fc fusion proteins 
In order to generate tag free Fc fusion proteins, the scFv and the scDb were 
transferred to an already existing pSecTagA-Fc vector via the restriction site SfiI and 
NotI from the vectors mentioned above. The scFv-scCLCH1-Fc had to be cloned in 
several steps, adding one immunoglobulin domain at a time. First, the PCR product 
of the primers BamHI-CH1-back and NotI-CH1-for (Table 2-6) with the vector 
pEE14.4 IgG1CEA as template was integrated via BamHI and NotI. Next, a PCR was 
performed in order to generate the CL domain with restriction sites for BsiWI and 
BamHI using the primers BsiWI-CLkappa-back and BamHI-CLkappa-for for the IgG 
template. Since the scFv could not be transferred via the NotI site as previously 
described, the BsiWI restriction site had to be added using the primers pET-Seq1 
(Table 2-3) and BsiWI-scFv-for for amplification of the scFv out of the vector 
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pSecTag scFv-Fc. The scDb-CH2 was cloned via PCR with the primers 
NotI-CH2-back and BamHI-CH2-for and the IgG template. The resulting PCR product 
was digested with NotI and BamHI and ligated into the cut pSecTagA scDb-SpGC3Fab.  
2.2.5 Polymerase chain reaction 
The polymerase chain reaction (PCR) was used in order to amplify desired 
sequences with the necessary restriction sites or to introduce single amino acid 
substitutions. The PCR protocol for the generation of the libraries 1 – 3 was identical 
to other PCR reaction, only using degenerate primers to create diversity.  
 
  PCR Taq buffer with (NH4)2SO4 (10 x)  5 µl 
  MgCl2 (25 mM)     4 µl 
  dNTP mix (5 mM each nucleotide)  2.5 µl 
  Forward primer (50 µM)    1 µl 
  Reverse primer (50 µM)    1 µl 
  Template (100 ng/µl)    1 µl 
  H2O       34.25 µl 
  Taq polymerase (1 U/µl)    1.25 µl 
 
The amplification was performed as described in Table 2-7, with an elongation time 
that was dependent on the resulting PCR product. A synthesis rate of 1000 
nucleotides per minute was assumed for the Taq polymerase, with a minimal 
elongation time of 0.5 min. For the generation of the libraries, only 25 cycles were 
applied. 
 
Table 2-7: PCR program 
 
PCR step Temperature Time [min] Number of cycles 
Initial denaturation 94 °C 5 1 x 
Denaturation 94 °C 0.5 
30 x Annealing 50 °C 0.5 
Elongation 72 °C dependent 
Final elongation 72 °C 5 1 x 
 
2.2.6 Error prone PCR 
In order to generate a library with amino acid substitutions distributed across the 
whole sequence, an error prone PCR approach was pursued. The PCR program was 
similar to the previously programs, using 0.5 min of elongation and 40 cycles. 
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  H2O       40 µl 
  Mutazyme II reaction buffer (10 x)  5 µl 
  dNTP mix (10 mM each nucleotide)  1 µl 
  Primer LMB3 (50 µM)    1 µl 
  Primer LMB4 (50 µM)    1 µl 
  Template pHEN3-SpGC3Fab (0.11 ng/µl)  1 µl   
  Mutazyme II DNA polymerase (2.5 U/μl) 1 µl 
 
2.2.7 DNA electrophoresis and gel extraction 
After amplification or digestion of DNA, the resulting fragments were analyzed and 
purified via horizontal agarose gel electrophoresis. Depending on the size of the 
fragments, 1 – 2 % (w/v) agarose was boiled in TAE buffer until it was completely 
dissolved. Subsequently, ethidium bromide was added to a final concentration of 
1 µg/ml. DNA was mixed 5 x DNA loading buffer and applied to the precast gel at 
80 V for 30 minutes. After analysis under ultra violet light, relevant bands were 
excised and purified with a NucleoSpin Gel and PCR Clean-up kit according to 
manufacturer’s protocol.  
2.2.8 Restriction digestion 
10 µg of vector DNA or alternatively the whole elution from previous DNA purification 
was digested in a total volume of 50 µl. When temperatures and buffer conditions 
were identical for both enzymes, the DNA was incubated with both enzymes (1 µl 
each) in the corresponding buffer for 2 h. If temperature or buffer conditions were 
unsuitable, the digestions were performed consecutively, with additional purification 
step. The buffer exchange was again performed with the NucleoSpin Gel and PCR 
Clean-up kit. The vector DNA was dephosphorylated using Fast alkaline 
phosphatase (1 µl) after the last digestion step for 1 h at 37 °C. Next, fragments were 
analyzed via agarose gel electrophoresis. 
2.2.9 Ligation and heat shock transformation 
A molar ratio of 1 : 3 was chosen for the ligation of vector and insert DNA with a total 
DNA amount of 250 ng. The ligation reaction was carried out at room temperature for 
1 h with 1 U of T4 DNA ligase in a total volume of 20 µl. Chemically competent 
E.coli TG1 were thawed on ice, the ligation was added to 100 µl of bacteria and 
incubated on ice for 5 minutes. Heat shock was subsequently applied for 45 seconds 
at 42 °C and cells were placed back on ice together with 1 ml of LB medium for 
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recovery for 2 minutes. Cells were harvested by centrifugation (10,000 g, 30 sec) and 
plated on LBAmp,Glc agar plates for over night incubation at 37 °C.  
2.2.10 Plasmid DNA isolation and sequence analysis 
One single clone was inoculated into an 5 ml/100 ml LB medium (Mini/Midi-
preparation) containing 1 % (w/v) glucose and ampicillin, shaken at 37 °C. Cells were 
harvested the next day and DNA was purified according to manufacturers protocol 
with the NucleoSpin Plasmid kit for Mini-preparation and the NuceloBond Xtra Midi kit 
for Midi-preparation. The DNA was sequenced by GATC Biotech AG (Konstanz, 
Germany) using the corresponding primers from Table 2-3. 
2.3 Phage display 
2.3.1 Preparation of electrocompetent cells 
A single colony of E.coli TG1 from a minimal plate was inoculated for a 10 ml over 
night culture. The next day, 5 ml thereof were inoculated into 450 ml SOB medium 
and vigorously shaken at 37 °C for about 3 h to reach an OD600 of about 0.75. The 
cells were chilled on ice for 1 h and harvested by centrifugation (2000 g, 10 min). All 
of the following steps were performed on ice and with chilled liquids, centrifuges and 
tubes. The bacteria pellet was resuspended in 200 ml H2O and again centrifuged at 
2000 g for 15 minutes. The resulting pellet was again resuspended in 200 ml H2O 
and incubated on ice for 30 min. Cells were harvested (2000 g, 15 min) and 
resuspended in 25 ml 10 % (v/v) glycerol. The solution was incubated for 30 minutes 
and again harvested by centrifugation (1500 g, 15 min). The ensuing cell pellet was 
resuspended in a final volume of 1 ml 10 % glycerol and immediately used for 
electroporation.  
2.3.2 Ethanol precipitation of DNA 
In order to guarantee a better quality and yield of DNA for the generation of libraries, 
the DNA was precipitated after the ligation. For a 50 µl sample, 5 µl of 3 M sodium 
acetate pH5.2 and 2.5 µl of glycogen (20 mg/ml stock concentration) were added. 
125 µl of 100 % ethanol were applied and after mixing, the solution was incubated at 
-80 °C for 1 h. After centrifugation (13,000 g, 15 min, 4 °C) the DNA pellet was 
washed twice with 70 % ethanol, air-dried and resuspended in 22 µl of water for a 
total of 10 electroporation runs.  
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2.3.3 Electroporation 
All tubes and cuvettes were previously chilled and always handled on ice. 40 µl of 
electrocompetent E.coli TG1 were mixed with 2 µl of ligated DNA and set on ice for 
1 minute. The electroporator was set to a voltage of 1700 V, a resistance of 200 Ω 
and a capacity of 25 µF. After a single pulse, the sample was immediately 
resuspended in 1 ml warm SOC medium and incubated for 1 h at 37 °C shaking. 
Afterwards, the cells were harvested and plated onto LBAmp,Glc agar plates over night 
at 37 °C. The next day, colonies were collected for phage rescue and for the 
generation of a library stock at -80 °C in 30 % glycerol. 
2.3.4 Phage rescue 
50 ml TY medium with ampicillin and 2 % (w/v) glucose were inoculated from the 
phagemid library or from previous selection rounds to an optical density of 0.05. Cells 
were incubated at 37 °C with vigorous shaking for about 2 h until reaching an OD600 
of 0.5, then VCS M13 helper phages were added and further incubated without 
shaking for 30 min, followed by 30 min with shaking. After harvesting the cells 
(3000 g, 10 min), the pellet was resuspended in 50 ml TY medium containing 
ampicillin and kanamycin and shook over night at 30 °C. The bacteria were removed 
by centrifugation (4700 g, 20 min, 4 °C) and phages were precipitated from 40 ml 
supernatant with 10 ml phage precipitation buffer for 1.5 h while rotating at 4 °C. The 
phages were pelleted by centrifugation (4700 g, 30 min) and the pellet was 
resuspended in 1 ml cold PBS. To remove residual bacteria, the phage solution was 
centrifuged for 1 minute at 13,000 g and phage-containing supernatant was collected.  
2.3.5 Immunotube selection 
Immunotubes were coated over night with 1 ml PBS containing 10 µg/ml human or 
mouse Fab fragment. A single E.coli TG1 colony from a minimal plate was inoculated 
in 10 ml TY medium for an over night culture. The next day, immunotubes were 
blocked with MPBS and 10 µl of phages were preincubated with MPBS. 
Subsequently the phages were incubated in the immunotube for 2 h, followed by 
20 washing steps with PBST (0.1 %) and PBS. In the mean time, 50 ml of TY 
medium were inoculated from the over night culture to an OD600 of 0.05 and grown 
until reaching 0.4 – 0.5. 1 ml of 100 mM triethylamine for 8 min eluted the phages 
and was neutralized with 0.5 ml 1 M Tris-HCl pH7.5. The phages were added to the 
log-phase bacteria and incubated 30 min standing and 30 min shaking at 37 °C, prior 
  
Materials and methods 
 
  
38 
to harvesting and plating the transduced cells on LBAmp,Glc agar plates over night. For 
subsequent rounds, the binding and washing conditions were more stringent by 
reducing the coated antigen and washing more harshly (more steps, additional 
incubation for dissociation, pH6 washing).  
2.3.6 Selection with biotinylated antigen 
Biotinylation of human Fab fragment was performed with the EZ-Link Sulfo-NHS-Biotin 
kit according to manufacturer’s protocol. E.coli TG1 were prepared as described for 
the immunotube selection. 10 µl of phages and 10 µl magnetic streptavidin coated 
dynabeads were blocked with 1 % BSA separately. Biotinylated antigen (100 nM) 
was added to the phages and incubated for 1 h. In order to remove unbound phages, 
the phage/biotinylated Fab solution was added to the magnetic dynabeads for 15 min 
and subsequently removed using a magnetic particle concentrator. The beads were 
washed 4 times with PBST (0.1 %) and twice with PBS. For elution of the phages, 
the beads were incubated with 200 µl 10 mM dithiothreitol for 5 min. Eluted phages 
were subsequently treated as described for the immunotube selection. Stringency 
was increased over the rounds by decreasing the concentration of biotinylated Fab 
fragment by factor 10 each round and performing the binding and washing steps at 
pH6.  
2.4 Cell culture and transfection 
All eukaryotic cell lines were cultivated at 37 °C in a humidified 5 % CO2 atmosphere 
in the corresponding medium (Table 2-2). Cell lines were passaged every third day, 
by detaching adherent cells with Trypsin/EDTA, centrifugation (500 g, 5 min) and 
splitting 1:20. For long-term storage, harvested cells were resuspended in FCS 
containing 10 % (v/v) DMSO and slowly frozen in isopropanol filled cryoboxes to -
80 °C. For thawing, cells were incubated at 37 °C, centrifuged (500 g, 5 min) to 
remove the residual DMSO and resuspended in the corresponding medium.  
 
For selection of HEK293 cells to express recombinant protein, pSecTagA plasmids 
were transfected by lipofection. 106 cells were seeded in a 6-well tissue culture plate 
over night in 2 ml culture medium. The next day, 330 µl of serum free Opti-MEM 
medium were incubated with 7 µl Lipofectamine 2000 for 5 min and subsequently 
mixed with 3 µg plasmid DNA. The culture medium was withdrawn from the cells and 
replaced by 1.5 ml Opti-MEM. After 20 min incubation, the lipofectamine-DNA 
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solution was carefully applied to the cells and incubated over night at 37 °C. 
Supernatant was then removed and cells were detached and transferred to 10 cm 
tissue culture plates with culture medium. For selection, zeocin was added after 4 h 
to a final concentration of 300 µg/ml. Upon successful selection, zeocin concentration 
was reduced to 50 µg/ml.  
2.5 Expression and purification of recombinant proteins 
2.5.1 Periplasmic protein expression in E.coli TG1 
2 l of TY medium containing ampicillin and 0.1 % (w/v) glucose were inoculated 
1:100 from an over night culture of pAB1 transformed E.coli TG1 and shook at 37 °C 
until reaching OD600 0.8. The protein expression was induced by the addition of IPTG, 
followed by 3 h shaking at room temperature. Cells were harvested (6000 g, 10 min, 
4 °C) and cell pellet was resuspended in 100 ml resuspension buffer. From now, all 
steps were performed on ice and with chilled liquids and centrifuges. Cell wall lysis 
was accomplished by addition of 10 mg lysozyme and 30 min incubation, followed by 
the addition of MgSO4 to a final concentration of 10 mM to stabilize spheroblasts. 
The supernatant was collected by centrifugation (10,000 g, 30 min) and dialyzed over 
night against 5 l PBS. This solution was subject to purification via IMAC. 
2.5.2 Protein expression in mammalian cells 
After selection, stably transfected cells were expanded to triple flasks (Thermo Fisher 
Scientific, Darmstadt, Germany) in their selection medium. HEK293 cells were 
incubated in RPMI 1640 with 5 % FCS and 50 µg/ml zeocin, pEE14.4 transfected 
CHO-K1 cells with glutamine free RPMI 1640 with 10 % dialyzed FCS and 25 µM 
methionine sulfoximine. Upon reaching 80 % confluence, the medium was changed 
to serum free Opti-MEM, which was collected every other day for up to two weeks. 
All further steps were carried out at 4 °C. Proteins from cell free supernatant 
(centrifugation at 500 g for 5 min) were precipitated by addition of 390 g/l (NH4)2SO4 
addition and stirring for 1 h. Consequently, the protein was harvested by 
centrifugation (11,250 g, 30 min) and the resulting pellet was resuspended in cold 
PBS. Recombinant proteins with His-tag were purified via IMAC, Fc fusion proteins 
with Protein A chromatography.  
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2.5.3 Immobilized metal affinity chromatography 
All proteins containing a His-tag were purified via IMAC, using a batch method, 
where the protein solution is incubated with 0.5 ml of beads for at least 1 h. All steps 
were carried out on ice and with chilled liquids. The beads were subsequently 
collected in a column and unspecifically bound proteins were washed away with at 
least 40 column volumes of IMAC wash buffer, containing 30 mM imidazole. Protein 
content of wash fractions as well as following elution fractions was determined using 
qualitative Bradford assay, where 90 µl of assay solution was mixed with 10 µl of 
fraction. Blue color identified eluted protein. After washing, the specifically bound 
protein was eluted with IMAC elution buffer, containing 250 mM imidazole, in 500 µl 
fractions and main elution fractions (determined by Bradford assay) were pooled for 
dialysis against 5 l PBS over night.  
2.5.4 Protein A chromatography 
All Fc fusion proteins and IgG molecules were purified via Protein A chromatography 
after ammonium sulfate precipitation. All steps were performed on ice and with 
chilled liquids. The resuspended protein was incubated with 250 µl Protein A beads 
over night and loaded onto a purification column. The beads were washed with 40 
column volumes of PBS and protein content of the wash was determined with 
Bradford reagent as described above. Specifically bound proteins were eluted in 
250 µl fractions with Protein A elution buffer (10 mM glycine-HCl pH3) and 
neutralized with 25 µl Protein A neutralization buffer (1 M Tris-HCl pH8). Main elution 
fractions were pooled and dialyzed against 5 l PBS over night. 
2.6 Biochemical characterization 
2.6.1 Protein concentration 
The concentration of all proteins was determined with a spectrophotometer 
(NanoDrop), based on the absorbance of tryptophan and tyrosine residues at a 
wavelength of 280 nm. The molar extinction coefficient ε [l/(mol x cm)] and molecular 
weight (MW [g/mol]) were calculated by the online tool ‘ProtParam’ and the 
concentration was computed as follows, where b [cm] represents the path length: 
 
  c [µg/ml] = OD280 x MW / (ε x b) 
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2.6.2 SDS-PAGE 
In order to determine integrity and purity of the recombinant proteins, SDS-PAGE 
analysis was performed. Samples were mixed with 5 x reducing or non-reducing 
Laemmli buffer and boiled at 94 °C for 5 min. Depending on the molecular mass of 
the protein, different acrylamide concentrations were used when preparing the gels 
(Table 2-8). Samples and molecular mass standard were applied to the precast 
polyacrylamide gel, which was then run for 1 h at 40 mA. After boiling in deionized 
water to remove residual salt and detergent, the gel was incubated with Coomassie 
staining solution for more than 1 h and destained over night in water.  
 
Table 2-8: Polyacrylamide gels for SDS-PAGE 
 
Substance Stacking gel Separating gel 
5 % 10 % 12 % 
dH2O 2.1 ml 2.95 ml 2.45 ml 
30 % Acrylamide mix 500 µl 2.5 ml 3 ml 
1.5 M Tris-HCl pH8.8 - 1.9 ml 1.9 ml 
1 M Tris-HCl pH6.8 380 µl - - 
10 % (w/v) SDS 30 µl 75 µl 75 µl 
10 % APS 30 µl 75 µl 75 µl 
TEMED 5 µl 5 µl 5 µl 
 
2.6.3 Deglycosylation of proteins 
10 µg of glycosylated protein were diluted in 50 µl PBS and denatured for 5 min at 
94 °C. After reaching room temperature, 2 U of N-glycosidase F, O-glycosidase and 
neuraminidase were added and incubated over night at 37 °C. The next day, 
samples were diluted with 5 x Laemmli buffer and boiled, followed by SDS-PAGE 
analysis together with untreated samples.  
2.6.4 Size exclusion chromatography 
High performance liquid chromatography was performed using size exclusion 
columns for the determination of purity and integrity of the purified proteins. 20 µl of 
protein sample with a concentration ranging from 0.3 to 0.5 mg/ml were injected at a 
PBS mobile phase flow rate of 0.5 ml/min. The following standard proteins were used 
for calculation of molecular mass and hydrodynamic radius: thyroglobulin (669 kDa, 
8.5 nm), apoferritin (443 kDa, 6.1 nm), bovine γ globulin (158 kDa, 5.3 nm), 
β-amylase (200 kDa, 5.4 nm), bovine serum albumin (67 kDa, 3.55 nm), ovalbumin 
  
Materials and methods 
 
  
42 
(44 kDa, 3.2 nm), carbonic anhydrase (29 kDa, 2.35 nm) and cytochrome c 
(12.5 kDa, 1.77 nm).  
2.6.5 Thermal stability 
The melting point of proteins was determined by thermal denaturation via the 
ZetaSizer Nano ZS. 100 µg of recombinant protein in 1 ml PBS were sterile-filtered 
into a quartz cuvette. The temperature at which the protein starts to aggregate was 
determined by the increase of the mean count rate of dynamic laser light scattering 
and defined as the melting point. Hereby, the temperature was raised in 1 °C 
intervals from 35 to 92 °C with 2 minutes equilibration time.  
2.7 Quartz crystal microbalance 
Affinities of the IgBD fusion proteins towards immunoglobulins and fragments were 
determined via quartz crystal microbalance, using the Attana Cell A200 instrument. 
Human and mouse full-length immunoglobulins, Fab fragments or Fc fragments were 
immobilized via the amine coupling kit (EDC + sNHS, Attana AB, Stockholm, 
Sweden) on the surface of low nonspecific-binding carboxyl chips in a density that 
resulted in a frequency change of 70 – 90 Hz. All measurements were performed at 
25 °C with a flow-rate of 25 µl/min of PBST (0.1 %) pH7.4 or pH6. Regeneration of 
the binding was performed twice with 10 mM glycine-HCl pH3 for 30 sec. After every 
second measurement a buffer injection was performed to determine the baseline, 
which was subsequently subtracted from the neighboring measurements. Proteins 
were injected in random order and a two-fold dilution series, with the highest 
concentration of 1 µM for the scDb-IgBD fusion proteins and 2 µM for the scFv-IgBD 
fusion proteins. Data were analyzed with the Attana evaluation software (Version 
3.3.4) and TraceDrawer 1.6, using a one-to-two binding model to determine the 
binding parameters. 
 
The interaction of the Fc fusion proteins with the mouse FcRn were also determined 
via QCM, using PBST (0.1 %) pH6 or pH7.4 as running buffer (25 µl/min) at 37 °C. 
The FcRn was immobilized via the streptavidin coupling kit on biotinylated sensor 
chip (Attana AB, Stockholm, Sweden) resulting in a frequency shift of 50 Hz. The 
highest analyte concentration was 100 nM for the Fc fusion proteins and 1 µM for the 
scDb-CH2 and two-fold dilution were prepared. PBST (0.1 %) pH7.4 was used for the 
  
Materials and methods 
 
  
43 
regeneration of the Fc fusion proteins, 20 mM glycine-HCl pH1.95 for the scDb-CH2. 
All other conditions were identical to the previously described method.  
2.8 Enzyme-linked immunosorbent assay 
In order to determine the half-maximal binding or the concentration of recombinant 
protein in a sample, CEA-binding ELISA was performed for all scDb, scFv or Fc 
fusion proteins. CEA was coated over night with a concentration of 3 µg/ml in 100 µl 
PBS per well of a 96-well plate. The next day, remaining binding sites were blocked 
with MPBS, which was also used for adjacent dilutions of samples and detection 
antibodies. Binding was also determined in the presence of excess amounts of 
human IgG (100 µg/ml), which was preincubated with the samples in MPBS. After 2 h 
of blocking, 100 µl of diluted samples in duplicates were added to the plate and 
incubated for 1 h. For the removal of unbound protein, the plates were washed twice 
with PBST (0.1 %) and once with PBS. Detection of His-tagged proteins was 
performed with 100 µl HRP coupled anti-His-tag antibody (1:2000) and 
anti-huIgG-HRP was used 1:5000 for the detection of Fc fusion proteins (Table 2-1). 
Another washing step was performed after 1 h incubation of the detection antibody. 
Finally, the ELISA was developed using 100 µl ELISA developing solution (100 mM 
NaOAc buffer pH6, 0.1 mg/ml TMB, 0.006 % H2O2). The enzymatic reaction was 
stopped upon addition of 50 µl ELISA stop solution (2 N H2SO4). The absorbance 
was measured at 450 nm in an ELISA reader. Data were fitted with GraphPad Prism 
software (La Jolla, USA) from three independent binding curves. 
 
The capability of phages to bind to immunoglobulins and fragments thereof was also 
determined via ELISA. The procedure was similar to the previously described 
protocol with following modifications: 1 µg/ml of immunoglobulins was coated over 
night and detection was performed with anti-M13-HRP antibody.  
2.9 Flow cytometry 
2.9.1 Flow cytometry 
The binding of the scDb-IgBD fusion proteins towards CEA and CD3 on the cell 
surface was investigated in a flow cytometric approach using CEA bearing LS174T 
cells and CD3 positive peripheral blood mononuclear cells purified from the buffy 
coat of healthy donors. Cells were detached from tissue culture flasks as described 
previously, centrifuged and resuspended in PBA to achieve a concentration of 
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2 x 106 cells/ml. All steps were subsequently performed on ice and with chilled liquids 
and centrifuges. All centrifugation steps were performed with 500 g for 5 minutes. 
The scDb-IgBD fusion proteins were diluted in PBA to a concentration of 1 µM, either 
in the absence or presence of 100 µg/ml huIgG. PBMCs were preincubated with 
100 µg/ml huIgG for 15 min to block Fcγ receptors in order to prevent unspecific 
binding of the detection antibody. 100 µl of cell suspension per well were transferred 
to a U-shaped 96-well plate and supernatant was removed after centrifugation. The 
cell pellets were resuspended in the samples and incubated for 2 h. Supernatant was 
again removed after centrifugation and cells were washed twice with 150 µl PBA. The 
cells were incubated with 1:150 diluted anti-His-tag antibody conjugated with 
phycoerythrin for 2 h in the dark and subsequently washed twice with 150 µl PBA. 
Finally, cells were analyzed via the MACSquant Analyzer 10 (Milteny, Bergisch 
Gladbach, Germany) using channel B2. Data were fitted with GraphPad Prism 
software (La Jolla, USA) from three independent binding curves. 
2.9.2 Purification of peripheral blood mononuclear cells 
PBMCs were isolated from the buffy coat of healthy donors provided by the 
Katharinenhospital (Stuttgart, Germany). The buffy coat was diluted in RPMI 1640 to 
a total volume of 240 ml. 30 ml thereof were carefully added to 10 ml Ficoll per tube, 
followed by centrifugation (800 g, 20 min, without brake). The resulting interphase 
was collected and diluted in RPMI 1640 to 40 ml and centrifuged (645 g, 15 min). 
The cell pellet was resuspended in RPMI 1640 and washed twice by centrifugation 
(200 g, 10 min) to remove residual platelets. For storage, cells were frozen in FCS 
containing 10 % DMSO in an isopropanol containing cryobox at -80 °C until usage.  
2.10 Serum stability 
Serum stability was determined for the Fc fusion proteins. The recombinant proteins 
were diluted to a final concentration of 200 nM in 50 % mouse serum and incubated 
at 37 °C for 0, 1 or 7 days and immediately frozen at -20 °C. The content of intact 
protein was determined by CEA-binding ELISA as described above. The samples 
were diluted to their previously determined EC50 value and concentrations were 
determined by interpolation from a standard curve.  
2.11 Interleukin release 
Carcinoembryonic antigen positive LS174T cells were seeded in a 96-well cell culture 
plate (105 cells per well in 100 µl culture medium). Additionally, purified PBMCs were 
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thawed and placed on tissue culture plates over night. The next day, supernatant 
was removed and the LS174T cells were incubated with serial dilutions of scDb-IgBD 
fusion proteins starting at a final concentration of 31.6 nM in RPMI 1640 and 10 % 
FCS. The fusion proteins were incubated with or without 100 µg/ml huIgG (final 
concentration) prior to the addition to the LS174T cells. After 1 h binding at 37 °C, 
2 x 105 PBMCs that were not attached to the plastic surface were added in each well 
and incubated at 37 °C. 24 h later, the tissue culture plate was centrifuged (500 g, 
5 min) and the cell-free supernatant was collected and frozen for further analysis via 
the IL-2 sandwich ELISA kit according to manufacturer’s protocol.  
2.12 EPO dependent proliferation 
UT-7/EPO cells were starved over night in IMDM with 10 % FCS, but without EPO. 
On day 0, 5000 cells per well were seeded into a flat bottom tissue culture 96-well 
plate. Dilutions of huEPO-IgBD proteins were incubated with or without an excess of 
huIgG (100 µg/ml) prior to addition to the cells. The tissue culture plate with a total 
volume of 100 µl per well was then incubated for 4 days at 37 °C. In order to 
determine the proliferative potential of the huEPO-IgBD fusion proteins, an MTT 
assay was performed. 10 µl of MTT were added to the cells and enzymatic reduction 
reaction of the thiazol blue tetrazolium bromide was carried out for 2 h at 37 °C. The 
reaction was stopped by adding 90 µl of MTT lysis buffer and shaking for 3 h at 37 °C, 
to dissolve the converted formazan. By measuring absorption at 570 and 660 nm in 
the ELISA reader, the relative amount of proliferating cells could be determined. Data 
were fitted with GraphPad Prism software (La Jolla, USA) from three independent 
binding curves. 
2.13 Pharmacokinetics 
Animal care and all experiments performed were in accordance with federal 
guidelines and have been approved by university and state authorities. Female CD1 
mice of 6-12 weeks (25-35 g) received one intravenous injection of 25 µg 
recombinant protein in a total volume of 150 µl. Blood samples (50 µl) were collected 
from the tail vein at 3 min, 30 min, 1 h, 2 h, 6 h, 1 day, 3 days and 7 days and 
immediately incubated on ice. Serum was separated by centrifugation (13,000 g, 
20 min, 4 °C) and stored at -20 °C. Serum concentration of CEA-binding scDb-IgBD, 
scFv-IgBD and Fc fusion proteins was determined by ELISA (as explained above) 
and normalized to the first time point (3 min). Concentration of huEPO-IgBD fusion 
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proteins was obtained by EPO dependent proliferation of UT-7/EPO cells as 
described above. Pharmacokinetic parameters (initial and terminal half-life and area 
under the curve) were calculated using Excel.  
2.14 Pharmacodynamics 
Animal care and all experiments performed were in accordance with federal 
guidelines and have been approved by university and state authorities. 20 µg of 
huEPO and 26.7 µg of huEPO-IgBD fusion proteins (due to the increased size of the 
IgBD fusion proteins) and the corresponding amount of Aranesp (3.3 µg, calculated 
from the bioactivity in UT-7/EPO proliferation) in a total volume of 100 µl were 
injected intravenously into female CD1 mice (6 weeks, 25 g, groups of 7 animals). 
Blood samples were collected at day 0, 3, 7, 10, 14, 17 and 21 from the tail vein with 
heparinized microhematocrit tubes (20 µl) to prevent clotting. Samples were diluted 
1:500 in water and hemoglobin concentration was determined via hemoglobin assay 
kit, according to manufacturer’s protocol, based on colorimetric conversion and 
measurement in the ELISA reader at 400 nm.  
2.15 Statistical analysis 
All in vitro values are shown as mean and the corresponding standard deviation. 
Likewise the pharmacokinetic experiments are displayed with mean and standard 
deviation, only the hemoglobin concentration was depicted as mean and standard 
error. Significances were always calculated with GraphPad prism one-way Anova 
with Tukey’s post-test. * represents a p-value below 0.05, ** below 0.01 and *** 
below 0.001. 
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3 Results 
3.1 New domains from Streptococcus Protein G 
The Streptococcus Protein G encloses three domains that are capable of high affinity 
binding to Immunoglobulin G, namely C1, C2 and C3 (Akerström and Björck 1986). 
These domains possess two different binding sites on an IgG molecule, one located 
at the CH1 domain of the Fab arm and the other at the interface of CH2 and CH3 
overlapping with the binding site of the neonatal Fc receptor (Figure 3-1) (DeLano et 
al. 2000). In an acidified endosome, an immunoglobulin-binding domain (IgBD) 
bound to the Fc part could possibly interfere with the FcRn and prevent the recycling. 
For that reason, we identified amino acids that are responsible for binding to the Fc 
and Fab part from the crystal structures of the homologous domain SpGC2 bound to 
the Fc part (Sauer-Eriksson et al. 1995) and the domain SpGC3 together with the Fab 
fragment (Derrick and Wigley 1994). Thus, we endeavored to generate mutants of 
SpGC3 that selectively bind to the Fc or Fab arm of an IgG molecule.  
3.1.1 Generation of a Fab and Fc fragment specific IgBD 
In order to create an IgBD that specifically binds to the Fab fragment of an IgG 
molecule, the binding to the Fc part had to be disrupted by converting three amino 
acids located in the α-helix of SpGC3 into alanines (SpGC3Fab: Glu27, Lys28, Lys31).  
 
 
Figure 3-1: Fab and Fc binding sites in SpGC3 
A) Alignment of the different Protein G derived IgBDs as well as the mutated variants for specific 
binding. Arrows indicate the position of β-strands, the cylinder represents the α-helix. (Derrick and 
Wigley 1994; Sauer-Eriksson et al. 1995) B) Schematic model of the genetic composition of an 
scDb-IgBD. The Ig kappa leader is represented by “L”, the hexahistidyl-tag by “H”. C) Crystallized 
structure of SpGC3 domain with the Fab binding site highlighted in blue, red and green and the Fc 
binding amino acids in orange. 
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The major binding site for the CH1 domain lies on the opposite site of the helix and is 
predominantly composed of β-strands. Analogously, three amino acids of that binding 
site were substituted by alanines (SpGC3Fc: Thr11, Lys13, Glu15). Furthermore, the 
homologue domain SpGC2, differing in 4 amino acids from SpGC3, was included in the 
study. The IgBDs were fused C-terminally to a bispecific single-chain diabody (scDb) 
directed against the carcinoembryonic antigen (CEA) and CD3. For detection and 
purification, a hexahistidyl-tag was endowed at the very C-terminus. The fusion 
proteins were stably transfected into HEK293 cells and purified from serum-free cell 
culture supernatant by immobilized metal affinity chromatography after protein 
precipitation with ammonium sulfate. The protein integrity was verified via 
SDS-PAGE analysis as well as size exclusion chromatography (Figure 3-2). All 
fusion proteins showed clear bands corresponding to their molecular mass of roughly 
60 kDa and single peaks with hydrodynamic radii between 2.9 and 3.3 nm (Table 
3-2).  
 
 
Figure 3-2: Size determination of purified scDb-fusion proteins 
A) 3 µg of purified scDb or scDb-IgBD fusion protein per lane were applied to a 12 % PAA-gel under 
reducing conditions. Lane 1: scDb, 2: scDb-SpGC3, 3: scDb-SpGC3Fab, 4:scDb-SpGC3Fc, 5: scDb-SpGC2. 
B-F) 20 µl of 0.5 mg/ml scDb-IgBD fusion proteins were analyzed for their purity and integrity via size 
exclusion chromatography on a Yarra SEC-2000 column, with PBS as liquid phase. Dashed lines 
represent the retention time of standard proteins with their molecular masses indicated above the lines.  
 
  
Results 
 
  
49 
3.1.2 In vitro characterization of new IgBDs 
The binding properties of the IgBDs towards immunoglobulins and fragments thereof 
were investigated by quartz crystal microbalance (QCM) measurements via the 
Attana Cell A200 system. For this purpose, human and mouse serum IgG as well as 
Fab or Fc fragments were chemically immobilized on the surface of sensor chips and 
binding was determined by a frequency shift upon applying the soluble scDb-IgBD 
fusion proteins. As seen in a previous study (Hutt et al. 2012), the unmodified SpGC3 
domain bound strongly to human and mouse IgG and in accordance to the literature 
both the Fab and the Fc part (Derrick and Wigley 1994; Sauer-Eriksson et al. 1995) 
(Figure 3-3 and Table 3-1). This could be confirmed for neutral conditions as well as 
at pH6. By identifying the amino acids that are responsible for binding to the Fc part 
and converting them to alanines, we were able to generate the mutant SpGC3Fab, 
which still showed strong binding to human and mouse IgG and Fab, but no or only 
minor binding was detected towards the Fc fragments at neutral pH. Of note, the 
affinity towards the Fab fragments was maintained or even slightly enhanced at 
acidic and physiological settings with below 100 nM for all conditions (Table 3-1). On 
the other side, the affinity to the full-length IgG could not be completely conserved, 
still showing an affinity of 120 nM and 61 nM to human and mouse IgG, respectively. 
Interestingly, the SpGC3Fab domain was able to bind to as well the human as the 
mouse Fc part to some extent under acidic conditions. All binding profiles revealed 
biphasic interaction curves, presumably due to the heterogeneity of the 
immunoglobulin preparations. Therefore, all dissociation constants were determined 
with a biphasic fit. The domains SpGC3Fc and SpGC2 displayed binding kinetics that 
were comparable with the ones determined for the SpGC3 domain and with 
dissociation constants in a similar range. Taken together, the amino acid 
substitutions of SpGC3Fab (E27A, K28A, K31A) specifically eliminated the binding of 
the domain to the Fc part, at least under neutral conditions. More importantly, the 
binding to the Fab fragment was sustained.  
 
All scDb-IgBD variants showed dose-dependent binding to CEA in ELISA with 
comparable EC50 values in the low or even sub-nanomolar range (Figure 3-4 and 
Table 3-2). Without IgG being present during the binding reaction, all fusion proteins 
displayed similar binding curves. Excess amounts of IgG in the surrounding medium 
did not alter the behavior of the scDb or the scDb-SpGC3Fab, but the fusion to either 
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the wild-type domains SpGC3 and SpGC2 or SpGC3Fc resulted in a lower binding to 
CEA. The EC50 values of these constructs that are able to bind to the Fc part are 
shifted significantly by a factor of 5 to 10, compared to the unmodified scDb as well 
as to the scDb-SpGC3Fab.  
 
Table 3-1: Affinities of IgBDs towards immunoglobulins and fragments  
 
 
pH 
human mouse 
 IgG Fab Fc IgG Fab Fc 
 KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 
SpGC3 
7.4 3 38 159 663 6 17 33 593 118 1100 79 926 
6 2 33 95 667 1 28 27 406 130 874 53 858 
SpGC3Fab 
7.4 120 983 88 969 - - 61 1030 96 1620 - - 
6 169 1520 83 753 767 896 54 822 93 826 38 414 
SpGC3Fc 
7.4 2 31 74 688 3 52 28 405 112 1860 1710 1870 
6 19 151 76 58 94 526 50 850 61 1050 48 474 
SpGC2 
7.4 1 26 42 1030 4 12 146 794 54 959 33 648 
6 55 525 42 426 125 803 671 857 75 398 34 389 
- no binding detected KDs in [nM] 
 
 
Figure 3-3: Specificity in immunoglobulin binding 
Two-fold serial dilutions of scDb-IgBDs in random order were injected into the Attana QCM system. All 
measurements were performed at pH7.4. The starting concentration was 1000 nM, except for the 
following conditions: scDb-SpGC3 was injected with 250 nM for huIgG, 40 nM for huFc, 500 nM for 
moIgG, 1500 nM for moFab, 1280 nM for moFc. scDb-SpGC3Fc was injected with 250 nM for huIgG. 
 
The binding properties of the scDb-moiety were also examined in a flow cytometric 
approach, using CEA bearing LS174T cells and CD3 positive PBMCs to determine 
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whether the IgBD impacts the cellular binding of the scDb (Figure 3-5 and Table 3-2). 
The CEA binding on cells was comparable to the binding in the ELISA study with 
similar EC50 values around 1 nM in the absence of IgG for all constructs. Interestingly, 
unlike in the ELISA, the EC50 values of scDb-SpGC3 and scDb-SpGC3Fc hardly 
changed with excess IgG, similar to the unmodified scDb and scDb-SpGC3Fab. Next, 
the binding to the CD3 was investigated, which is located on the surface of T-cells, a 
subpopulation of purified PBMCs. The binding profile of scDb-SpGC3 and 
scDb-SpGC3Fc already differed from the unmodified scDb and scDb-SpGC3Fab without 
the excess of IgG, causing a 4 to 5-fold weaker binding (3.4 and 2.2 nM, compared to 
0.6 nM). Again, no negative impact of IgG was observed for the scDb and 
scDb-SpGC3Fab, but especially the scDb-SpGC3 was strongly influenced resulting in 
an EC50 value of about 26 nM indicating a more than 40-fold decreased binding 
towards CD3 in the presence of IgG than the scDb alone.  
 
Table 3-2: Characterization of scDb-IgBD fusion proteins 
 
 
M 
[kDa] 
Sr 
[nm] 
ELISA EC50 FACS EC50 FACS EC50 
 CEA [nM] CEA [nM] CD3 [nM] 
 - IgG + IgG - IgG + IgG - IgG + IgG 
scDb 52.9 2.6 0.7 0.7 1.0 1.1 0.5   0.6 
scDb-SpGC3 59.6 3.2 0.4 3.4 1.2 2.1 3.4 26.3 
scDb-SpGC3Fab 59.5 3.0 0.3 0.4 0.7 1.0 0.6   0.6 
scDb-SpGC3Fc 59.5 3.3 0.3 3.2 0.8 1.5 2.2   7.6 
scDb-SpGC2 59.6 2.9 0.4 1.7 n.d. n.d. n.d. n.d. 
n.d. not determined 
 
 
Figure 3-4: CEA-binding ELISA 
Binding of scDb-IgBD fusion proteins to CEA was investigated by ELISA in the absence (A) or 
presence (B) of 100 µg/ml huIgG during the binding reaction. Serial dilutions of scDb-IgBD fusion 
proteins were applied to immobilized CEA on ELISA plates. The fusion proteins were detected via 
HRP coupled anti-His-tag antibody.  
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Figure 3-5: Flow cytometry 
Binding of CEA and CD3 by scDb-IgBD fusion proteins on the surface of cells was determined with 
CEA bearing LS174T cells (A and C) and CD3 positive PBMCs (B and D) in the absence (A and B) or 
presence (C and D) of 100 µg/ml huIgG during the binding reaction. In order to avoid unspecific 
binding of the PE-labeled anti-His-tag detection antibody, the Fc receptors on the surface of purified 
PBMCs were blocked with 100 µg/ml huIgG prior to the addition of the scDb fusion proteins.  
 
After the binding studies, the functionality of the scDb moiety to crosslink T-cells to 
antigen bearing cells and subsequently activate them was examined in an 
interleukin-2 release assay. The colon carcinoma cell line LS174T that is positive for 
the tumor-associated antigen CEA (Mayer et al. 1999) was incubated with PBMCs as 
effector cells with different concentrations of the scDb-IgBD fusion proteins. All of the 
scDb fusion proteins were able to stimulate effector T-cells to produce IL-2 in a dose 
dependent manner, resulting in a maximal secretion between 3 and 10 nM of 
scDb-IgBD (Figure 3-6). In the absence of excess amounts of human IgG, all scDb 
fusion proteins exhibited the same activation level as the unmodified scDb. 
Conversely, performing the assay in the presence of huIgG leads to a reduction in 
the secretion of IL-2 for the scDb-SpGC3 and scDb-SpGC3Fc. The scDb-SpGC3Fab is 
the only IgBD-fusion protein that was able to stimulate the T-cell response in the 
same manner as the unmodified scDb in the presence of human IgG.  
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Figure 3-6: scDb mediated IL-2 release through crosslinking of target and effector cell 
LS174T colon carcinoma cells were preincubated with serial dilutions of scDb-IgBD fusion proteins. 
Purified PBMCs were added and enclosed T-cells subsequently crosslinked to the target cell. 
Activation was determined via IL-2 ELISA from cell free supernatant. The assay was performed in the 
absence (open symbols) or presence of 100 µg/ml huIgG (filled symbols).  
 
3.1.3 In vivo characterization of new scDb-IgBDs 
The pharmacokinetic properties were investigated after a single injection of 25 µg of 
fusion protein intravenously into female CD1 mice. The serum concentration was 
determined in a CEA-binding ELISA. The unmodified scDb molecule was rapidly 
cleared from the bloodstream, reaching the limit for detection after only 6 h. This 
resulted in a terminal half-life of 1.3 h (Figure 3-7 and Table 3-3). By the fusion of the 
SpGC3Fab domain, we could elongate the half-life to 15.1 h, going along with a more 
than 18-fold enhancement in the area under the curve. Nonetheless, the 
pharmacokinetic properties of scDb-SpGC3 with a terminal half-life of 24.3 h could not 
be reached. The scDb-SpGC2 obtained a terminal retention time of 17.3 h and is only 
marginally better than the scDb-SpGC3Fab although it is able to bind to the Fc part. On 
the other side, the scDb-SpGC3Fc mutant exhibited a terminal half-life of 32.5 h and is 
even better than the unmodified SpGC3 fusion protein. These finding are all reflected 
in the bioavailability of the molecules determined as area under the curve. The 
elongation in half-life strongly correlated with an increase in the AUC, with the 
scDb-SpGC3 augmenting the AUC by a factor of more than 33 and the SpGC3Fc fused 
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scDb even 38-fold. However, the fusion of the SpGC3Fab domain also resulted in a 
more than 18-fold amelioration of the bioavailability of the scDb moiety. 
 
 
Figure 3-7: Pharmacokinetic properties of scDb-IgBD fusion proteins 
25 µg of purified scDb-IgBD fusion protein were injected intravenously in to female CD1 mice. Blood 
samples were collected at indicated time points and serum concentration was determined using a 
CEA-binding ELISA. Concentrations were normalized to the value determined at 3 minutes.  
 
Table 3-3: Pharmacokinetic properties of the scDb-IgBD fusion proteins 
 
 Initial half-life [h] Terminal half-life [h] AUC [%h] 
scDb 0.4 ± 0.1   1.3 ± 0.2   56 ± 15 
scDb-SpGC3 3.8 ± 1.4 24.3 ± 6.8 1879 ± 279 
scDb-SpGC3Fab 3.7 ± 2.7 15.1 ± 4.8 1027 ± 506 
scDb-SpGC3Fc 5.3 ± 1.0 32.5 ± 7.2 2146 ± 243 
scDb-SpGC2 4.3 ± 0.9 17.3 ± 4.1 1364 ± 332 
 
3.2 Affinity maturation of SpGC3Fab  
A plausible reason for the shortened half-life of the scDb-SpGC3Fab might be the loss 
of affinity towards the whole IgG molecule and thus an increased clearance. 
Therefore, we attempted to increase the affinity towards the CH1 domain in order to 
get the same protection from renal filtration and to avoid the possible interference 
with the FcRn during the recycling process. A phage display approach was chosen to 
fulfill this requirement and the amino acids that were identified to contribute to the 
CH1 binding were randomized.  
3.2.1 Phage display selection of affinity maturated SpGC3Fab variants 
Four different libraries were generated, three of them with site-directed mutagenesis 
via degenerate primers comprising a set of 4 amino acid substitutions each, the 
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fourth via error prone PCR over the whole SpGC3Fab domain (Figure 3-8). For the 
libraries with site-directed mutagenesis, 4 amino acids were substituted with all 20 
possible amino acids, meaning a diversity of 204 = 160,000 mutants. To cover the full 
diversity of the library, at least a ten-fold excess of different mutants in the generation 
of the library is needed. Having a size of 2 to 8 x 106 clones, all libraries met this 
criterion and were subsequently rescued for phage display. Library 4 was generated 
using a random mutagenesis approach for the whole sequence of the SpGC3Fab 
domain. This resulted in a library comprising of 25 x 106 clones, with a rate of about 
2.4 nucleotide exchanges per 168 nucleotide long sequence and an average of 1.5 
amino acid substitutions per domain.  
 
All libraries were selected over three to four rounds, either by immunotube selection 
against mouse Fab fragment or by incubation with biotinylated mouse Fab fragment 
and subsequent pull-down with streptavidin-coated beads with increasing stringency. 
In order to reveal the progress of the selection, polyclonal phage ELISA was 
conducted to see the enrichment of high affinity phages (Figure 3-9). After selection, 
single clones were picked and a small-scale rescue in a 96-well plate was performed 
to screen for the best binders. Top candidates were sequenced and subject to further 
investigation and subcloning as scDb-fusion proteins.  
 
 
Figure 3-8: Libraries for phage display 
Three different libraries were generated with 4 amino acid substitutions into all 20 possible amino 
acids (Library 1: blue, library 2: red, library 3: green). Library 4 was derived from a random 
mutagenesis approach via error prone PCR, including the whole SpGC3Fab domain.  
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Figure 3-9: Polyclonal phage ELISA 
The binding of the phages from the rescued library 3 was compared to the third selection round 
against biotinylated mouse Fab fragment. Similar amounts of precipitated phages were incubated with 
immobilized immunoglobulins and Fab fragments from mouse and human and detection was carried 
out with an anti-M13 HRP-conjugated antibody. 
 
The binding of the resulting SpGC3Fab mutants towards IgGs and fragments thereof 
was examined by quartz crystal microbalance measurements of the scDb fusion 
proteins to immobilized IgGs and fragments (Table 3-4). Most of the new mutants 
showed similar binding affinities as the wild-type. The two selected clones that 
exhibited the best binding properties, especially to mouse Fab fragment, were 
SpGC3FabRR and SpGC3FabK10Q,HNS, originating from library 3 and 4, respectively. 
In particular, their affinity under acidic conditions was augmented, for the murine Fab 
(19 and 25 nM, compared to 93 nM of SpGC3Fab) and the whole IgG molecule (34 and 
1 nM, compared to 54 nM of SpGC3Fab), but their binding to the Fc part was not 
altered. They both displayed a marginally enhanced affinity at neutral pH towards the 
whole mouse IgG and Fab fragment, but as the SpGC3Fab wild-type no binding to the 
mouse Fc part. Concerning the binding towards the human equivalents, SpGC3FabRR 
revealed the highest affinities towards the Fab fragment and full-length IgG molecule 
at acidic conditions with 40-50 nM. The binding to human IgG at pH7.4 was also 
more than 4-fold improved compared to the SpGC3Fab domain and no affinity towards 
the human Fc part at physiological pH could be detected. Since the mutation E15V 
was discovered frequently in the selected clones from library 4, this mutant was 
combined with the SpGC3FabRR for SpGC3FabRR,E15V. This arrangement resulted in 
the lowest dissociation constant for mouse Fab at neutral pH (28 nM) and is also 
amongst the top candidates for binding to mouse IgG with a minor loss of affinity 
under acidic conditions. Interestingly, the binding to mouse Fc was restored to some 
extent at pH7.4, still showing a similar affinity as the wild-type at pH6. The affinity of 
the SpGC3FabRR,E15V domain towards human immunoglobulin and Fab fragment 
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was decreased under neutral and acidic conditions compared to SpGC3FabRR, with a 
complete loss of binding to the Fc part. 
 
Table 3-4: Affinities of phage display derived SpGC3Fab mutants 
 
scDb-
SpGC3Fab 
pH 
human mouse 
Lib IgG Fab Fc IgG Fab Fc 
KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 
wt 
7.4 120 983 88 969 - - 61 1030 96 1620 - - 
- 
6 169 1520 83 753 767 896 54 822 93 826 38 414 
TTR 
7.4 1460 2500 n.d. n.d. n.d. n.d. 207 1660 369 1220 n.d. n.d. 
1 
6 66 1560 n.d. n.d. n.d. n.d. 81 1080 95 1550 n.d. n.d. 
HTM 
7.4 579 2060 n.d. n.d. n.d. n.d. 237 1570 n.d. n.d. n.d. n.d. 
1 
6 328 1080 n.d. n.d. n.d. n.d. 92 1150 n.d. n.d. n.d. n.d. 
K13S 
7.4 127 1730 n.d. n.d. n.d. n.d. 72 889 95 1220 n.d. n.d. 
2 
6 179 1570 n.d. n.d. n.d. n.d. 44 729 147 771 n.d. n.d. 
FRQ 
7.4 94 800 n.d. n.d. n.d. n.d. 87 857 129 775 n.d. n.d. 
3 
6 n.d. n.d. n.d. n.d. n.d. n.d. 48 688 n.d. n.d. n.d. n.d. 
RR 
7.4 29 385 167 1040 - - 55 388 62 413 - - 
3 
6 49 191 43 461 39 227 34 296 19 255 40 289 
T1A,E15Q 
7.4 84 1120 251 1080 - - 61 1440 91 1210 - - 
4 
6 341 727 n.d. n.d. 416 634 60 567 93 618 n.d. n.d. 
E15V 
7.4 89 1000 157 1700 - - 69 838 73 876 - - 
4 
6 610 2060 47 648 517 1540 43 584 66 677 41 371 
E15V,YY 
7.4 123 854 150 1030 - - 40 247 50 342 - - 
4 
6 184 805 147 1270 91 424 14 177 45 241 78 460 
K10Q,HNS 
7.4 159 1330 277 1280 - - 36 380 58 525 - - 
4 
6 122 1070 83 795 19 427 1 233 25 315 75 560 
N35Y 
7.4 92 1120 n.d. n.d. n.d. n.d. 56 880 64 840 n.d. n.d. 
4 
6 n.d. n.d. n.d. n.d. n.d. n.d. 25 579 41 414 n.d. n.d. 
K50Q 
7.4 112 1320 173 1210 - - 65 1160 80 996 - - 
4 
6 695 1280 50 610 596 2050 53 516 90 530 45 462 
RR,E15V 
7.4 326 1570 243 1730 - - 38 177 28 161 106 617 
3+4 
6 118 1080 242 1550 - - 68 205 71 172 38 750 
n.d. not determined - no binding detected wt wild-type Lib Library KDs in [nM] 
 
3.2.2 In vitro characterization of affinity maturated SpGC3Fab mutants 
The antigen binding of all scDb fusion proteins was subsequently examined in an 
ELISA to determine whether the modification of the SpGC3Fab sequence had an 
impact on the functionality of the fusion partner. As seen before, all scDb-IgBDs that 
were derived from the SpGC3Fab domain revealed full binding potential towards CEA 
in the subnanomolar range, independent from the presence of excess amounts of 
human IgG (Figure 3-10, data not shown). Analogous results were seen for the flow 
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cytometry with CEA bearing LS174T cells. Without IgG, the EC50 values were in the 
low nanomolar range and were not changed upon addition of IgG. Only the binding 
curves of scDb-SpGC3 and SpGC3Fc were slightly, but significantly, shifted towards 
lower binding. The binding towards CD3 on cells was also only impacted for 
scDb-IgBDs that can bind strongly to the Fc part. All IgBDs originating from the 
SpGC3Fab domain had similar EC50 values under both conditions.  
 
 
Figure 3-10: CEA-binding ELISA of affinity maturated SpGC3Fab mutants 
All scDb-IgBD constructs were titrated without (A, B, C) or with (D, E, F) 100 µg/ml huIgG to detect the 
binding of the scDb moiety. Binding to CEA was detected in an ELISA (A, D) and on LS174T colon 
carcinoma cells (B, E) via flow cytometry. Binding to CD3 was examined by flow cytometry on PBMCs 
(C, F). The EC50 values were calculated from the resulting binding curves with GraphPad Prism and 
were compared using one-way Anova together with Tukey’s post-test.  
 
The functionality of the new scDb-IgBDs was investigated by an IL-2 release assay 
(Figure 3-11). For each protein a different batch of PBMCs had to be used, but the 
unmodified scDb was always included as a positive control. Therefore, the maxima in 
activation were similar for all scDb-IgBD fusion proteins, only varying due to the 
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activity of the corresponding PBMC batch. The activation went along with the already 
obtained results that the scDb-IgBD variants derived from SpGC3Fab were not 
hindered in their functionality in the presence of excess IgG. Hence, both new fusion 
proteins scDb-SpGC3FabRR and scDb-SpGC3FabRR,E15V stimulated the PBMCs to 
secrete IL-2 in an equivalent manner as the unmodified scDb.   
 
 
Figure 3-11: IL-2 release of affinity maturated SpGC3Fab mutants 
The IL-2 release assay was performed as described above with different batches of PBMCs for 
different proteins. Open symbols represent the scDb-IgBD in the absence of excess IgG, solid 
symbols represent the presence of 100 µg/ml huIgG.  
 
3.2.3 In vitro characterization of scFv-IgBD fusion proteins 
In order to demonstrate the power of the immunoglobulin-binding domains to improve 
the pharmacokinetics for different proteins than the scDb, a set of scFv-IgBD fusion 
proteins was generated and investigated to see the half-life extension effect also on 
molecules that possess half the size of an scDb. The proteins were expressed in 
HEK293 cells and purified via IMAC after ammonium sulfate precipitation. All scFv 
fusion proteins showed single bands at the calculated molecular mass of about 
33 kDa in an SDS-PAGE analysis, both under reducing and non-reducing conditions 
(Figure 3-12). Additionally, the protein integrity and tendency to aggregate was 
determined via size exclusion chromatography. Again, all scFv-fusion proteins eluted 
in one single peak with similar hydrodynamic radii that were smaller than those of the 
corresponding scDb-IgBD fusion proteins (Table 3-6).   
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Figure 3-12: Purification of scFv and scDb-IgBDs 
A) SDS-PAGE analysis was performed under reducing (left) and non-reducing (right) conditions on a 
12 % PAA-gel. Lane 1: scFv; 2: scFv-SpGC3; 3: scFv-SpGC3Fab; 4: scFv-SpGC3FabRR; M: protein ladder 
with molecular masses in kDa. B-G) Size exclusion chromatography was performed to determine the 
integrity of scDb and scFv fusion proteins. Dashed lines represent the retention time of standard 
proteins with their molecular masses indicated above the lines. 
 
3.2.4 In vivo characterization of affinity maturated scFv and scDb-IgBDs 
Ultimately, the pharmacokinetic properties of the affinity maturated SpGC3Fab mutants 
were determined by injection of scDb and scFv fusion proteins into CD1 mice (Figure 
3-13). The variants of SpGC3Fab that arose from library 1 displayed a pharmacokinetic 
profile below that of the scDb-SpGC3Fab, going along with lower terminal half-lives and 
areas under the curve (Table 3-5). The only variant from library 2, SpGC3FabK13S, 
had equal properties in increasing the serum concentration as the wild-type SpGC3Fab 
domain. The domain SpGC3FabRR that already exhibited superior binding properties 
extended the terminal half-life to 47.8 h, which is a more than 36-fold enhancement 
compared to the unmodified scDb and more than 3-fold the half-life of scDb-SpGC3Fab. 
This elongation even exceeded the performance of the scDb-SpGC3 by almost a 
factor of 2 (24.3 h). Moreover, this gain in half-life was also reflected in an 
augmented area under the curve, where the scDb-SpGC3FabRR also had the best 
effect with about twice the area of the scDb-SpGC3Fab and an almost 40-fold raised 
AUC compared to the scDb alone. Besides the scDb, we also used scFvs as model 
molecules and together with the SpGC3FabRR variant the fusion protein experienced 
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the strongest increase in half-life extension (Figure 3-14, Table 3-6). The half-life as 
well as the AUC are both more than 26-fold improved compared to the unmodified 
scFv and slightly better than for the scFv-SpGC3. The remaining domain from library 3 
(SpGC3FabFRQ) and the variants from library 4 were also examined in 
pharmacokinetic studies.  
 
 
Figure 3-13: Pharmacokinetics of affinity maturated SpGC3Fab mutants as scDb fusion proteins 
25 µg of scDb-fusion protein were injected intravenously into female CD1 mice. Blood samples were 
taken at indicated time points and serum concentration was determined via CEA-binding ELISA. 
Concentrations were normalized to the 3 minute value. The affinity maturated mutants from library 1 
and 2 are shown in A), library 3 in B) and library 4 in C) and D). 
 
Table 3-5: Pharmacokinetic properties of affinity maturated SpGC3Fab variants 
 
 Initial half-life [h] Terminal half-life [h] AUC [%h] 
scDb 0.4 ± 0.1   1.3 ± 0.2   56 ± 15 
scDb-SpGC3 3.8 ± 1.4 24.3 ± 6.8 1879 ± 279 
scDb-SpGC3Fab 3.7 ± 2.7 15.1 ± 4.8 1027 ± 506 
scDb-SpGC3FabTTR 2.1 ± 0.7   6.2 ± 1.1   582 ± 322 
scDb-SpGC3FabHTM 3.8 ± 1.5   8.0 ± 1.8   784 ± 123 
scDb-SpGC3FabK13S 1.7 ± 0.3 15.4 ± 4.1 1187 ± 421 
scDb-SpGC3FabFRQ 3.2 ± 2.2   8.7 ± 2.0   994 ± 435 
scDb-SpGC3FabRR 2.1 ± 0.3   47.8 ± 10.3 2228 ± 380 
scDb-SpGC3FabT1A,E15Q 1.6 ± 0.6   8.5 ± 2.4   719 ± 244 
scDb-SpGC3FabE15V 1.5 ± 0.4 19.0 ± 5.0   981 ± 233 
scDb-SpGC3FabE15V,YY 2.5 ± 0.5 14.2 ± 1.8   761 ± 202 
scDb-SpGC3FabK10Q,HNS 4.7 ± 9.8 13.9 ± 2.1 1310 ± 325 
scDb-SpGC3FabN35Y 1.3 ± 0.1   8.4 ± 0.7 614 ± 44 
scDb-SpGC3FabK50Q 1.4 ± 0.1 14.4 ± 1.6 1004 ± 256 
scDb-SpGC3FabRR,E15V 2.7 ± 1.8   67.0 ± 24.4 2843 ± 831 
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Only scDb-SpGC3FabE15V exhibited a slightly longer terminal half-life than 
scDb-SpGC3Fab, all the other mutations did not improve the performance of the fusion 
protein. Combining these results, the new mutant SpGC3FabRR,E15V was generated 
and investigated as fusion partner for the scDb. This domain was able to further 
promote the terminal half-life to 67 h, a more than 50-fold amelioration of the original 
scDb. This strong benefit in half-life was also mirrored in a strongly amplified AUC 
(2843 %h) that is significantly better than the AUC of scDb-SpGC3. 
 
 
Figure 3-14: Pharmacokinetic studies of most improved IgBDs 
25 µg of scDb-IgBDs (A) or scFv-IgBDs (C) were injected intravenously into CD1 mice to determine 
the pharmacokinetic properties. Half-lives and AUC were calculated with Excel and statistical analysis 
was performed with GraphPad Prism as one-way Anova with Tukey’s post-test (B).   
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Table 3-6: Characterization and pharmacokinetics of scFv-IgBDs 
 
 MW [kDa] Sr [nm] Initial half-life [h] Terminal half-life [h] AUC [%h] 
scFv 26.7 2.5 0.2 ± 0.1   0.6 ± 0.2 16 ± 4 
scFv-SpGC3 33.3 2.9 1.2 ± 0.5 13.1 ± 6.1   426 ± 175 
scFv-SpGC3Fab 33.2 2.8 1.0 ± 0.1   4.4 ± 1.6 252 ± 43 
scFv-SpGC3FabRR 33.2 2.8 0.9 ± 0.1 15.7 ± 9.4   458 ± 229 
 
3.3 Deimmunization of SpGC3Fab 
Since the immunoglobulin-binding domains are derived from bacterial proteins, it is 
likely that the immune system will recognize IgBD fusion proteins as foreign and 
direct an immunological reaction. However, the bacterial origin itself is not a reason 
for immunogenicity, since even fully human proteins can cause an immunologic 
response and the generation of anti drug antibodies (Bertolotto et al. 2004; Radstake 
et al. 2009). The crucial factor for immunogenicity is the recognition and binding of 
the processed peptides to major histocompatibility complex class II molecules on the 
surface of antigen presenting cells. If the therapeutic protein contains such a 
recognition sequence, which is always dependent on the HLA set of the patient, it 
can cause the production of anti-drug antibodies.  
3.3.1 Identification and elimination of possible T-cell epitopes 
Therefore, the sequence of SpGC3Fab was analyzed for possible T-cell epitopes. Not 
only sequence, but also structure based prediction methods were used for the 
evaluation of the recognition sites. The methods used have their origin in the 
TEPTIOPE method (Sturniolo et al. 1999), which describes the binding potential of 
9-mer peptides to a rather large set of HLA-DRB1 alleles (MHC class II). This 
scanning was performed for a set of the 8 most frequent HLA class II alleles that 
represent a majority of the complete human population (Gragert et al. 2013; Maiers, 
Gragert, and Klitz 2007). With this computational approach, 9 possible T-cell 
epitopes within the sequence of SpGC3Fab were detected that fulfill the sequential and 
structural requirements to bind to human MHC class II molecules on the surface of 
APCs (Figure 3-15). Additionally, the affinity maturated variant SpGC3FabRR was 
added to the panel for deimmunization as it revealed strongly beneficial 
pharmacokinetic properties. The scanning of the SpGC3FabRR mutant revealed three 
additional possible T-cell epitopes compared to the wild-type SpGC3Fab fragment, two 
of them overlapping in DRB1_0801 and one in DRB1_1301. 
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SpGC3Fab          10        20        30        40        50      
           .         .         .         .         . 
DRB1_0101 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0301 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0401 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0701 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0801 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_1101 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_1301 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_1501 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
 
SpGC3FabRR          10        20        30        40        50      
           .         .         .         .         . 
DRB1_0101 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
DRB1_0301 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
DRB1_0401 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
DRB1_0701 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
DRB1_0801 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
DRB1_1101 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
DRB1_1301 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
DRB1_1501 TTYKLVINGKTLKGETTTKAVDAETAAAAFAQYARRNGVDGVWTYDDATKTFTVTE 
 
Figure 3-15: Predicted HLA-DRB1 epitopes in SpGC3Fab and SpGC3FabRR for the 8 most frequent 
HLA class II alleles in the western population. 
Sequential and structure based prediction algorithms were used to determine possible sites for 
immunogenicity of SpGC3Fab and SpGC3FabRR. Possible anchor sequences of T-cell epitopes are 9 
amino acids long and underlined in red. Blue denotes the corresponding starting position of new or 
overlapping T-cell epitopes.  
 
After identification of the T-cell epitopes, a calculation of which and how many amino 
acid exchanges was necessary to eliminate these epitopes, using amongst others 
the DPDP approach (Parker et al. 2010). One of the main challenges is to abolish as 
many epitopes as possible with a minimal amount of amino acid changes to 
guarantee the functionality of the domain without generating new epitopes. Since 8 of 
the 9 epitopes are located in close proximity, a single amino acid exchange can 
possibly eliminate multiple epitopes. The variants SpGC3FabV6A and SpGC3FabRR 
Y33T,DI1 were selected as example for such a process (Figure 3-16). Starting with 9 
epitopes for SpGC3Fab, the introduction of alanine at position 6 eliminates 4 possible 
epitopes in DRB1_0301, *1101, *1301 and *1501, but also generates one new 
epitope in DRB1_0401, resulting in a final reduction of 3 T-cell epitopes. Combining 
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selected mutations can further reduce the number of epitopes, as presented for 
SpGC3FabRR Y33T,DI1 that has only one possible epitope in DRB1_0401 left. Several 
single amino acid mutations as well as combinations with the highest impact on 
immunogenicity were produced as scFv or scDb fusion protein (Table 3-7).  
 
SpGC3FabV6A          10        20        30        40        50      
           .         .         .         .         . 
DRB1_0101 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0301 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0401 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0701 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_0801 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_1101 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_1301 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
DRB1_1501 TTYKLAINGKTLKGETTTKAVDAETAAAAFAQYANDNGVDGVWTYDDATKTFTVTE 
 
SpGC3FabRR Y33T,DI1   10        20        30        40        50      
           .         .         .         .         . 
DRB1_0101 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
DRB1_0301 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
DRB1_0401 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
DRB1_0701 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
DRB1_0801 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
DRB1_1101 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
DRB1_1301 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
DRB1_1501 TTYELAINGQTLKGETTTKAVDAETAAAAFAQTARRNGVDGVWSYDDATKTFTVTE 
 
Figure 3-16: Deimmunization of SpGC3Fab  
After the identification of possible T-cell epitopes, single or multiple amino acid exchanges were 
applied to the sequence to disrupt a multitude of epitopes without the generation of new epitopes and 
the maintaining of binding activity. Possible anchor sequences of T-cell epitopes are 9 amino acids 
long and underlined in red. Blue denotes the corresponding starting position of new or overlapping 
T-cell epitopes. Substituted amino acids for deimmunization are highlighted.  
 
3.3.2 Characterization of deimmunized IgBD variants in vitro 
All of the newly generated fusion proteins were tested for their binding capability 
towards immobilized mouse IgG in quartz crystal microbalance measurements at 
physiological pH as scFv-IgBD fusion proteins (Table 3-7). Most modified IgBDs with 
single amino acid mutations showed binding to mouse IgG with similar or slightly 
decreased affinity, but two variants, namely SpGC3FabT44S and A48G could even 
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improve the binding to some extent. The combinations of several amino acid 
exchanges all resulted in variants that show less affinity at neutral pH. 
 
For a more detailed analysis, selected mutants were subcloned as scDb-IgBD fusion 
proteins and produced in stably transfected HEK293 cells. An SDS-PAGE analysis 
was performed subsequent to IMAC purification after ammonium sulfate precipitation 
(Figure 3-17). The scDb-SpGC3Fab as well as the single mutants N8D, K10Q and 
T44S displayed one clear band at the expected molecular weight. The deimmunized 
variants with more mutations appeared to have a slightly higher molecular weight, but 
mostly formed also single bands. Due to this change, the functionality of all 
scDb-IgBD fusion proteins was assayed via CEA-binding ELISA with all fusion 
proteins showing a dose dependent binding comparable to the wild-type 
scDb-SpGC3Fab (Data not shown).   
 
 
Figure 3-17: SDS-PAGE analysis of deimmunized scDb-IgBD fusion proteins 
3 µg of purified scDb-IgBD fusion protein per lane were applied to a 12 % polyacrylamide gel. 
M denotes the protein ladder with indicated molecular masses in kDa on the left.                              
Lane 1: scDb-SpGC3Fab; 2: scDb-SpGC3FabDI1; 3: scDb-SpGC3FabDI2; 4: scDb-SpGC3FabDI3;                  
5: scDb-SpGC3FabDI4; 6: scDb-SpGC3FabN8D; 7: scDb-SpGC3FabK10Q; 8: scDb-SpGC3FabT44S;             
9: scDb-SpGC3FabT44S; 10: scDb-SpGC3FabRR Y33T,DI1 
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In order to get a more detailed idea about the binding properties of the deimmunized 
variants, quartz crystal microbalance measurements comprising different immobilized 
immunoglobulins and fragments thereof at physiological and acidic conditions were 
performed. The single mutants N8D, K10Q and T44S exhibited a similar binding 
towards human and mouse IgG and also their fragments. All KD values were in a 
range that was previously measured for the wild-type SpGC3Fab domain, with a 
marginal tendency towards improved affinity for N8D and T44S. No binding to Fc part 
was detectable at neutral pH for any of the fusion proteins, but again the shift 
towards acidic conditions lead to the establishment of a low affinity towards human 
and mouse Fc part as seen before. The variants with multiple mutations 
(SpGC3FabDI1 and DI2) also showed affinity towards mouse IgG at neutral pH, but 
less binding compared to the wild-type domain could be detected (Figure 3-18). Here, 
no affinity could be computed due to the low maximal binding that strongly influenced 
the quality of the fit. The combination of deimmunized and affinity maturated mutant, 
SpGC3FabRR Y33T,DI1, resulted in a somewhat lower affinity towards mouse IgG at 
neutral pH compared to the SpGC3Fab domain (199 nM compared to 61 nM of 
SpGC3Fab), but similar affinity at physiological pH.  
 
Table 3-8: Affinity of deimmunized SpGC3Fab variants to IgG and fragments 
 
scDb-
SpGC3Fab 
pH 
human mouse 
IgG Fab Fc IgG Fab Fc 
KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 KD1 KD2 
wt 
7.4 120 983 88 969 - - 61 1030 96 1620 - - 
6 169 1520 83 753 767 896 54 822 93 826 38 414 
N8D 
7.4 67 6270 79 696 - - 42 1320 75 1290 - - 
6 71 745 93 661 94 843 48 1260 58 624 46 910 
K10Q 
7.4 83 1030 155 1430 - - 71 1550 93 1230 - - 
6 94 1040 137 760 130 1540 36 670 86 591 55 713 
T44S 
7.4 69 1260 293 1180 - - 76 1190 92 1240 - - 
6 88 909 83 595 63 543 37 863 60 426 80 439 
RR Y33T,DI1 
7.4 
n.d. 
199 2970 
n.d. 
6 79 995 
RR 
7.4 29 385 167 1040 - - 55 388 62 413 - - 
6 49 191 43 461 39 227 34 296 19 255 40 289 
-: no binding detected  n.d.: not determined KDs in [nM] 
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Figure 3-18: Affinity of deimmunized scDb-SpGC3Fab variants towards mouse IgG 
The binding kinetics of scDb-SpGC3Fab (A), scDb-SpGC3FabDI1 (B) and scDb-SpGC3FabDI2 (C) towards 
immobilized full-length mouse IgG were determined in a QCM approach at pH7.4. Two-fold serial 
dilutions in random order were applied with a starting concentration of 1000 nM for all fusion proteins. 
3 to 4 binding curves were measured for each concentration.  
 
3.3.3 Pharmacokinetic behavior of deimmunized scDb-IgBD fusion proteins 
Having determined the affinity of the deimmunized fusion proteins towards 
immunoglobulins, their pharmacokinetic behavior in CD1 mice was determined. All 
IgBD fusion proteins were able to improve the pharmacokinetics compared to the 
unmodified scDb molecule alone, meaning that even with numerous amino acid 
exchanges the binding was not completely abolished (Figure 3-19). However, none 
of the tested variants exhibited a terminal half-life that was better than the wild-type 
SpGC3Fab. Although the single mutations exhibited an improved affinity towards the 
whole IgG molecule as well as the Fab fragment, their serum concentration 
decreased more rapidly than the one of scDb-SpGC3Fab. The combination of several 
mutations to decrease the immunogenicity of the immunoglobulin-binding domain 
also improved the performance of the scDb, but the terminal half-life of 
scDb-SpGC3FabDI1 that contained the lowest amounts of T-cell epitopes resulted in 
only 60 % of the wild-type half-life. When combining the SpGC3FabDI1 with the 
deimmunized version of the SpGC3FabRR mutant to SpGC3FabRR Y33T,DI1, a terminal 
half-life of 11.8 h could be achieved, which is about 9-fold as high as for the 
unmodified scDb. The serum concentration at later time points almost reaches the 
concentrations of the SpGC3Fab molecule. This also reflected in the area under the 
curve, which is roughly 10-fold improved compared to the scDb.  
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Figure 3-19: Pharmacokinetics of deimmunized SpGC3Fab variants 
25 µg of purified fusion protein were injected intravenously into CD1 mice. The serum concentration 
for scDb-IgBD fusion proteins with a single mutation (A), multiple mutations (B) and the combination 
with the affinity maturated SpGC3FabRR mutant (C) was determined in a CEA-binding ELISA and 
normalized to the 3 minute value.   
 
Table 3-9: Pharmacokinetic properties of deimmunized SpGC3Fab variants 
 
 Terminal half-life [h] AUC [%h] 
scDb-SpGC3Fab 15.1 ± 4.8   954 ± 389 
scDb-SpGC3FabN8D   8.4 ± 2.0   925 ± 351 
scDb-SpGC3FabK10Q   5.8 ± 2.2   754 ± 310 
scDb-SpGC3FabT44S   7.8 ± 1.0   703 ± 157 
scDb-SpGC3FabDI1   9.1 ± 1.0  464 ± 96 
scDb-SpGC3FabDI2   8.8 ± 0.5   584 ± 193 
scDb-SpGC3FabDI3   7.8 ± 1.1   525 ± 141 
scDb-SpGC3FabDI4   5.9 ± 0.6 235 ± 45 
scDb-SpGC3FabRR   47.8 ± 10.3 2228 ± 380 
scDb-SpGC3FabRR Y33T,DI1 11.8 ± 5.8   559 ± 195 
scDb   1.3 ± 0.2   56 ± 15 
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3.4 Half-life extension of recombinant human erythropoietin 
Already since the 1980s, recombinant human erythropoietin became clinically 
available and was used for numerous purposes. More than 1 million of patients have 
responded effectively to treatment with recombinant huEPO or a derivate (Bunn 
2013). However, a major limitation for therapy with huEPO is the frequency of 
administration that is necessary in order to maintain a therapeutically effective 
concentration (Kontermann 2012). For this reason, half-life extension strategies have 
been applied to huEPO, focusing on the increase of the hydrodynamic radius to 
reduce renal filtration. Exceeding this strategy, the fusion of the immunoglobulin-
binding domains is to reduce lysosomal degradation via binding to IgG and 
subsequent recycling via the FcRn.  
3.4.1 Characterization of huEPO-IgBD fusion proteins 
Unmodified human erythropoietin as well as EPO fusion proteins with C-terminal 
SpGC3, SpGC3Fab or SpGC3FabRR domain were produced in stably transfected 
HEK293 cells and purified via immobilized metal affinity chromatography (Figure 
3-20). Since human EPO has 3 possible N-glycosylation and one O-glycosylation site 
in its sequence, the proteins appear as multiple bands without treatment of 
glycosidases in an SDS-PAGE. Upon treatment with N- and O-glycosidase, all 
huEPO fusion proteins appear as single bands with the calculated molecular mass of 
the peptide sequence of 19.5 and about 26 kDa, respectively (Table 3-10). 
 
  
Figure 3-20: Deglycosylation of recombinant human EPO-IgBD fusion proteins 
10 µg of purified huEPO-IgBD fusion protein were analyzed by SDS-PAGE (12 % acrylamide) after 
over night treatment with (left) or without (right) N- and O-glycosidase. Lane 1: huEPO; 
2: huEPO-SpGC3; 3: huEPO-SpGC3Fab; 4: huEPO-SpGC3FabRR; M: protein ladder with indicated 
molecular mass on the left in kDa.  
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The functionality of the purified huEPO fusion proteins was determined via a 
proliferation assay of erythropoietin dependent UT-7/EPO cells. Aranesp was 
included to determine the quality of an industrially produced biopharmaceutical and 
to compare its proliferative effect for subsequent in vivo studies. All huEPO-IgBD 
fusion proteins as well as Aranesp were able to stimulate UT-7/EPO cells in a dose 
dependent manner (Figure 3-21). In the absence of excess amounts of human IgG, 
no differences in maximal stimulation could be determined. The concentration of 
half-maximal stimulation for all small scale produced huEPO fusion proteins was in a 
comparable range of 45 - 87 pM (Table 3-10). Aranesp exhibited a slightly better 
activation of the UT-7/EPO cells with an EC50 value of 11 pM. While the presence of 
human IgG during the whole 4 day incubation time did not influence the bioactivity of 
huEPO, huEPO-SpGC3Fab and huEPO-SpGC3FabRR, the proliferative effect of 
huEPO-SpGC3 was significantly lowered almost 4-fold. This finding corresponds with 
the CEA binding and the IL-2 stimulatory potential of the scDb-IgBD fusion proteins 
mentioned above. 
 
 
Figure 3-21: Erythropoietin dependent proliferation of UT-7/EPO cells 
Previously starved UT-7/EPO cells were stimulated with indicated concentrations of huEPO fusion 
proteins for 4 days in the absence (A) or presence (B) of excess amounts of huIgG (100 µg/ml). 
Proliferation was measured via an MTT assay and EC50 values from three independent measurements 
were calculated and statistically evaluated with GraphPad Prism using one-way Anova and Tukey’s 
post-test (C). 
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Table 3-10: Characterization of huEPO-IgBD fusion proteins 
 
 Molecular mass (peptide) 
Glycosylation  
sites Tag 
Proliferation UT-7/EPO [pM] 
- IgG + IgG 
huEPO 19.5 kDa 3 N / 1 O His   87 ± 38   81 ± 32 
huEPO-SpGC3 26.2 kDa 3 N / 1 O His   53 ± 19 198 ± 20 
huEPO-SpGC3Fab 26.0 kDa 3 N / 1 O His   45 ± 15   45 ± 10 
huEPO-SpGC3FabRR 26.1 kDa 3 N / 1 O His 65 ± 5 65 ± 6 
Aranesp 18.4 kDa 5 N / 1 O - 11 ± 1    n.d. 
 
3.4.2 Pharmacokinetics of huEPO-IgBD fusion proteins 
After having determined the bioactivity of the huEPO-IgBD fusion proteins in vitro, 
their pharmacokinetic properties in CD1 mice were investigated. Due to the addition 
of an immunoglobulin-binding domain to recombinant human erythropoietin, the 
retention time in the bloodstream could be elongated for all variants (Figure 3-22). 
Already the initial half-life of the huEPO-IgBD fusion proteins could be elongated 
compared to the unmodified huEPO up to a factor of 3 for huEPO-SpGC3FabRR (1.2 h 
compared to 0.4 h of unmodified huEPO) (Table 3-11). However, this did not reach 
the strong improvement that could be achieved by the hyperglycosylation of Aranesp 
that had ameliorated the initial half-life more than 5-fold to 2.1 h. The IgBD effect 
became even more obvious for the terminal half-life of the huEPO fusion proteins. 
Whereas the unmodified huEPO exhibited a terminal half-life of only 4 h, the fusion of 
the SpGC3 domain resulted in an almost 3-fold gain in terminal circulation time and 
even SpGC3Fab ended up in a more than 50 % longer retention endurance. These 
values were topped by huEPO-SpGC3FabRR that lasted in the bloodstream more than 
5 times longer than the unmodified huEPO and could even significantly surpass the 
half-life of Aranesp. These results were also reflected in the area under the curve, 
where already huEPO-SpGC3Fab with 167 %h reached approximately 4 times the area 
under the curve of the unmodified huEPO. The SpGC3 variant concluded in a 9-fold 
augmented AUC and huEPO-SpGC3FabRR managed to enhance the area by a factor 
of 15. Due to its high initial half-life, Aranesp showed the highest bioavailability and 
reached an AUC of 1028 %h.  
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Table 3-11: Pharmacokinetic properties of huEPO-IgBD fusion proteins 
 
 Initial half-life [h] Terminal half-life [h] AUC [%h] 
huEPO 0.4 ± 0.1   4.0 ± 0.1 44 ± 8 
huEPO-SpGC3 0.8 ± 0.2 11.8 ± 3.2 403 ± 42 
huEPO-SpGC3Fab 0.7 ± 0.1   6.3 ± 0.4 167 ± 31 
huEPO-SpGC3FabRR 1.2 ± 0.2 21.5 ± 4.2   661 ± 213 
Aranesp 2.1 ± 0.5 12.4 ± 1.2 1028 ± 222 
 
 
Figure 3-22: Pharmacokinetics of recombinant huEPO fusion proteins 
25 µg of recombinant protein was injected i.v. into female CD1 mice. Serum concentrations were 
determined via MTT viability assay with erythropoietin dependent UT-7/EPO cells and subsequently 
normalized to the 3 minute concentration (A). Initial half-life (B), terminal half-life (C) and the area 
under the curve (D) were calculated using Excel and statistically analyzed with GraphPad Prism using 
a one-way Anova analysis with Tukey’s post-test.   
 
3.4.3 Pharmacodynamic study with huEPO-IgBDs 
The pharmacodynamic properties of the huEPO-IgBD fusion proteins were examined 
after a single intravenous injection of huEPO fusion protein and the subsequent 
proliferation of erythrocytes together with the higher hemoglobin concentration in the 
blood of CD1 mice. For comparability, the same amount of bioactivity, based on the 
proliferative effect of the huEPO-IgBD fusion proteins and Aranesp from the 
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UT-7/EPO cell proliferation assay, was injected. This meant similar molarities for the 
proteins that were produced in-house (20 µg of huEPO and 26 µg of the other 
huEPO-IgBD fusion proteins) and one sixth of Aranesp (3.3 µg), as it was 6 times as 
active in the in vitro study. The average bodyweight of the mice was 24.4 g at the 
time point of injection. At day 3, no effect of treatment was detectable yet, being in 
well accordance to previous studies (Egrie and Browne 2002) (Figure 3-23). Starting 
from day 7, the hemoglobin concentration of the animals treated with 
huEPO-SpGC3FabRR and Aranesp increased, whereas no change was observed for 
the other huEPO fusion proteins as well as the PBS control. The hemoglobin level of 
Aranesp rose up to 27990 mg/dl at day 10, which is a 26.3 % improvement compared 
to the PBS control. huEPO-SpGC3FabRR already reached its peak at day 7 and could 
enhance the hemoglobin level 15.4 % above the control mice. These two proteins 
could maintain an elevated level of hemoglobin until day 21, when all levels declined 
back to the starting level and level of the control mice. Hence, for the calculation of 
the treatment benefit, the hemoglobin level was integrated over the time, starting at 
day 3 until day 21, resulting in the area under the curve. Over this time period, 
huEPO-SpGC3FabRR had an about 12 % increased area under the curve compared to 
the group that was treated with unmodified huEPO, showing a significant progress in 
treatment benefit. Aranesp showed the strongest beneficial effect of roughly 15 % 
increased AUC compared to the PBS control group. 
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Figure 3-23: Hemoglobin level of huEPO-IgBD treated CD1 mice 
20 µg of huEPO or the corresponding amount of huEPO-IgBD fusion proteins, Aranesp or PBS were 
injected i.v. into 7 CD1 mice per group. Blood samples were taken at indicated time points and 
investigated for hemoglobin concentration, shown with standard error of the mean (A). The area under 
the curve displays the treatment benefit by integrating the hemoglobin level over the time between day 
3 and day 21 (B). AUC was statistically analyzed via GraphPad Prism’s one-way Anova together with 
Tukey’s post-test. 
 
3.5 Pharmacokinetic properties of Fc fusion proteins 
Despite all the progress that has been made on increasing the pharmacokinetics of 
small recombinant molecules, full-length immunoglobulins and Fc fusion proteins are 
state of the art for industrial production and purification of protein therapeutics. 
Although these proteins are above the threshold for renal filtration and incorporate 
the same Fc part that is responsible for the recycling via the neonatal Fc receptor, 
they experience strongly different elimination from the bloodstream (Hopp et al. 
2010).  
3.5.1 Characterization of various Fc fusion proteins 
For this study, a chimeric anti-CEA IgG1 was generated, whose murine variable 
domains from the antibody MFE-23 (Chester et al. 2000) were fused to the human 
constant domains (Stork et al. 2008) (Figure 3-24). Furthermore, an scFv-Fc fusion 
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protein was produced, consisting of the corresponding scFv MFE-23 fused to the 
human γ1 Fc part, including the hinge region. Since the scFv-Fc fusion protein 
differed in size from the IgG, an scDb-Fc fusion protein was generated to roughly 
reach the size of a full-length IgG molecule. Here, instead of the scFv a bispecific 
single-chain diabody directed against CEA and CD3 was fused to the Fc part (Korn 
et al. 2004). In order to determine whether not only the size is the decisive factor, but 
also the CH1 or the CL domain are crucial for a longer half-life, a single-chain variant 
of a full-length IgG molecule was developed. Here, an scFv was fused to a 
single-chain version of the CL and CH1 domain that is linked to the Fc part via the 
hinge domain, finally resulting in scFv-scCLCH1-Fc. Furthermore, a fusion protein 
was generated comprising of the scDb and the IgG1 CH2 domain without hinge 
region, as this domain could prove useful as half-life extension module (Gehlsen et al. 
2012; Ying et al. 2014). All proteins were produced in stably transfected HEK293 
cells and purified from supernatant after ammonium sulfate precipitation. Additionally, 
the IgG molecule was also produced in CHO-K1 cells to determine, whether its 
glycosylation plays a role in the pharmacokinetic properties.  
 
 
Figure 3-24: Composition of Fc fusion proteins 
A) Schematic presentation of the fusion proteins used in this study. The green pentagonal structures 
represent the N-glycosylation at asparagine 297. Red and blue ovals represent the CEA-binding 
variable domains, the green and yellow ovals the CD3-binding variable domains. B) Genetic structure 
of the Fc fusion proteins. “L” denotes the Igκ leader sequence that is cleaved off. “H” symbolizes the 
hexahistidyl-tag for detection and purification. C) Sequences of the transition between antigen binding 
moiety and Fc part, including the hinge domain, or the CH2 domain. 
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Protein A affinity chromatography was used for the purification of the proteins with 
Fc-part, the scDb-CH2 was purified via its His-tag by IMAC. The Fc part including the 
hinge domain is also responsible for the dimerization of the Fc fusion proteins, which 
is verifiable under non-reducing conditions in a denaturing SDS-PAGE (Figure 3-25). 
All Fc fusion proteins showed bands that ran with the calculated molecular weight of 
the dimer under non-reducing conditions, only the scDb-CH2 showed a band for the 
monomeric form, owing to the missing dimerization module (Table 3-12). Under 
reducing conditions, all Fc fusion proteins exhibited bands corresponding to the size 
of the monomeric polypeptide chain. The reduction of disulfide bonds resulted in the 
separation of light and heavy chain for both IgG molecules. The size exclusion 
demonstrated that the Fc fusion proteins eluted as a single major peak with the 
hydrodynamic radius of dimers. The Stokes radii of the IgG molecules (5.6 nm), both 
from CHO and HEK293 cells, were almost identical to the radii of the scDb-Fc 
(5.5 nm) and the scFv-scCLCH1-Fc (5.6 nm). The smaller scFv-Fc was detected with 
a hydrodynamic radius of 4.8 nm.  
 
 
Figure 3-25: SDS-PAGE and size exclusion chromatography of Fc fusion proteins 
3 µg of purified protein were run on a 10 % polyacrylamide SDS-PAGE under non-reducing conditions 
(A) or on a 12 % polyacrylamide SDS-PAGE under reducing conditions (B). Lane 1: IgG (CHO); 2: 
scFv-Fc; 3: scDb-Fc; 4: scFv-scCLCH1-Fc; 5: IgG (HEK); 6: scDb-CH2; M: protein ladder with 
indicated molecular masses in kDa. C, D, E, F) Size exclusion chromatography was performed to 
determine purity and integrity of the Fc fusion proteins. The molecular mass of the standard proteins is 
indicated with the dashed lines.  
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Additionally, the glycosylation status of the different Fc fusion proteins was 
investigated via deglycosylation with N-glycosidase F. On a reducing SDS-PAGE, all 
treated samples run with a slightly lower apparent molecular weight than the 
untreated samples (Figure 3-26), which became especially obvious for the lower 
molecular weight bands such as the IgG molecules and the scFv-Fc. 
 
 
Figure 3-26: Deglycosylation of Fc fusion proteins 
2 µg of purified fusion protein were boiled and subsequently incubated over night with (+) or without (-) 
N-glycosidase F. The protein sample was again boiled with Laemmli buffer and loaded onto a 12 % 
PAA-gel. Lane 1: IgG (CHO); 2: IgG (HEK293); 3: scDb-Fc; 4: scFv-Fc; 5: scFv-scCLCH1-Fc; 
6: scDb-CH2; M: molecular mass standard in kDa 
 
The functionality in terms of antigen binding was determined in a CEA-binding ELISA 
for all proteins (Figure 3-27). All Fc fusion proteins bound with an EC50 in the same 
subnanomolar range. Due to being a monomeric format, the scDb-CH2 could not 
reach this high binding, but showed binding that is similar to the unmodified scDb or 
scFv (Table 3-12).  
 
Table 3-12: Characterization of Fc fusion proteins 
 
 Molecular mass Sr pI Tags Format 
EC50 CEA 
 [kDa] [nm] [nM] 
IgG 148 5.6 6.4 - Dimer 0.12 ± 0.03 
scFv-Fc 104 4.8 6.0 - Dimer 0.14 ± 0.03 
scDb-Fc 157 5.5 7.2 - Dimer 0.15 ± 0.02 
scFv-scCLCH1-Fc 151 5.6 6.5 - Dimer 0.14 ± 0.03 
scFv 27 2.5 5.9 His Monomer 0.48 ± 0.05 
scDb 53 2.6 7.7 His Monomer 0.70 ± 0.19 
scDb-CH2 67 n.d. 7.6 His Monomer 0.65 ± 0.10 
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Figure 3-27: CEA-binding ELISA of Fc fusion proteins 
Correct assembly and functionality of Fc fusion proteins was investigated in a CEA-binding ELISA. 
Serial dilutions of Fc fusion proteins were applied to immobilized CEA and binding was detected via 
anti-huIgG antibody (Fc specific) coupled with HRP. scDb and scDb-CH2 were detected via 
anti-His-tag antibody coupled with HRP.  
 
3.5.2 Stability determination 
The stability of all Fc fusion proteins was analyzed by thermal denaturation as well as 
stability in serum. Dynamic light scattering was used to determine the melting 
temperature of the Fc fusion proteins. The scFv displayed a melting point of 46 °C 
(Figure 3-28, Table 3-14). Likewise, the scFv-Fc revealed a melting point of 46 °C, 
but also showed a second strong incline in the mean count rate at about 76 °C, likely 
indicating the denaturation point for the Fc part (Traxlmayr et al. 2012; Wozniak-
Knopp, Stadlmann, and Rüker 2012). The low melting point of the scFv was slightly 
improved by the incorporating of the sequence into an scDb molecule, that has a 
melting temperature of 51 °C. This transition point was likewise seen for the scDb-Fc 
that also shows the Fc denaturation at 76 °C. The scDb-CH2 exhibited a similar 
denaturation as the unmodified scDb (50 °C). By generating a single chain version of 
the Fab fragment together with the Fc fragment (scFv-scCLCH1-Fc), the thermal 
stability could be augmented to 54 °C. This stabilizing effect was even topped by the 
full-length IgG molecule with a regular Fab fragment and a first thermal transition 
point of 58 °C.  
 
Investigation of the serum stability of the Fc proteins was performed in 50 % mouse 
serum over 7 days and subsequent functional detection via CEA-binding ELISA 
(Figure 3-29). Both IgGs as well as scFv-Fc and scDb-Fc did not show degradation 
after 7 days incubation in serum. On the other hand, scFv-scCLCH1-Fc already 
presented lower levels of intact protein after day 1 and roughly 35 % lower levels 
after day 7. Likewise, less active protein could be detected for the scDb-CH2 after 
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day 7 by detection of the C-terminal His-tag (more than 45 % loss). Nevertheless, 
detection via Protein L-HRP, binding to the variable domain of the kappa light chain, 
revealed no significant loss in activity of scDb-CH2 over one week.  
 
 
Figure 3-28: Thermal stability of Fc fusion proteins 
The point of thermal denaturation was determined via dynamic light scattering. The protein sample 
was heated in 1 °C intervals with 2 minutes of equilibration time. The dashed vertical lines indicate the 
melting points, defined by an intense increase in mean count rate.  
 
 
Figure 3-29: Serum stability of Fc fusion proteins 
Serum stability was investigated over 7 days in 50 % mouse serum at 37 °C. Samples were frozen 
at -20 °C at indicated time points and subsequently tested for active protein content in a CEA-binding 
ELISA. Binding of Fc fusion proteins was detected by HRP conjugated anti-huIgG antibody (Fc 
specific), scDb-CH2 by HRP labeled anti-His-tag antibody or Protein L.  
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3.5.3 Neonatal Fc receptor binding 
The recycling via the neonatal Fc receptor is one of the key requirements for the long 
half-life of IgG molecules. Therefore the binding properties at neutral pH and in 
particular at acidic pH were closely investigated using an immobilized, biotinylated 
mouse FcRn in a quartz crystal microbalance approach (Figure 3-30). No or only 
negligible binding was traceable under physiological conditions. Therefore, running 
buffer with pH7.4 was able to regenerate the binding at pH6. Binding was detectable 
under acidic conditions with similar biphasic curves for all the Fc fusion proteins and 
KD values for the monovalent binding around 100 nM (Table 3-13). The scDb-CH2 
only showed weak binding to the mouse FcRn at neutral pH and even less affinity 
under acidic conditions, although 10-fold the concentration was injected compared to 
the Fc fusion proteins.   
 
Table 3-13: Affinity towards mouse FcRn at pH6 
 
 kon1 [(M x s)-1] koff1 [s-1] KD1 [nM] KD2 [M] 
IgG 1.5 x 105 1.6 x 10-2 108 1.9 x 10-17 
scFv-Fc 1.7 x 105 1.8 x 10-2 107 1.8 x 10-16 
scDb-Fc 2.0 x 105 1.6 x 10-2 82 1.4 x 10-10 
scFv-scCLCH1-Fc 1.7 x 105 1.2 x 10-2 121 2.5 x 10-10 
 
 
Figure 3-30: Binding to mouse FcRn 
The binding of Fc fusion proteins was investigated on immobilized mouse FcRn via quartz crystal 
microbalance measurements. 100 nM of fusion protein was applied at pH6 and at pH7.4 and 
regeneration was performed twice with running buffer at pH7.4 (A-D). A concentration of 1000 nM was 
injected to determine the binding of scDb-CH2 under both conditions (E). Here, regeneration was 
performed with 10 mM HCl pH1.95.  
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3.5.4 Pharmacokinetics of Fc fusion proteins 
Pharmacokinetics were determined via a single injection of 25 µg protein into the tail 
vein of female CD1 mice. Serum concentrations were determined via CEA-binding 
ELISA and normalized to the 3 minute value. Both IgG1 molecules exhibited almost 
congruent pharmacokinetic profiles, together with a terminal half-life of about 9 days 
and a comparable AUC of about 8000 %h that is much higher than that of all other 
proteins tested (Figure 3-31, Table 3-14). The scDb-Fc with a similar molecular 
weight as the IgGs had a strongly reduced terminal half-life and also AUC of 140 h 
and 4143 %h, respectively. As seen in previous studies, the scFv-Fc also exhibited 
lower serum persistence than the IgG molecules (Hopp et al. 2010), with serum 
concentrations and an AUC that are similar to the scDb-Fc. The terminal half-life of 
the scFv-Fc with 104 h was somewhat inferior due to the marginally lower 
concentration at day 7. With 53 h, the scFv-scCLCH1-Fc had the shortest terminal 
half-life of all Fc fusion proteins tested and just less than a fourth of the full-length 
IgG molecules. This also went along with a significantly reduced area under the 
curve. Nevertheless, all four Fc fusion proteins demonstrated massively improved 
pharmacokinetic properties compared with the scDb and scFv. On the other hand, 
the scDb-CH2 had a terminal half-life similar to that of the unmodified scDb, also 
reflected in a poor AUC.  
 
Table 3-14: Stability and pharmacokinetic properties of Fc fusion proteins 
 
 Melting point [°C] Initial half-life [h] Terminal half-life [h] AUC [%h] 
IgG (CHO) 58 / 76 7.0 ± 3.0 222 ± 8 7945 ± 222 
IgG (HEK) 58 / 76 23.9 ± 15.6   236 ± 35 8349 ± 633 
scFv-Fc 46 / 76 2.5 ± 0.9 104 ± 6 3966 ± 828 
scDb-Fc 51 2.8 ± 1.4   140 ± 35   4143 ± 1378 
scFv-scCLCH1-Fc 54 / 76 3.2 ± 0.6     53 ± 11 2349 ± 403 
scFv 46 0.2 ± 0.1     0.6 ± 0.2 16 ± 4 
scDb 51 0.4 ± 0.1     1.3 ± 0.2   56 ± 15 
scDb-CH2 50 0.6 ± 0.1     0.8 ± 0.1   80 ± 20 
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Figure 3-31: Pharmacokinetics of Fc fusion proteins 
After a single injection of 25 µg protein, blood samples were collected at indicated time points. The 
remaining concentration was determined via CEA-binding ELISA and normalized to the 3 minute value. 
The pharmacokinetic properties were determined via Excel and the means were compared by 
one-way Anova with Tukey’s post-test in GraphPad Prism (C-E).  
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4 Discussion 
4.1 Immunoglobulin binding domains 
The proteins exhibiting the longest circulation time in the blood are γ immuno-
globulins and albumin with terminal half-lives of up to 21 and 19 days in humans, 
respectively (Morell, Terry, and Waldmann 1970; Peters 1995). This long retention 
time in the blood stream is influenced by many factors and one of the most important 
is the salvage from lysosomal degradation via the neonatal Fc receptor (Roopenian 
and Akilesh 2007). Exploiting the long serum persistence of these molecules 
therefore seems to present strong advantages, for example by fusion of an Fc part or 
albumin to the protein of interest (Kontermann 2012). Additionally, transient 
interactions via a binding moiety towards IgG or albumin also present a possibility to 
benefit from their long half-life. Albumin has been a target for these transient 
interactions for a long time and many studies have been performed using domains 
that can bind to albumin and successfully prolong the retention time in the 
bloodstream (Dennis et al. 2002; Hopp et al. 2010; Stork et al. 2009). On the other 
hand, the transient interaction with IgG molecules for a half-life extension purpose did 
not attract too much attention so far (Harmsen et al. 2005; Hoffmann et al. 2013; P 
Holliger et al. 1997; Hutt et al. 2012; Sockolosky, Kivimäe, and Szoka 2014; 
Unverdorben et al. 2012).  
 
Some important factors have to be taken into account when generating a long lasting 
fusion protein with immunoglobulin-binding moieties. First, the selectivity for the IgG 
subclasses with long serum persistence (IgG1, IgG2 and IgG4) has to be assured 
(Hutt et al. 2012; Mankarious et al. 1988; Morell, Terry, and Waldmann 1970) and in 
particular the stability of binding under both physiological and acidic pH conditions 
has to be confirmed. This is necessary to maintain the high apparent hydrodynamic 
radius in the bloodstream (pH7.4) in order to exclude rapid renal elimination and to 
be able to benefit from the recycling effect in the acidified endosome. An interference 
with the neonatal Fc receptor, for example by occupying the same binding site on an 
IgG Fc part, can also negatively impact the pharmacokinetic behavior (Low and Mezo 
2009; Mezo et al. 2008; Sockolosky, Kivimäe, and Szoka 2014). To avoid the 
formation of immune complexes, only one major binding site per IgBD-molecule 
would be beneficial, as otherwise the ensuing complexes might lead to a rapid 
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clearance of the fusion protein (Rehlaender and Cho 1998). For this reason, a 
monovalent use of IgBDs seems appropriate. Compared to the terminal half-life of 
endogenous IgG in humans (up to 21 days), the murine IgG does not have such a 
preferential retention time and remains in the bloodstream for 6 to 8 days (Vieira and 
Rajewsky 1988). This represents the maximal half-life that fusion proteins with IgBDs 
could exhibit in a mouse. 
4.2 Novel immunoglobulin binding domains 
Analogous to the well-described albumin-binding domain, the domain C3 (SpGC3), 
also derived from Streptococcus Protein G, is able to bind towards IgG molecules 
and as a fusion partner can elongate the retention time in the bloodstream. The 
specificity for the long lasting IgG species was confirmed by a quartz crystal 
microbalance approach using both human serum IgG and purified IgG1 (Hutt et al. 
2012). In accordance to previous studies, the SpGC3 domain was able to bind the 
Fab fragment as well as the Fc part of an IgG molecule (Erntell et al. 1988) with a 
higher affinity towards the Fc part. In order to circumvent the possible interference 
with the FcRn during the recycling of the IgG molecule (McDonnell et al. 2010), 
3 central residues for the Fc binding were mutated into alanines to disrupt this 
binding site, resulting in the Fab-specific domain SpGC3Fab. However, deletion of the 
Fc binding site resulted in reduced pharmacokinetics of scDb-SpGC3Fab, compared to 
the corresponding SpGC3 fusion protein. This is presumably due to the deletion of Fc 
binding at neutral pH and the ensuing loss of affinity towards the full-length IgG 
molecules, since SpGC3Fab is able to bind the Fab fragments of mouse and human 
with a similar or even slightly improved affinity compared to SpGC3. The pH 
dependent changes in binding towards the Fc part were previously described for the 
SpGC3 domain, probably due to the protonation of histidine residues in the Fc part 
that are in close proximity to the bound domain (Sauer-Eriksson et al. 1995; Spassov 
and Yan 2013; Watanabe et al. 2009). 
 
Similar to SpGC3Fab, 3 residues involved in the binding towards CH1 were substituted 
by alanines to generate SpGC3Fc. The rationale behind this approach was to generate 
an IgBD that specifically binds towards the Fc parts of IgG molecules and by 
interference with FcRn recycling possibly lowers the serum half-life of endogenous 
IgG. Thus, the terminal half-life of the SpGC3Fc fusion protein should be lower 
compared to the parental SpGC3 fusion protein that also binds the CH1 domain. The 
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lower retention time and therefore lower serum IgG level would be advantageous in 
autoimmune diseases (Z. Liu et al. 1997). Conversely, the pharmacokinetic 
properties of the scDb-SpGC3Fc exhibited an increased retention time, which cannot 
be correlated to the affinity determination. The performed amino acid substitutions 
hardly had an effect on IgG, Fc and Fab binding with comparable affinities of SpGC3. 
Furthermore, domain C2 from Protein G was investigated for its properties in half-life 
extension as a fusion moiety and exhibited similar serum concentrations as well as 
comparable affinities towards IgG molecules as SpGC3.   
 
In order to determine the influence of the IgBD on the scDb moiety, an ELISA against 
the carcinoembryonic antigen and flow cytometry with CEA- or CD3-positive cells 
were performed. In the absence of excess amounts of IgG during the binding 
reaction to CEA, none of the IgBD had an impact on the binding properties, but in the 
presence of IgG all proteins that were able to bind the Fc part (scDb-SpGC3, 
scDb-SpGC2 and scDb-SpGC3Fc) showed decreased binding and a higher EC50 value. 
A plausible explanation therefore is sterical hindrance of CEA binding when the IgG 
molecule is bound with high affinity (up to 3 nM, Table 3-1) via its Fc part. 
Comparable findings were made in previous studies with the albumin-binding domain 
and additional albumin in the media (Stork, Müller, and Kontermann 2007; 
Tolmachev et al. 2007). The binding to CD3 on purified PBMCs was already altered 
without the addition of human serum IgG during the binding reaction, likely due to 
interactions with IgG that was used for the blocking of Fcγ receptors. This impact of 
IgG on the binding properties of the scDb moiety was also reflected in the IL-2 
release. Whereas scDb-SpGC3Fab showed the same activation of T-cells as the 
unmodified scDb, scDb-SpGC3 and scDb-SpGC3Fc only efficiently activated the IL-2 
secretion without additional IgG. Again, the binding towards the antigens of the scDb 
moiety could be affected as seen in ELISA and flow cytometry. Alternatively, the 
proper formation of a cytolytic synapse via the scDb between T-cell and target cell is 
disturbed by the additional IgG that could enlarge the interspace required for 
activation of the T-cells (Bluemel et al. 2010; Choudhuri et al. 2005).  
4.3 Affinity maturation towards the CH1 domain 
Due to the lower affinity of SpGC3Fab towards the complete IgG molecule and the 
ensuing drawback in pharmacokinetics, phage display libraries were generated in 
order to select for improved affinity towards the CH1 domain. Special attention was 
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placed on the selection of clones that exhibit strong binding also at acidic conditions, 
since the dissociation from or missing association towards IgG at low pH would result 
in lysosomal degradation. The affinity maturation resulted in SpGC3FabRR, which 
presented significantly improved terminal half-life and bioavailbility as scDb fusion 
protein, compared to SpGC3Fab. The reason for the enhancement is the improved 
affinity towards the IgG molecules and the Fab fragment under physiological and 
acidic conditions. In particular, the binding to the Fab fragment at acidic pH is 
increased more than 4-fold compared to SpGC3Fab, indicating the formation of more 
stable complexes during FcRn recycling. Likewise, other studies could draw a 
correlation between increased affinity towards the long-lasting serum protein and 
half-life of the therapeutic protein, when using albumin together with albumin-binding 
domains or peptides (Hopp et al. 2010; Nguyen et al. 2006; Tolmachev et al. 2007). 
Importantly, the binding towards the Fc part at neutral pH is still eliminated. The data 
suggest that the partially reestablished binding to the Fc part at pH6 does not impede 
with the recycling via the neonatal Fc receptor, presumably due to a dominant 
binding to the Fab fragment. Otherwise, scDb-SpGC3FabRR could not reach its long 
half-life of 47.8 h and especially the high serum concentrations at day 3 and 7, as 
seen for scDbs fused to IgBDs originating from Protein A that only bind to the Fc part 
(Hutt et al. 2012; Unverdorben et al. 2012). Hereby, the maximal half-life would be 
determined by the half-life of IgG molecules in FcRn deficient mice, which is about 
19 h (Chaudhury et al. 2003). 
 
Apparently, residues 35 and 36 of SpGC3Fab have strong influence on affinity and 
pharmacokinetics. Many clones derived from the error-prone PCR library 
(SpGC3FabE15V,YY, SpGC3FabK10Q,HNS, SpGC3FabN35Y) exhibited amino acid 
substitutions within this region, which was previously assigned for binding to the Fab 
fragment and mutated for library 3 (Figure 3-1) and could even achieve higher or 
comparable affinity towards mouse IgG compared to SpGC3FabRR. Nevertheless, 
their serum concentration after injection as scDb fusion proteins decreased more 
rapidly than that of scDb-SpGC3Fab. Besides the mutation of the residues 35 and 36 
only the SpGC3FabE15V modification showed preferential serum concentrations. This 
substitution is also located in a previously assigned Fab binding area that was 
mutated with library 1. Combining this variant with the so far best candidate 
SpGC3FabRR resulted in SpGC3FabRR,E15V, which could further improve the 
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pharmacokinetics of the scDb. Again, the slight affinity towards the Fc part apparently 
does not interfere with the FcRn recycling, but is negotiated by the affinity towards 
the CH1 domain. The reason for these favorable pharmacokinetic properties is 
probably the highest affinity of all IgBDs towards mouse Fab fragment at neutral pH. 
In order to further highlight the effect of size on the elimination of proteins, IgBD 
fusion with scFvs, which have about half the molecular weight of an scDb, were 
created. All of these scFv fusion proteins were able to substantially improve the 
circulation time, but exhibited a shorter half-life than the corresponding scDb fusion 
protein. This is possibly due to dissociation at physiological pH and subsequent renal 
clearance because of an even lower hydrodynamic radius than the scDb-IgBD fusion 
proteins. The size effect on terminal half-life of the antibody moiety was already seen 
in earlier studies (Hutt et al. 2012; Müller et al. 2007). Nevertheless, the IgBDs were 
able to elongate the retention time in a similar manner as for the scDb, with 
SpGC3FabRR exhibiting the best pharmacokinetic properties, followed by SpGC3 and 
SpGC3Fab.  
 
Furthermore, these affinity-maturated mutants were characterized in vitro to 
determine whether the change in affinity also alters the behavior in binding and 
functionality of the fused scDb moiety. All new IgBD variants exhibited as scDb fusion 
proteins full binding potential to immobilized carcinoembryonic antigen as well as 
CEA or CD3 present of the surface of cells. These favorable binding properties were 
also reflected in the activation of T-cells that was seen in the IL-2 release assay for 
scDb-SpGC3FabRR and scDb-SpGC3FabRR,E15V. Similar to the SpGC3Fab domain, the 
affinity maturated mutants did not interfere with the activation of T-cells in the 
presence of excess amounts of IgG as it was seen for the SpGC3 domain or an 
increased affinity ABD domain together with human serum albumin or even a 
PEGylated version of the scDb (Hopp et al. 2010; Stork et al. 2008). Therefore, the 
newly developed IgBDs seem to be particularly useful in extending the half-life of 
small bispecific T-cell engagers that need close contact between T-cell and target 
cell for effective retargeting and activation (Baeuerle and Reinhardt 2009; Müller and 
Kontermann 2010).   
4.4 Deimmunization of SpGC3Fab 
Increasing the retention time in the bloodstream and retaining the therapeutic 
potential are crucial steps in improving the performance of small recombinant 
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proteins, but it is also important how the body reacts to the application of the drug. 
Even without effects of the therapeutic, the application can cause an immunologic 
reaction against the injected protein. Consequences can reach from neutralizing 
antibodies (Barbosa and Celis 2007) up to allergic reactions and anaphylactic shocks 
(Pedotti et al. 2001; Rosenberg 2006). Even fully human proteins can lead to the 
generation of anti-drug antibodies, depending on the recognition of certain 
sequences by antigen presenting cells with their major histocompatibility antigens of 
class II as foreign antigens (Rup 2003).  
 
Since the IgBDs are derived from bacterial proteins, they will certainly not be 
compatible to the human self-proteins, but more important is whether their 
sequences are recognized by distinct HLA class II alleles (M. Baker et al. 2010). 
Therefore, a scanning of the sequence of SpGC3Fab was performed including not only 
sequence, but also structure-based algorithms. Within the 8 most frequently 
distributed human leukocyte antigen class II alleles 9 possible T-cell epitopes were 
detected for SpGC3Fab. The majority of the recognition patterns were concentrated 
within a cluster at the beginning of the sequence, between amino acids 3 and 20 
(Figure 3-15). Thus, only few substitutions are necessary in order to remove these 
epitopes, since by one substitution multiple epitopes can be influenced. Due to the 
addition of the positively charged arginine residues in SpGC3FabRR, the scanning 
revealed three additional epitopes. Single as well as combinations of amino acid 
substitutions were able to disrupt possible T-cell epitopes. In order to access the 
quality of prediction and deimmunization from the in silico calculation, a validation of 
T-cell epitopes in vitro could have further determined their location and magnitude 
(Baker and Jones 2007). This would have been particularly useful, since in silico 
predictions often tend to over-prediction of epitopes (Perry, Jones, and Baker 2008).  
 
In order to determine the functional binding of the deimmunized IgBDs towards IgG 
molecules, they were produced as scFv-IgBD fusion proteins and analyzed via quartz 
crystal microbalance. All combinations, but also most single amino acid mutations 
revealed reduced binding, indicating worse pharmacokinetic properties than the wild-
type SpGC3Fab due to less stable binding under physiological conditions. A 
combination to remove all possible epitopes would have been possible, but since the 
necessary mutation L12A already purged the binding completely, no combination 
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with that mutation was generated. For a more detailed analysis, selected domains 
were subcloned as scDb-IgBD fusion proteins and pharmacokinetics were 
investigated. Interestingly, these single mutants all showed similar serum 
concentrations as the SpGC3Fab domain until day 1, but the concentration at day three 
dropped drastically. This cannot be explained by the affinity towards IgG and Fab 
fragment, since they are comparable or even slightly enhanced. However, the loss of 
affinity of the variants with multiple substitutions can explain the weak performance, 
which was at least partially remitted by the combination with the affinity maturated 
variant SpGC3FabRR.  
 
In order to perform an in vivo experiment for immunogenicity of the SpGC3Fab domain 
and its deimmunized variants, several requirements are necessary. Apart from the 
basic differences in human and mouse immune systems (Mestas and Hughes 2004), 
the mouse does not have the human set of MHC molecules, the human leukocyte 
antigens. Therefore, it remains unclear to what extent the mouse and human 
specificities overlap and whether also the murine epitopes are eliminated. The usage 
of transgenic mice that express the human MHC class II molecules on their cell 
surface might be an adequate solution (Taneja and David 1999). Since the 
development of immunogenicity is also dependent on the time of exposure and the 
dosage (Harro et al. 2010), the deimmunized version should exhibit similar half-life 
extension properties as the reference protein. This issue could be addressed by 
using the SpGC3FabRR, Y33T,DI1 variant that resembles the SpGC3Fab variant most in 
serum concentrations. Additionally, the fusion partner of the IgBD must not contain 
any T-cell epitopes, as the resulting anti-drug antibodies would alter the 
pharmacokinetic behavior of the fusion protein. Alternatives to the here used scDb or 
scFv include for example deimmunized BiTEs or single-chain diabodies (Hammond 
et al. 2007; Vallera et al. 2010) or other therapeutic proteins (Cantor et al. 2011; 
Tangri et al. 2005). Even more important than these concerns is the detection of 
antibodies directed against the SpGC3Fab domain. Since the domain has an innate 
affinity for IgG molecules, it is difficult to detect, whether antibodies specifically 
recognize the domain or whether IgGs are bound via the IgBD affinity. In a 
preliminary test with mouse serum, the immobilized SpGC3Fab domain bound to 
endogenous mouse IgG in ELISA (data not shown). Furthermore, detection via an 
immunoblot with the denaturation of the SpGC3Fab domain and subsequent incubation 
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with the serum of treated mice is not possible, as upon transfer to the membrane a 
spontaneous refolding of the domain occurs, again exhibiting binding to endogenous 
mouse IgG (data not shown). It also remains unclear, how the pharmacokinetic 
behavior of an IgBD would be altered upon binding of specific ADAs via their CDRs 
and not via the CH1 domain. 
4.5 Half-life extension of recombinant human erythropoietin 
A therapy with small recombinant protein therapeutics offers a huge benefit to the 
patient, but due to their limited retention time in the bloodstream they often require 
multiple applications and are a very costly treatment. Using therapeutics with the 
same specificity and potency, but better pharmacokinetic properties will strongly 
reduce the burden for the patient as well as the caregivers (Powell and Gurk-Turner 
2002). Therefore, the half-life extension strategy via immunoglobulin-binding domains 
was applied to a well-known and widely used therapeutic protein, recombinant 
human erythropoietin. Much effort has been placed in improving the pharmacokinetic 
properties so far, for example by PEGylation or hyperglycosylation of huEPO (Elliott 
et al. 2003; Macdougall 2008). With the use of immunoglobulin-binding domains we 
want to profit not only from the increased hydrodynamic radius, but also from the 
salvage of lysosomal degradation via the neonatal Fc receptor.  
 
Eukaryotic production of huEPO with C-terminal addition of SpGC3Fab, SpGC3 or 
SpGC3FabRR and subsequent purification via IMAC resulted in highly glycosylated 
proteins that exhibited single bands in an SDS-PAGE analysis after removal of the 
glycosylation. Their activity and proliferative potential was investigated with 
UT-7/EPO-cells, revealing that the addition of the IgBDs did not influence the activity 
per se, as was seen for other protein modifications like PEGylation and 
hyperglycosylation (Sinclair 2013). This reduced in vitro activity is due to a lower 
affinity towards the EPO receptor, presumably as consequence to sterical hindrance 
or charge effects (Egrie and Browne 2001). Analogous to the activity of the 
scDb-IgBD fusion proteins, the addition of excess amounts of human IgG to the 
medium changed the activity of huEPO-SpGC3, but did neither influence unmodified 
huEPO, nor huEPO-SpGC3Fab and huEPO-SpGC3FabRR. This effect could on the one 
hand be mediated by decreased binding towards the EPO receptor (Gross and 
Lodish 2006), like it was previously seen for IgBD-fused scDb and its antigens CEA 
and CD3. On the other hand, the steric hindrance could prevent the EPO receptor 
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dimer from undergoing conformational changes, suppressing signal transduction and 
proliferation (Hodges et al. 2007). Nevertheless, the pharmacokinetic studies were 
performed with all huEPO-IgBD fusion proteins, since the 4-fold decreased activity of 
huEPO-SpGC3 is similar to the 3-fold decreased activity of Aranesp, which can be 
overcome by the strong increase in half-life (Egrie and Browne 2001). Aranesp was 
also included in this proliferation assay and displayed favorable activation compared 
to all huEPO fusion proteins that were produced in-house. This is probably due to the 
higher product quality of the clinic material or owing to the additional poly-histidine 
tag for purification of the in-house produced fusion proteins.  
 
Since the serum concentrations have been normalized to the serum concentration at 
the 3 minute time point, the product quality does not play the key role for the 
pharmacokinetic parameters. For both, huEPO and Aranesp previously reported 
terminal half-lives have been confirmed, with Aranesp showing a three times higher 
terminal half-life (Egrie and Browne 2001; Powell and Gurk-Turner 2002). By adding 
the immunoglobulin-binding domains, the terminal half-life of huEPO could be 
elongated, which is also reflected in a higher bioavailability. Similar to the previous 
studies, SpGC3FabRR was the IgBD that provided the best pharmacokinetic effect with 
a 5-fold increased terminal elimination time and also 15-fold higher area under the 
curve. Although the terminal half-life of huEPO-SpGC3FabRR exceeds Aranesp, the 
AUC is lower due to the higher initial half-life of Aranesp. Several other authors 
suggest that the recycling via the neonatal Fc receptor reveals its potential primarily 
in the terminal elimination phase (Datta-Mannan et al. 2007; Hinton et al. 2006; 
Medesan et al. 1998), well corresponding to the here obtained data. An additional 
issue is the way of clearance of huEPO from the bloodstream. With its nonlinear 
pharmacokinetics, huEPO is not mainly cleared via liver or kidney (Dinkelaar et al. 
1981; Yoon et al. 1997), but the EPO receptor and its turnover seem to have strong 
influence on the serum concentration of huEPO. It was shown that upon binding and 
activation a rapid degradation of receptor and cytokine occurs. If the dissociation 
happens fast enough, only the receptor will be internalized and degraded after 
activation, leading to a longer serum persistence of those huEPO variants that exhibit 
less affinity towards the receptor, like Aranesp (Gross and Lodish 2006; Walrafen et 
al. 2005). Thus, apart from the direct effects of the hyperglycosylation to the 
pharmacokinetics, also the decreased affinity and activation of the EPO receptor 
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increase the serum concentrations of Aranesp compared to the other huEPO fusion 
proteins. Since huEPO-SpGC3 also displayed decreased activity in the presence of 
excess amounts of IgG during the proliferation assay, the pharmacokinetics could 
possibly also be influenced by diminished receptor binding, similar to Aranesp. In 
order to evaluate this hypothesis, an internalization study of all huEPO fusion 
proteins would have been necessary (Gross and Lodish 2006).  
 
The augmented terminal half-life and bioavailability of Aranesp also translated into a 
higher efficacy of treatment, resulting in an about 13-fold higher biological activity 
when administered once a week, compared to unmodified huEPO (Egrie et al. 2003; 
Sasu et al. 2005). Whereas huEPO, huEPO-SpGC3Fab and huEPO-SpGC3 did not 
increase the hemoglobin level of CD1 mice by a single injection, Aranesp and 
huEPO-SpGC3FabRR could benefit from their better pharmacokinetic properties and 
strongly increase the hemoglobin concentration for 18 days. The differences in 
biological activity can mostly be explained by the bioavailability of the huEPO fusion 
proteins. The concentration of huEPO, together with SpGC3Fab and SpGC3, apparently 
has not been within a therapeutic window for a sufficient amount of time to promote 
the onset of additional erythrocyte production. On the other side, Aranesp and 
huEPO-SpGC3FabRR maintained a high serum concentration and increased the 
hemoglobin concentration. The reason for the better performance of Aranesp 
compared to huEPO-SpGC3FabRR is probably the higher initial half-life and thus also 
higher AUC, as well as reduced receptor affinity, which presumably lead to less 
degradation after activation. For comparison reasons, all fusion proteins should be 
manufactured with the same product quality to exclude differences in bioactivity and 
therefore different effects during pharmacodynamic studies.  
 
A very interesting issue is the translation of these results into human patients. Apart 
from the question of half-life elongation via the immunoglobulin-binding domains, the 
retention time for both unmodified and hyperglycosylated huEPO is about twice as 
high in humans as in the murine system (Macdougall et al. 1999). Moreover, there is 
a drastic difference in receptor affinity. Whereas the affinity in mice, rats and 
monkeys is similar with about 0.11 - 0.15 nM, the affinity of the human EPO receptor 
is 10-fold higher with 0.012 nM (Todokoro et al. 1987; Woo et al. 2007). Other 
approaches with EPO have been launched that utilize FcRn recycling, for example 
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Fusion of huEPO towards an Fc part. However, the permanent increase in size 
(112 kDa) results in lower bioavailability, since moving through endothelial cells is 
probably limited (Bitonti et al. 2004).  
4.6 Fc fusion proteins 
Monoclonal antibodies of the gamma immunoglobulin class are amongst the most 
widely used recombinant therapeutic proteins, due to their high producibility, stability 
and long serum half-life (Carter 2011). In accordance to earlier studies, the 
pharmacokinetic performance of a full-length IgG molecule exceeded other Fc fusion 
proteins, although an identical IgG1 Fc part was used for all fusion proteins (Suzuki 
et al. 2010). The effect of differing half-lives is already prominent for various IgG 
molecules like Trastuzumab and Daclizumab, where the terminal half-life ranges from 
2.7 days to 20 days (Tokuda et al. 1999; Vincenti et al. 1998). Among other factors, 
the non-linear clearance with internalization and subsequent degradation of the 
antigen together with the antibody plays an important role and is jointly responsible 
for the weak pharmacokinetics of Trastuzumab (Mould and Sweeney 2007). For this 
reason, the carcinoembryonic antigen was chosen as target antigen for all Fc fusion 
proteins, since CEA does not get actively internalized upon antibody binding and it is 
not endogenous in mice and will therefore not impact the pharmacokinetics by 
unwanted side effects (Schmidt, Thurber, and Wittrup 2008). After the first 
exploration that the scFv-Fc exhibits a lower terminal half-life than the parental 
full-length antibody, we decided to investigate the size effect of the Fc fusion proteins 
by generating an scDb-Fc matching the molecular weight and additionally an 
scFv-scCLCH1-Fc to have a similar amino acid composition as the unmodified IgG. 
Apart from the CEA binding, scDb-Fc can also bind to the epsilon chain of human 
CD3 (Arnett et al. 2004), but as the parental antibody UCHT-1 is species-specific, no 
interference in the mouse system should occur. The integrity and purity of the Fc 
fusion proteins was determined via size exclusion chromatography, revealing a single 
elution peak for all proteins and a hydrodynamic radius of 5.6 nm for the IgG that is in 
well accordance to previous determinations (Stork et al. 2008). Both scDb-Fc and 
scFv-scCLCH1-Fc fulfilled the requirement to resemble the IgG molecule in size, only 
scFv-Fc had a smaller hydrodynamic radius reflecting the lower molecular weight. 
Increasing the size from the scFv-Fc towards the scDb-Fc hardly had an influence on 
the pharmacokinetic properties, with both proteins revealing an area under the curve 
about half of the unmodified IgG. Introduction of the constant domains of the Fab 
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fragment as a single chain variant (scFv-scCLCH1-Fc) also resulted in the same size 
as an IgG, but the bioavailability deteriorated to just 30 % of the aimed AUC. 
 
A further factor for the elimination of proteins from the serum is the net charge of 
circulating molecules (Igawa et al. 2010). A protein with a low isoelectric point will be 
negatively charged under physiological conditions and possibly be repulsed from the 
likewise negatively charged cell surface (Boswell et al. 2010), as well as the 
glomerular fenestrations of the kidney (Kontos and Hubbell 2012). Hence, rapid renal 
degradation is avoided and the protein will not undergo fluid phase endocytosis and 
can avoid possible degradation in the lysosome, independent of the FcRn recycling 
(Gurbaxani, Dostalek, and Gardner 2013). The IgG molecule has a low isoelectric 
point, but with scFv-Fc having a lower, scDb-Fc having a higher and 
scFv-scCLCH1-Fc having a similar pI, no correlation concerning the half-life can be 
drawn. The susceptibility of recombinant proteins to serum proteases also affects the 
potency and retention time of the therapeutic in the blood stream. In particular, linker 
sequences between the immunoglobulin domains that are exposed to surrounding 
media can often be subject to proteolytic cleavage (Le Gall et al. 2004; Holliger and 
Hudson 2005). After 7 days of incubation with mouse serum neither the IgG 
molecules, nor scFv-Fc or scDb-Fc displayed a decreased level of active protein. In 
contrast, scFv-scCLCH1-Fc only showed about 65 % of the starting activity, denoting 
that one or more of the linker sequences between the scFv and the Fc part are not 
resistant to proteolytic cleavage. Furthermore, scDb-CH2 is prone to serum protease 
digestion, since after serum incubation only about half of the protein was completely 
intact. Of note, after detection of the binding of scDb-CH2 not via His-tag, but via 
Protein L (binding directly to the scDb via the variable domain of the kappa light 
chain), no loss in activity was noticeable, meaning that the linker sequences between 
the scDb and the CH2 domain or the subsequent sequence must be affected, since 
the scDb moiety is still able to fully bind CEA.  
 
Since all Fc fusion proteins are endowed with the identical Fc part of human IgG1, 
the capability to bind to the neonatal Fc receptor at acidic conditions should be 
comparable if no sterical hindrance prevents the correct complex formation. The 
assays were performed using the mouse FcRn to assess the in vitro binding kinetics 
as well as the in vivo pharmacokinetics in the same species system. With an affinity 
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of around 100 nM for all Fc fusion proteins, the binding, but also association and 
dissociation constants are in well accordance to previous studies, suggesting that 
intact FcRn binding is crucial, but not sufficient to reach the long half-life of a 
full-length IgG molecule (Gurbaxani et al. 2006). Thus, the poor binding properties of 
the scDb-CH2 towards moFcRn, especially under acidic conditions, explain the rapid 
elimination from the bloodstream and the missing recycling effect. The ratio of 
association and dissociation rate also plays a role for the pharmacokinetic behavior 
of the Fc fusion proteins. Slowing down the dissociation rate at acidic pH translates 
into better serum half-life (Datta-Mannan et al. 2007). However, the kinetic rates of all 
Fc fusion proteins are comparable and therefore not the key factor for the differences 
in the pharmacokinetics. Additionally, the kinetics, i.e. the dissociation of bound Fc 
fusion protein from the FcRn, upon returning to a physiological pH, accompany with a 
longer in vivo half-life (Wang et al. 2011). Other studies highlight the importance of 
the Fab fragment for the recycling effect of the FcRn. An interaction between the Fab 
fragment and the FcRn was detected by hydrogen-deuterium exchange studies and 
subsequent mass spectrometry (Jensen et al. 2015). Although using full-length 
antibodies with identical Fc region, the Fab fragment was responsible for differences 
in FcRn binding and subsequently also pharmacokinetics (Wang et al. 2011). Since 
the affinity of all Fc fusion proteins towards the FcRn is similar, the fusion partner of 
the Fc part does not seem to have a strong impact on the in vitro interaction, but the 
question to what extent the N-terminal domains of the Fc part contribute to the 
recycling process or obstruct it remains unsolved. The high affinity calculated for KD2 
is far from physiologically reasonable data and can be considered as artifact. 
 
Besides the fluid phase endocytosis, binding of the Fc part towards Fcγ receptors on 
immune effector cells like macrophages, neutrophils, dendritic cells or natural killer 
cells can also cause the internalization and subsequent degradation of Fc fusion 
proteins (Comber et al. 1989; Gillies et al. 1999). Fc fusion proteins have to be 
glycosylated at asparagine 297 for the binding towards Fcγ receptors (Clark 1997). 
Therefore, also the glycosylation status influences the pharmacokinetic profile of Fc 
fusion proteins and the content of negatively charged sialic acid is even able to 
modify FcRn affinity. Although a high content of sialic acid decreases the affinity 
towards FcRn, the pharmacokinetic properties are enhanced (L. Liu et al. 2012). The 
issue of varying glycosylation was addressed by the generation of the CHO-produced 
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IgG molecule, but this did neither alter the in vitro properties, nor the serum 
concentration during the pharmacokinetic study. In accordance to literature, no single 
in vitro parameter could be isolated to accurately predict the in vivo pharmacokinetic 
behavior (Datta-Mannan and Wroblewski 2014). Rather an interplay of many factors, 
including size, stability, net charge, FcRn binding and others is necessary to explain 
the exceeding performance of the IgG molecule compared to other Fc formats.  
4.7 Translation of animal results 
In order to translate the pharmacokinetic findings of this study into the human 
situation, further studies are necessary using the human FcRn for binding studies, as 
well as evaluation in a more human-like system, like transgenic mice endowed with 
the human FcRn (Proetzel and Roopenian 2014). In general, the principles of 
allometric scaling calculated for small molecules used in an animal system into the 
human system is not appropriate for recombinant proteins, since many additional 
factors influence the performance of biotherapeutics (Deng et al. 2011). These 
parameters include, besides the biological effect of the therapeutic, likewise oxygen 
utilization, caloric expenditure, basal metabolism, blood volume, circulating plasma 
proteins, renal function and FcRn recycling (Reagan-Shaw et al. 2008). There are 
methods to roughly predict the pharmacokinetic behavior of protein drugs in humans, 
but a lot of effort and different animal models are necessary in order to reliably 
precalculate these parameters (Mahmood 2009).  
4.8 Conclusion and outlook 
The present study could demonstrate that immunoglobulin-binding domains 
represent a versatile tool for the half-life extension of small recombinant therapeutic 
proteins. Via affinity maturation of the CH1 specific domain SpGC3Fab, resulting in 
SpGC3FabRR, the terminal half-life of fusion proteins with antibody fragments (scFv 
and scDb), but also human erythropoietin could be significantly elongated. In the 
mean time, full functionality like IL-2 secretion for the scDb and proliferative effect of 
huEPO could be retained upon fusion of SpGC3FabRR, in contrast to other half-life 
extension strategies like PEGylation, hyperglycosylation or addition of an 
albumin-binding domain (Sinclair 2013; Stork et al. 2008; Tolmachev et al. 2007).  
 
A pharmacodynamic study with a single injection of huEPO fusion proteins showed 
the beneficial properties of huEPO-SpGC3FabRR, only exceeded by Aranesp due to its 
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long initial half-life and lower receptor affinity. A combination of hyperglycosylation 
together with IgBDs could further enhance the pharmacokinetic and 
pharmacodynamic potential and simultaneously retain a low hydrodynamic radius for 
tissue penetration. Another pharmacodynamic study with the scDb could reinforce 
the potential of the IgBDs. For this purpose, a syngeneic mouse model with an scDb 
that is targeting a tumor antigen and the murine CD3 has to be established. A 
possible setup could be generated with an scDb against Fibroblast activation protein 
(FAP) combined with the scFv 2C11 against mouse CD3 in a B16-FAP tumor model 
in C57BL/6 mice (Brocks et al. 2001; Kermer et al. 2012; Liao et al. 2000) or with 
other antigens like EpCAM in a 4T1 breast cancer model (Amann et al. 2008). 
 
By application of sequence and structure-based algorithms, T-cell epitopes in the 
sequence of SpGC3Fab were identified and eliminated via a combination of amino acid 
substitutions. These deimmunized IgBDs exhibited the potential to increase the 
half-life as scDb fusion proteins, but the affinity maturated SpGC3FabRR could not be 
reached. In order to improve the affinity towards the Fab fragment and also the 
pharmacokinetics, a phage display approach could be used, generating a library that 
is only comprised of deimmunized SpGC3Fab mutants. Since the residues that are 
responsible for immunogenicity are known, the corresponding amino acids can be 
substituted to amino acids that do not form epitopes. Such a library had been 
generated during this study with a diversity of 36 x 106 clones (6.7 x 106 different 
possible sequences), but the selection was not yet performed.  
 
Full-length IgG has shown to have advantages in pharmacokinetic behavior 
compared to other Fc fusion proteins due to factors like size, net charge and stability. 
Redesigning linkers, especially for scFv-scCLCH1-Fc and scDb-CH2, could eliminate 
the susceptibility of the recombinant fusion proteins to serum proteases and further 
stabilize the biotherapeutics in the bloodstream. Various substitutions in the Fc part 
have been described to improve the pharmacokinetic behavior by increasing the 
affinity towards the FcRn at acidic pH with simultaneous release at pH7.4. Those 
mutations include for example the substitution of asparagine 434 by alanine (N434A) 
or the triple mutation M252Y/S254T/T256E (YTE) that generate a new hydrophobic 
interaction site and the creation of salt-bridges, respectively (Dall’Acqua et al. 2006; 
Deng et al. 2010; Oganesyan et al. 2014). 
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6 Sequences 
pSecTagA scDb-IgBD 
                                                                                      SfiI  
                                                                                      | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCC CAG GTG AAA CTG CAG C  < 100 
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   Q   V   K   L   Q    
            10           20           30            40           50           60            70           80           90  
   
AG TCT GGG GCA GAA CTT GTG AGG TCA GGG ACC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT AAA GAC TCC TAT ATG CAC TGG TTG AGG CA  < 200 
Q   S   G   A   E   L   V   R   S   G   T   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   S   Y   M   H   W   L   R   Q 
            110          120           130          140          150           160          170          180           190  
  
G GGG CCT GAA CAG GGC CTG GAG TGG ATT GGA TGG ATT GAT CCT GAG AAT GGT GAT ACT GAA TAT GCC CCG AAG TTC CAG GGC AAG GCC ACT TTT ACT ACA  < 300 
   G   P   E   Q   G   L   E   W   I   G   W   I   D   P   E   N   G   D   T   E   Y   A   P   K   F   Q   G   K   A   T   F   T   T  
            210          220          230          240           250          260          270           280          290  
   
GAC ACA TCC TCC AAC ACA GCC TAC CTG CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC TAT TAT TGT AAT GAG GGG ACT CCG ACT GGG CCG TAC T  < 400 
 D   T   S   S   N   T   A   Y   L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   N   E   G   T   P   T   G   P   Y    
            310          320          330           340          350          360           370          380          390  
   
AC TTT GAC TAC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA GGC GGT GGC GGA TCG GAT ATC CAG ATG ACC CAG TCC CCG AGT TCC CTG TCC GCC TC  < 500 
Y   F   D   Y   W   G   Q   G   T   T   V   T   V   S   S   G   G   G   G   S   D   I   Q   M   T   Q   S   P   S   S   L   S   A   S 
            410          420           430          440          450           460          470          480           490  
   
T GTG GGC GAT AGA GTC ACC ATC ACC TGT CGT GCC AGT CAG GAC ATC CGT AAT TAT CTG AAC TGG TAT CAA CAG AAA CCA GGA AAA GCT CCG AAA CTA CTG  < 600 
   V   G   D   R   V   T   I   T   C   R   A   S   Q   D   I   R   N   Y   L   N   W   Y   Q   Q   K   P   G   K   A   P   K   L   L  
            510          520          530          540           550          560          570           580          590   
  
ATT TAC TAT ACC TCC CGC CTG GAG TCT GGA GTC CCT TCT CGC TTC TCT GGT TCT GGT TCT GGG ACG GAT TAC ACT CTC ACC ATC AGC AGT CTG CAA CCG G  < 700 
 I   Y   Y   T   S   R   L   E   S   G   V   P   S   R   F   S   G   S   G   S   G   T   D   Y   T   L   T   I   S   S   L   Q   P    
            610          620          630           640          650          660           670          680          690  
   
AG GAC TTC GCA ACC TAT TAC TGT CAG CAA GGT AAT ACT CTG CCG TGG ACG TTC GGA CAG GGC ACC AAG GTG GAG ATC AAA CGT GGA GGC GGT GGC AGC GG  < 800 
E   D   F   A   T   Y   Y   C   Q   Q   G   N   T   L   P   W   T   F   G   Q   G   T   K   V   E   I   K   R   G   G   G   G   S   G 
            710          720           730          740          750           760          770          780           790  
 
T GGG CGC GCC TCG GCC GGA GGT GGC TCA GAG GTT CAG CTG GTG GAG TCT GGC GGT GGC CTG GTG CAG CCA GGG GGC TCA CTC CGT TTG TCC TGT GCA GCT  < 900 
   G   R   A   S   A   G   G   G   S   E   V   Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A  
            810          820          830          840           850          860          870           880          890  
 
TCT GGC TAC TCC TTT ACC GGC TAC ACT ATG AAC TGG GTG CGT CAG GCC CCA GGT AAG GGC CTG GAA TGG GTT GCA CTG ATT AAT CCT TAT AAA GGT GTT T  < 1000 
 S   G   Y   S   F   T   G   Y   T   M   N   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   L   I   N   P   Y   K   G   V    
            910          920          930           940          950          960           970          980          990  
 
CC ACC TAT AAC CAG AAA TTC AAG GAT CGT TTC ACG ATA TCC GTA GAT AAA TCC AAA AAC ACA GCC TAC CTG CAA ATG AAC AGC CTG CGT GCT GAG GAC AC  < 1100 
S   T   Y   N   Q   K   F   K   D   R   F   T   I   S   V   D   K   S   K   N   T   A   Y   L   Q   M   N   S   L   R   A   E   D   T 
            1010         1020          1030         1040         1050          1060         1070         1080          1090  
 
T GCA GTC TAT TAT TGT GCT AGA AGC GGA TAC TAC GGC GAT AGC GAC TGG TAT TTT GAC GTC TGG GGT CAA GGA ACC CTA GTC ACC GTC TCC TCG GGA GGC  < 1200 
   A   V   Y   Y   C   A   R   S   G   Y   Y   G   D   S   D   W   Y   F   D   V   W   G   Q   G   T   L   V   T   V   S   S   G   G  
            1110         1120         1130         1140          1150         1160         1170          1180         1190  
 
GGG GGT TCG GAC ATC GAG CTC ACC CAG TCT CCA GCA ATC ATG TCT GCA TCT CCA GGG GAG AAA GTC ACC ATA ACC TGC AGT GCC AGC TCA AGT GTA AGT T  < 1300 
 G   G   S   D   I   E   L   T   Q   S   P   A   I   M   S   A   S   P   G   E   K   V   T   I   T   C   S   A   S   S   S   V   S    
            1210         1220         1230          1240         1250         1260          1270         1280         1290  
 
AC ATG CAC TGG TTC CAG CAG AAG CCA GGC ACT TCT CCC AAA CTC TGG ATT TAT AGC ACA TCC AAC CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AG  < 1400 
Y   M   H   W   F   Q   Q   K   P   G   T   S   P   K   L   W   I   Y   S   T   S   N   L   A   S   G   V   P   A   R   F   S   G   S 
            1310         1320          1330         1340         1350          1360         1370         1380          1390  
   
T GGA TCT GGG ACC TCT TAC TCT CTC ACA ATC AGC CGA ATG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAA AGG AGT AGT TAC CCA CTC ACG TTC  < 1500 
   G   S   G   T   S   Y   S   L   T   I   S   R   M   E   A   E   D   A   A   T   Y   Y   C   Q   Q   R   S   S   Y   P   L   T   F  
            1410         1420         1430         1440          1450         1460         1470          1480         1490  
 
                                        NotI                                         BamHI                                   EcoRI      XbaI 
                                        |                                            |                                       |          | 
GGT GCT GGC ACC AAG CTG GAG CTG AAA CGG GCG GCC GCA GGC GGA TCT GGC GGA ... ... GGC GGA TCC CAC CAC CAC CAT CAC CAC TGA TGA GAA TTC CGC TCT AGA ... 
 G   A   G   T   K   L   E   L   K   R   A   A   A   G   G   S   G   G  ... ...  G   G   S   H   H   H   H   H   H   * 
            1510         1520         1530          1540          
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pAB1 scFv-IgBD 
                                                              SfiI 
                                                              |          
ATG AAA TAC CTA TTG CCT ACG GCA GCC GCT GGA TTG TTA TTA CTC GCG GCC CAG CCG GCC ATG GCC CAG GTG AAA CTG CAG CAG TCT GGG GCA GAA CTT G  < 100 
 M   K   Y   L   L   P   T   A   A   A   G   L   L   L   L   A   A   Q   P   A   M   A   Q   V   K   L   Q   Q   S   G   A   E   L    
            10           20           30            40           50           60            70           80           90  
 
TG AGG TCA GGG ACC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT AAA GAC TCC TAT ATG CAC TGG TTG AGG CAG GGG CCT GAA CAG GGC CT  < 200 
V   R   S   G   T   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   S   Y   M   H   W   L   R   Q   G   P   E   Q   G   L 
            110          120           130          140          150           160          170          180           190  
 
G GAG TGG ATT GGA TGG ATT GAT CCT GAG AAT GGT GAT ACT GAA TAT GCC CCG AAG TTC CAG GGC AAG GCC ACT TTT ACT ACA GAC ACA TCC TCC AAC ACA  < 300 
   E   W   I   G   W   I   D   P   E   N   G   D   T   E   Y   A   P   K   F   Q   G   K   A   T   F   T   T   D   T   S   S   N   T  
            210          220          230          240           250          260          270           280          290  
 
GCC TAC CTG CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC TAT TAT TGT AAT GAG GGG ACT CCG ACT GGG CCG TAC TAC TTT GAC TAC TGG GGC C  < 400 
 A   Y   L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   N   E   G   T   P   T   G   P   Y   Y   F   D   Y   W   G    
            310          320          330           340          350          360           370          380          390  
 
AA GGG ACC ACG GTC ACC GTC TCC TCA GGT GGA GGC GGT TCA GGG GGA GGT GGA TCC GGT GGA GGC GGT TCA GAC ATC GAG CTC ACC CAG TCT CCA GCA AT  < 500 
Q   G   T   T   V   T   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   D   I   E   L   T   Q   S   P   A   I 
            410          420           430          440          450           460          470          480           490  
 
C ATG TCT GCA TCT CCA GGG GAG AAA GTC ACC ATA ACC TGC AGT GCC AGC TCA AGT GTA AGT TAC ATG CAC TGG TTC CAG CAG AAG CCA GGC ACT TCT CCC  < 600 
   M   S   A   S   P   G   E   K   V   T   I   T   C   S   A   S   S   S   V   S   Y   M   H   W   F   Q   Q   K   P   G   T   S   P  
            510          520          530          540           550          560          570           580          590  
 
AAA CTC TGG ATT TAT AGC ACA TCC AAC CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AGT GGA TCT GGG ACC TCT TAC TCT CTC ACA ATC AGC CGA A  < 700 
 K   L   W   I   Y   S   T   S   N   L   A   S   G   V   P   A   R   F   S   G   S   G   S   G   T   S   Y   S   L   T   I   S   R    
            610          620          630           640          650          660           670          680          690  
 
               NotI 
     | 
TG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAA AGG AGT AGT TAC CCA CTC ACG TTC GGT GCT GGC ACC AAG CTG GAG CTG AAA CGG GCG GCC GC  < 800 
M   E   A   E   D   A   A   T   Y   Y   C   Q   Q   R   S   S   Y   P   L   T   F   G   A   G   T   K   L   E   L   K   R   A   A   A 
            710          720           730          740          750           760          770          780           790  
 
                                                                          EcoRI 
                                                                          | 
A GGC GGA TCT GGC ... ... GGC GGC GGA TCC CAC CAC CAC CAT CAC CAC TGA TGA GAA TTC   
   G   G   S   G  ... ...  G   G   G   S   H   H   H   H   H   H   *   *  
Novel immunoglobulin-binding domains 
SpGC3  
 
ACC ACC TAC AAG CTG GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAG GCC GTG GAC GCC GAG ACA GCC GAG AAG GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   E   K   A 
 
TTC AAG CAG TAC GCC AAC GAC AAC GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG   
 F   K   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E 
 
SpGC3Fab  
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3Fc 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG GCC CTG GCT GGC GCC ACC ACA ACA AAA GCC GTC GAC GCC GAG ACA GCC GAG AAG GCC  
 T   T   Y   K   L   V   I   N   G   K   A   L   A   G   A   T   T   T   K   A   V   D   A   E   T   A   E   K   A  
 
TTT AAG CAG TAC GCC AAC GAC AAC GGC GTG GAC GGC GTG TGG ACC TAC GAC GAT GCC ACC AAG ACC TTC ACC GTG ACC GAG 
 F   K   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E 
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SpGC2  
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC GAA GCC GTC GAC GCC GCC ACA GCC GAG AAG GTG  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   E   A   V   D   A   A   T   A   E   K   V    
 
TTC AAG CAG TAC GCC AAC GAC AAC GGC GTG GAC GGC GAG TGG ACC TAC GAC GAT GCC ACC AAG ACC TTC ACC GTG ACC GAG 
 F   K   Q   Y   A   N   D   N   G   V   D   G   E   W   T   Y   D   D   A   T   K   T   F   T   V   T   E 
Affinity maturated IgBDs 
Amino acids of the determined Fab binding site are colored according to their use for 
the generation of phage display libraries (Library 1: blue, library 2: red, library 3: 
green) (Figure 3-1).  
 
SpGC3FabTTR 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC ACT ACG CGT ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   T   T   R   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabHTM 
 
ACA ACA TAC AGG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC CAT ACG ATG ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   R   L   V   I   N   G   K   T   L   K   G   H   T   M   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabK13S 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG TCT GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   S   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabFRQ 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TGG GCC TTT AGG CAG GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG 
F   A   Q   W   A   F   R   Q   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabRR 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAT GCC AGG AGG AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG 
F   A   Q   Y   A   R   R   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
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SpGC3FabT1A,E15Q  
 
GCA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC CAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC 
 A   T   Y   K   L   V   I   N   G   K   T   L   K   G   Q   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabE15V  
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GTG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   V   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG   
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabE15V,YY  
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GTG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   V   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC TAC TAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG 
 F   A   Q   Y   A   Y   Y   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabK10Q,HNS 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC CAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   Q   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC CAC AAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC TCC AAG ACC TTC ACC GTG ACC GAG 
 F   A   Q   Y   A   H   N   N   G   V   D   G   V   W   T   Y   D   D   A   S   K   T   F   T   V   T   E  
 
SpGC3FabN35Y  
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGA GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC 
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC TAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG  
 F   A   Q   Y   A   Y   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabK50Q 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC CAG ACC TTC ACC GTG ACC GAG 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   Q   T   F   T   V   T   E  
 
SpGC3FabRR,E15V 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GTG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   V   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAT GCC AGG AGG AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAG 
 F   A   Q   Y   A   R   R   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
  
Sequences 
 
  
117 
Deimmunized IgBDs 
SpGC3FabK4E 
 
ACA ACA TAC GAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   E   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E 
 
SpGC3FabL5A 
 
ACA ACA TAC AAG GCC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   A   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabV6A 
 
ACA ACA TAC AAG CTC GCG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   A   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabI7L 
 
ACA ACA TAC AAG CTC GTG CTC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   L   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabN8D 
 
ACA ACA TAC AAG CTC GTG ATC GAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   D   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabK10Q 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC CAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   Q   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
 
 
  
Sequences 
 
  
118 
SpGC3FabL12A  
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC GCG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   A   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabT44S 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG TCC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   S   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabA48G 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GGC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   G   T   K   T   F   T   V   T   E  
 
SpGC3FabDI1 
 
ACA ACA TAC GAG CTC GCG ATC AAC GGC CAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   E   L   A   I   N   G   Q   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GGC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   G   T   K   T   F   T   V   T   E  
 
SpGC3FabDI2 
 
ACA ACA TAC AAG GTC GCG ATC AAC GGC CAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   V   A   I   N   G   Q   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GGC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   T   Y   D   D   G   T   K   T   F   T   V   T   E  
 
SpGC3FabDI3 
 
ACA ACA TAC AAG CTC ACG ATC GAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   T   I   D   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG TCC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   S   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabDI4 
 
ACA ACA TAC AAG CTC ACG ATC AAC GGC GAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   T   I   N   G   E   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG TCC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   S   Y   D   D   A   T   K   T   F   T   V   T   E  
  
Sequences 
 
  
119 
SpGC3FabDI5 
 
ACA ACA TAC AAG CTC GTG CTC AAC GGC GAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   L   N   G   E   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG TAC GCC AAC GAT AAT GGC GTG GAC GGC GTG TGG TCC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   Y   A   N   D   N   G   V   D   G   V   W   S   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabRR,Y33A 
 
ACA ACA TAC AAG CTC GTG ATC AAC GGC AAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   K   L   V   I   N   G   K   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG GCT GCC AGG AGG AAT GGC GTG GAC GGC GTG TGG ACC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   A   A   R   R   N   G   V   D   G   V   W   T   Y   D   D   A   T   K   T   F   T   V   T   E  
 
SpGC3FabRR,Y33T,DI1 
 
ACA ACA TAC GAG CTC GCG ATC AAC GGC CAG ACC CTG AAG GGC GAG ACA ACC ACC AAA GCC GTC GAC GCC GAA ACA GCC GCC GCT GCC  
 T   T   Y   E   L   A   I   N   G   Q   T   L   K   G   E   T   T   T   K   A   V   D   A   E   T   A   A   A   A   
 
TTT GCC CAG ACT GCC AGG AGG AAT GGC GTG GAC GGC GTG TGG TCC TAC GAC GAC GCC ACC AAG ACC TTC ACC GTG ACC GAA 
 F   A   Q   T   A   R   R   N   G   V   D   G   V   W   S   Y   D   D   A   T   K   T   F   T   V   T   E  
huEPO fusion proteins 
pSecTagAL1 huEPO 
 
 AgeI  
                                                                        | 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACC GGT GAC GCC CCC CCT AGA CTG ATC TGC GAC AGC CGG GTG CTG G  < 100 
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   P   P   R   L   I   C   D   S   R   V   L    
            10           20           30            40           50           60            70           80           90  
 
AA AGA TAC CTG CTG GAA GCC AAA GAG GCC GAG AAC ATC ACC ACC GGC TGC GCC GAG CAC TGC TCC CTG AAC GAG AAT ATC ACC GTG CCC GAC ACC AAA GT  < 200 
E   R   Y   L   L   E   A   K   E   A   E   N   I   T   T   G   C   A   E   H   C   S   L   N   E   N   I   T   V   P   D   T   K   V 
            110          120           130          140          150           160          170          180           190  
 
G AAC TTC TAC GCC TGG AAG CGG ATG GAA GTG GGC CAG CAG GCT GTG GAA GTG TGG CAG GGA CTG GCC CTG CTG TCT GAG GCT GTG CTG AGA GGA CAG GCT  < 300 
N   F   Y   A   W   K   R   M   E   V   G   Q   Q   A   V   E   V   W   Q   G   L   A   L   L   S   E   A   V   L   R   G   Q   A  
210          220          230          240           250          260          270           280          290  
 
CTG CTC GTG AAC AGC AGC CAG CCT TGG GAG CCT CTC CAG CTG CAC GTG GAC AAG GCC GTG TCT GGC CTG AGA AGC CTG ACC ACC CTG CTG AGA GCA CTG G  < 400 
 L   L   V   N   S   S   Q   P   W   E   P   L   Q   L   H   V   D   K   A   V   S   G   L   R   S   L   T   T   L   L   R   A   L    
            310          320          330           340          350          360           370          380          390  
 
GA GCC CAG AAA GAG GCC ATC AGC CCT CCA GAT GCC GCC TCT GCT GCC CCC CTG AGA ACC ATC ACC GCC GAC ACC TTC AGA AAG CTG TTC CGG GTG TAC AG  < 500 
G   A   Q   K   E   A   I   S   P   P   D   A   A   S   A   A   P   L   R   T   I   T   A   D   T   F   R   K   L   F   R   V   Y   S 
            410          420           430          440          450           460          470          480           490  
           NotI          XbaI 
           |             | 
C AAC TTC CTG AGA GGC AAG CTG AAG CTG TAC ACA GGC GAG GCC TGT CGG ACC GGC GAC AGA GCG GCC GCC CAC CAT CAT CAC CAT CAC TAA TCT AGA ... 
   N   F   L   R   G   K   L   K   L   Y   T   G   E   A   C   R   T   G   D   R   A   A   A   H   H   H   H   H   H   *    
            510          520          530          540           550          560          570           580          590  
 
 
 
 
 
 
  
Sequences 
 
  
120 
Fc fusion proteins 
The sequence of the Fc fusion proteins is shown until the beginning of domain CH2. 
The subsequent Fc part is identical to the Fc part of IgG CEA.  
 
IgG CEA – Heavy chain 
 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCC CAG GTG AAA CTG CAG C  < 100 
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   Q   V   K   L   Q    
            10           20           30            40           50           60            70           80           90  
   
AG TCT GGG GCA GAA CTT GTG AGG TCA GGG ACC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT AAA GAC TCC TAT ATG CAC TGG TTG AGG CA  < 200 
Q   S   G   A   E   L   V   R   S   G   T   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   S   Y   M   H   W   L   R   Q 
            110          120           130          140          150           160          170          180           190  
 
G GGG CCT GAA CAG GGC CTG GAG TGG ATT GGA TGG ATT GAT CCT GAG AAT GGT GAT ACT GAA TAT GCC CCG AAG TTC CAG GGC AAG GCC ACT TTT ACT ACA  < 300 
   G   P   E   Q   G   L   E   W   I   G   W   I   D   P   E   N   G   D   T   E   Y   A   P   K   F   Q   G   K   A   T   F   T   T  
             210          220          230          240           250          260          270           280          290  
   
GAC ACA TCC TCC AAC ACA GCC TAC CTG CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC TAT TAT TGT AAT GAG GGG ACT CCG ACT GGG CCG TAC T  < 400 
 D   T   S   S   N   T   A   Y   L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   N   E   G   T   P   T   G   P   Y    
            310          320          330           340          350          360           370          380          390  
 
AC TTT GAC TAC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCG AGT GCC TCC ACC AAG GGC CCA TCG GTC TTC CCC CTG GCA CCC TCC TCC AAG AGC ACC TC  < 500 
Y   F   D   Y   W   G   Q   G   T   T   V   T   V   S   S   A   S   T   K   G   P   S   V   F   P   L   A   P   S   S   K   S   T   S 
            410          420           430          440          450           460          470          480           490  
   
T GGG GGC ACA GCG GCC CTG GGC TGC CTG GTC AAG GAC TAC TTC CCC GAA CCG GTG ACG GTG TCG TGG AAC TCA GGC GCC CTG ACC AGC GGC GTG CAC ACC  < 600 
   G   G   T   A   A   L   G   C   L   V   K   D   Y   F   P   E   P   V   T   V   S   W   N   S   G   A   L   T   S   G   V   H   T  
             510          520          530          540           550          560          570           580          590  
   
TTC CCG GCT GTC CTA CAG TCC TCA GGA CTC TAC TCC CTC AGC AGC GTG GTG ACC GTG CCC TCC AGC AGC TTG GGC ACC CAG ACC TAC ATC TGC AAC GTG A  < 700 
 F   P   A   V   L   Q   S   S   G   L   Y   S   L   S   S   V   V   T   V   P   S   S   S   L   G   T   Q   T   Y   I   C   N   V    
            610          620          630           640          650          660           670          680          690  
   
AT CAC AAG CCC AGC AAC ACC AAG GTG GAC AAA CGC GTT GAG CCC AAA TCT TGT GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GG  < 800 
N   H   K   P   S   N   T   K   V   D   K   R   V   E   P   K   S   C   D   K   T   H   T   C   P   P   C   P   A   P   E   L   L   G 
            710          720           730          740          750           760          770          780           790  
   
G GGA CCG TCA GTC TTC CTC TTC CCC CCA AAA CCC AAG GAC ACC CTC ATG ATC TCC CGG ACC CCT GAG GTC ACA TGC GTG GTG GTG GAC GTG AGC CAC GAA  < 900 
   G   P   S   V   F   L   F   P   P   K   P   K   D   T   L   M   I   S   R   T   P   E   V   T   C   V   V   V   D   V   S   H   E  
             810          820          830          840           850          860          870           880          890  
   
GAC CCT GAG GTC AAG TTC AAC TGG TAC GTG GAC GGC GTG GAG GTG CAT AAT GCC AAG ACA AAG CCG CGG GAG GAG CAG TAC AAC AGC ACG TAC CGG GTG G  < 1000 
 D   P   E   V   K   F   N   W   Y   V   D   G   V   E   V   H   N   A   K   T   K   P   R   E   E   Q   Y   N   S   T   Y   R   V    
            910          920          930           940          950          960           970          980          990  
   
TC AGC GTC CTC ACC GTC CTG CAC CAG GAC TGG CTG AAT GGC AAG GAG TAC AAG TGC AAG GTC TCC AAC AAA GCC CTC CCA GCC CCC ATC GAG AAA ACC AT  < 1100 
V   S   V   L   T   V   L   H   Q   D   W   L   N   G   K   E   Y   K   C   K   V   S   N   K   A   L   P   A   P   I   E   K   T   I 
            1010         1020          1030         1040         1050          1060         1070         1080          1090  
 
C TCC AAA GCC AAA GGG CAG CCC CGA GAA CCA CAG GTG TAC ACC CTG CCC CCA TCC CGG GAT GAG CTG ACC AAG AAC CAG GTC AGC CTG ACC TGC CTG GTC  < 1200 
   S   K   A   K   G   Q   P   R   E   P   Q   V   Y   T   L   P   P   S   R   D   E   L   T   K   N   Q   V   S   L   T   C   L   V  
             1110         1120         1130         1140          1150         1160         1170          1180         1190  
   
AAA GGC TTC TAT CCC AGC GAC ATC GCC GTG GAG TGG GAG AGC AAT GGG CAG CCG GAG AAC AAC TAC AAG ACC ACG CCT CCC GTG CTG GAC TCC GAC GGC T  < 1300 
 K   G   F   Y   P   S   D   I   A   V   E   W   E   S   N   G   Q   P   E   N   N   Y   K   T   T   P   P   V   L   D   S   D   G    
            1210         1220         1230          1240         1250         1260          1270         1280         1290  
   
CC TTC TTC CTC TAC AGC AAG CTC ACC GTG GAC AAG AGC AGG TGG CAG CAG GGG AAC GTC TTC TCA TGC TCC GTG ATG CAT GAG GCT CTG CAC AAC CAC TA  < 1400 
S   F   F   L   Y   S   K   L   T   V   D   K   S   R   W   Q   Q   G   N   V   F   S   C   S   V   M   H   E   A   L   H   N   H   Y 
            1310         1320          1330         1340         1350          1360         1370         1380          1390  
   
C ACG CAG AAG AGC CTC TCC CTG TCT CCG GGT AAA TAA ...  
   T   Q   K   S   L   S   L   S   P   G   K   *  
             1410         1420         1430  
 
 
 
 
  
Sequences 
 
  
121 
IgG CEA – Light chain 
 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC GAC ATC GAG CTC ACC CAG TCT C  < 100 
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   D   I   E   L   T   Q   S    
            10           20           30            40           50           60            70           80           90  
 
CA GCA ATC ATG TCT GCA TCT CCA GGG GAG AAA GTC ACC ATA ACC TGC AGT GCC AGC TCA AGT GTA AGT TAC ATG CAC TGG TTC CAG CAG AAG CCA GGC AC  < 200 
P   A   I   M   S   A   S   P   G   E   K   V   T   I   T   C   S   A   S   S   S   V   S   Y   M   H   W   F   Q   Q   K   P   G   T 
            110          120           130          140          150           160          170          180           190  
 
T TCT CCC AAA CTC TGG ATT TAT AGC ACA TCC AAC CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AGT GGA TCT GGG ACC TCT TAC TCT CTC ACA ATC  < 300 
   S   P   K   L   W   I   Y   S   T   S   N   L   A   S   G   V   P   A   R   F   S   G   S   G   S   G   T   S   Y   S   L   T   I  
            210          220          230          240           250          260          270           280          290  
   
AGC CGA ATG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAA AGG AGT AGT TAC CCA CTC ACG TTC GGT GCT GGC ACC AAG CTG GAG CTG AAA CGG A  < 400 
 S   R   M   E   A   E   D   A   A   T   Y   Y   C   Q   Q   R   S   S   Y   P   L   T   F   G   A   G   T   K   L   E   L   K   R    
            310          320          330           340          350          360           370          380          390  
 
CT GTG GGC GCG CCA TCT GTC TTC ATC TTC CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA ACT GCC TCT GTT GTG TGC CTG CTG AAT AAC TTC TAT CCC AG  < 500 
  T   V   G   A   P   S   V   F   I   F   P   P   S   D   E   Q   L   K   S   G   T   A   S   V   V   C   L   L   N   N   F   Y   P   R 
              410          420           430          440          450           460          470          480           490  
 
A GAG GCC AAA GTA CAG TGG AAG GTG GAT AAC GCC CTC CAA TCG GGT AAC TCC CAG GAG AGT GTC ACA GAG CAG GAC AGC AAG GAC AGC ACC TAC AGC CTC  < 600 
     E   A   K   V   Q   W   K   V   D   N   A   L   Q   S   G   N   S   Q   E   S   V   T   E   Q   D   S   K   D   S   T   Y   S   L  
               510          520          530          540           550          560          570           580          590  
   
AGC AGC ACC CTG ACG CTG AGC AAA GCA GAC TAC GAG AAA CAC AAA GTC TAC GCC TGC GAA GTC ACC CAT CAG GGC CTG AGC TCG CCC GTC ACA AAG AGC T  < 700 
 S   S   T   L   T   L   S   K   A   D   Y   E   K   H   K   V   Y   A   C   E   V   T   H   Q   G   L   S   S   P   V   T   K   S    
            610          620          630           640          650          660           670          680          690  
 
TC AAC AGG GGA GAG TGT TAA ... 
F   N   R   G   E   C   *    
            710          720 
 
scFv-Fc 
 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCC CAG GTG AAA CTG CAG C  < 100 
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   Q   V   K   L   Q    
            10           20           30            40           50           60            70           80           90  
 
AG TCT GGG GCA GAA CTT GTG AGG TCA GGG ACC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT AAA GAC TCC TAT ATG CAC TGG TTG AGG CA  < 200 
Q   S   G   A   E   L   V   R   S   G   T   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   S   Y   M   H   W   L   R   Q 
            110          120           130          140          150           160          170          180           190  
 
G GGG CCT GAA CAG GGC CTG GAG TGG ATT GGA TGG ATT GAT CCT GAG AAT GGT GAT ACT GAA TAT GCC CCG AAG TTC CAG GGC AAG GCC ACT TTT ACT ACA  < 300 
   G   P   E   Q   G   L   E   W   I   G   W   I   D   P   E   N   G   D   T   E   Y   A   P   K   F   Q   G   K   A   T   F   T   T  
             210          220          230          240           250          260          270           280          290  
 
GAC ACA TCC TCC AAC ACA GCC TAC CTG CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC TAT TAT TGT AAT GAG GGG ACT CCG ACT GGG CCG TAC T  < 400 
 D   T   S   S   N   T   A   Y   L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   N   E   G   T   P   T   G   P   Y    
            310          320          330           340          350          360           370          380          390  
 
AC TTT GAC TAC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA GGT GGA GGC GGT TCA GGG GGA GGT GGA TCC GGT GGA GGC GGT TCA GAC ATC GAG CT  < 500 
Y   F   D   Y   W   G   Q   G   T   T   V   T   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   D   I   E   L 
            410          420           430          440          450           460          470          480           490  
 
C ACC CAG TCT CCA GCA ATC ATG TCT GCA TCT CCA GGG GAG AAA GTC ACC ATA ACC TGC AGT GCC AGC TCA AGT GTA AGT TAC ATG CAC TGG TTC CAG CAG  < 600 
   T   Q   S   P   A   I   M   S   A   S   P   G   E   K   V   T   I   T   C   S   A   S   S   S   V   S   Y   M   H   W   F   Q   Q  
             510          520          530          540           550          560          570           580          590  
 
AAG CCA GGC ACT TCT CCC AAA CTC TGG ATT TAT AGC ACA TCC AAC CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AGT GGA TCT GGG ACC TCT TAC T  < 700 
 K   P   G   T   S   P   K   L   W   I   Y   S   T   S   N   L   A   S   G   V   P   A   R   F   S   G   S   G   S   G   T   S   Y    
            610          620          630           640          650          660           670          680          690  
 
CT CTC ACA ATC AGC CGA ATG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAA AGG AGT AGT TAC CCA CTC ACG TTC GGT GCT GGC ACC AAG CTG GA  < 800 
S   L   T   I   S   R   M   E   A   E   D   A   A   T   Y   Y   C   Q   Q   R   S   S   Y   P   L   T   F   G   A   G   T   K   L   E 
            710          720           730          740          750           760          770          780           790  
 
G CTG AAA CGG GCg gcc GCA GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA ... 
   L   K   R   A   A   A   D   K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G  ...  
            810          820          830          840           850          860          870  
 
 
 
  
Sequences 
 
  
122 
scDb-Fc 
 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC Cag cCG GCC ATG GCC CAG GTG AAA CTG CAG C  < 100 
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   Q   V   K   L   Q    
            10           20           30            40           50           60            70           80           90  
 
AG TCT GGG GCA GAA CTT GTG AGG TCA GGG ACC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT AAA GAC TCC TAT ATG CAC TGG TTG AGG CA  < 200 
Q   S   G   A   E   L   V   R   S   G   T   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   S   Y   M   H   W   L   R   Q 
            110          120           130          140          150           160          170          180           190  
 
G GGG CCT GAA CAG GGC CTG GAG TGG ATT GGA TGG ATT GAT CCT GAG AAT GGT GAT ACT GAA TAT GCC CCG AAG TTC CAG GGC AAG GCC ACT TTT ACT ACA  < 300 
   G   P   E   Q   G   L   E   W   I   G   W   I   D   P   E   N   G   D   T   E   Y   A   P   K   F   Q   G   K   A   T   F   T   T  
             210          220          230          240           250          260          270           280          290  
 
GAC ACA TCC TCC AAC ACA GCC TAC CTG CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC TAT TAT TGT AAT GAG GGG ACT CCG ACT GGG CCG TAC T  < 400 
 D   T   S   S   N   T   A   Y   L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   N   E   G   T   P   T   G   P   Y    
            310          320          330           340          350          360           370          380          390  
 
AC TTT GAC TAC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA GGC GGT GGC GGA TCG GAT ATC CAG ATG ACC CAG TCC CCG AGT TCC CTG TCC GCC TC  < 500 
Y   F   D   Y   W   G   Q   G   T   T   V   T   V   S   S   G   G   G   G   S   D   I   Q   M   T   Q   S   P   S   S   L   S   A   S 
            410          420           430          440          450           460          470          480           490  
 
T GTG GGC GAT AGA GTC ACC ATC ACC TGT CGT GCC AGT CAG GAC ATC CGT AAT TAT CTG AAC TGG TAT CAA CAG AAA CCA GGA AAA GCT CCG AAA CTA CTG  < 600 
   V   G   D   R   V   T   I   T   C   R   A   S   Q   D   I   R   N   Y   L   N   W   Y   Q   Q   K   P   G   K   A   P   K   L   L  
             510          520          530          540           550          560          570           580          590  
 
ATT TAC TAT ACC TCC CGC CTG GAG TCT GGA GTC CCT TCT CGC TTC TCT GGT TCT GGT TCT GGG ACG GAT TAC ACT CTC ACC ATC AGC AGT CTG CAA CCG G  < 700 
 I   Y   Y   T   S   R   L   E   S   G   V   P   S   R   F   S   G   S   G   S   G   T   D   Y   T   L   T   I   S   S   L   Q   P    
            610          620          630           640          650          660           670          680          690  
 
AG GAC TTC GCA ACC TAT TAC TGT CAG CAA GGT AAT ACT CTG CCG TGG ACG TTC GGA CAG GGC ACC AAG GTG GAG ATC AAA CGT GGA GGC GGT GGC AGC GG  < 800 
E   D   F   A   T   Y   Y   C   Q   Q   G   N   T   L   P   W   T   F   G   Q   G   T   K   V   E   I   K   R   G   G   G   G   S   G 
            710          720           730          740          750           760          770          780           790  
 
T GGG CGC GCC TCG GGC GGA GGT GGC TCA GAG GTT CAG CTG GTG GAG TCT GGC GGT GGC CTG GTG CAG CCA GGG GGC TCA CTC CGT TTG TCC TGT GCA GCT  < 900 
   G   R   A   S   G   G   G   G   S   E   V   Q   L   V   E   S   G   G   G   L   V   Q   P   G   G   S   L   R   L   S   C   A   A  
             810          820          830          840           850          860          870           880          890  
 
TCT GGC TAC TCC TTT ACC GGC TAC ACT ATG AAC TGG GTG CGT CAG GCC CCA GGT AAG GGC CTG GAA TGG GTT GCA CTG ATT AAT CCT TAT AAA GGT GTT T  < 1000 
 S   G   Y   S   F   T   G   Y   T   M   N   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   L   I   N   P   Y   K   G   V    
            910          920          930           940          950          960           970          980          990  
 
CC ACC TAT AAC CAG AAA TTC AAG GAT CGT TTC ACG ATA TCC GTA GAT AAA TCC AAA AAC ACA GCC TAC CTG CAA ATG AAC AGC CTG CGT GCT GAG GAC AC  < 1100 
S   T   Y   N   Q   K   F   K   D   R   F   T   I   S   V   D   K   S   K   N   T   A   Y   L   Q   M   N   S   L   R   A   E   D   T 
            1010         1020          1030         1040         1050          1060         1070         1080          1090  
 
T GCA GTC TAT TAT TGT GCT AGA AGC GGA TAC TAC GGC GAT AGC GAC TGG TAT TTT GAC GTC TGG GGT CAA GGA ACC CTA GTC ACC GTC TCC TCG GGA GGC  < 1200 
   A   V   Y   Y   C   A   R   S   G   Y   Y   G   D   S   D   W   Y   F   D   V   W   G   Q   G   T   L   V   T   V   S   S   G   G  
             1110         1120         1130         1140          1150         1160         1170          1180         1190  
 
GGG GGT TCG GAC ATC GAG CTC ACC CAG TCT CCA GCC ATC ATG TCT GCA TCT CCA GGG GAG AAG GTC ACC ATA ACC TGC AGT GCC AGC TCA AGT GTA AGT T  < 1300 
 G   G   S   D   I   E   L   T   Q   S   P   A   I   M   S   A   S   P   G   E   K   V   T   I   T   C   S   A   S   S   S   V   S    
            1210         1220         1230          1240         1250         1260          1270         1280         1290  
 
AC ATG CAC TGG TTC CAG CAG AAG CCA GGC ACT TCT CCC AAA CTC TGG ATT TAT AGC ACA TCC AAC CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AG  < 1400 
Y   M   H   W   F   Q   Q   K   P   G   T   S   P   K   L   W   I   Y   S   T   S   N   L   A   S   G   V   P   A   R   F   S   G   S 
            1310         1320          1330         1340         1350          1360         1370         1380          1390  
 
T GGA TCT GGG ACC TCT TAC TCT CTC ACA ATC AGC CGA ATG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAA AGG AGT AGT TAC CCA CTC ACG TTC  < 1500 
   G   S   G   T   S   Y   S   L   T   I   S   R   M   E   A   E   D   A   A   T   Y   Y   C   Q   Q   R   S   S   Y   P   L   T   F  
             1410         1420         1430         1440          1450         1460         1470          1480         1490  
 
GGT GCT GGC ACC AAG CTG GAG CTG AAA CGG GCg gcc GCA GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA ... 
 G   A   G   T   K   L   E   L   K   R   A   A   A   D   K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G  ... 
            1510         1520         1530          1540         1550         1560          1570         1580         1590  
 
 
 
 
 
 
 
  
Sequences 
 
  
123 
scFv-scCLCH1-Fc 
 
ATG GAG ACA GAC ACA CTC CTG CTA TGG GTA CTG CTG CTC TGG GTT CCA GGT TCC ACT GGT GAC GCG GCC CAG CCG GCC ATG GCC CAG GTG AAA CTG CAG C  < 100 
 M   E   T   D   T   L   L   L   W   V   L   L   L   W   V   P   G   S   T   G   D   A   A   Q   P   A   M   A   Q   V   K   L   Q    
            10           20           30            40           50           60            70           80           90  
   
AG TCT GGG GCA GAA CTT GTG AGG TCA GGG ACC TCA GTC AAG TTG TCC TGC ACA GCT TCT GGC TTC AAC ATT AAA GAC TCC TAT ATG CAC TGG TTG AGG CA  < 200 
Q   S   G   A   E   L   V   R   S   G   T   S   V   K   L   S   C   T   A   S   G   F   N   I   K   D   S   Y   M   H   W   L   R   Q 
            110          120           130          140          150           160          170          180           190  
 
G GGG CCT GAA CAG GGC CTG GAG TGG ATT GGA TGG ATT GAT CCT GAG AAT GGT GAT ACT GAA TAT GCC CCG AAG TTC CAG GGC AAG GCC ACT TTT ACT ACA  < 300 
   G   P   E   Q   G   L   E   W   I   G   W   I   D   P   E   N   G   D   T   E   Y   A   P   K   F   Q   G   K   A   T   F   T   T  
             210          220          230          240           250          260          270           280          290  
   
GAC ACA TCC TCC AAC ACA GCC TAC CTG CAG CTC AGC AGC CTG ACA TCT GAG GAC ACT GCC GTC TAT TAT TGT AAT GAG GGG ACT CCG ACT GGG CCG TAC T  < 400 
 D   T   S   S   N   T   A   Y   L   Q   L   S   S   L   T   S   E   D   T   A   V   Y   Y   C   N   E   G   T   P   T   G   P   Y    
            310          320          330           340          350          360           370          380          390  
   
AC TTT GAC TAC TGG GGC CAA GGG ACC ACG GTC ACC GTC TCC TCA GGT GGA GGC GGT TCA GGG GGA GGT GGA TCC GGT GGA GGC GGT TCA GAC ATC GAG CT  < 500 
Y   F   D   Y   W   G   Q   G   T   T   V   T   V   S   S   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   D   I   E   L 
            410          420           430          440          450           460          470          480           490  
   
C ACC CAG TCT CCA GCA ATC ATG TCT GCA TCT CCA GGG GAG AAA GTC ACC ATA ACC TGC AGT GCC AGC TCA AGT GTA AGT TAC ATG CAC TGG TTC CAG CAG  < 600 
   T   Q   S   P   A   I   M   S   A   S   P   G   E   K   V   T   I   T   C   S   A   S   S   S   V   S   Y   M   H   W   F   Q   Q  
             510          520          530          540           550          560          570           580          590  
 
AAG CCA GGC ACT TCT CCC AAA CTC TGG ATT TAT AGC ACA TCC AAC CTG GCT TCT GGA GTC CCT GCT CGC TTC AGT GGC AGT GGA TCT GGG ACC TCT TAC T  < 700 
 K   P   G   T   S   P   K   L   W   I   Y   S   T   S   N   L   A   S   G   V   P   A   R   F   S   G   S   G   S   G   T   S   Y    
            610          620          630           640          650          660           670          680          690  
   
CT CTC ACA ATC AGC CGA ATG GAG GCT GAA GAT GCT GCC ACT TAT TAC TGC CAG CAA AGG AGT AGT TAC CCA CTC ACG TTC GGT GCT GGC ACC AAG CTG GA  < 800 
S   L   T   I   S   R   M   E   A   E   D   A   A   T   Y   Y   C   Q   Q   R   S   S   Y   P   L   T   F   G   A   G   T   K   L   E 
            710          720           730          740          750           760          770          780           790  
   
G CTG AAA Cgt acG GTG GCA GCG CCA TCT GTC TTC ATC TTC CCG CCA TCT GAT GAG CAG TTG AAA TCT GGA ACT GCC TCT GTT GTG TGC CTG CTG AAT AAC  < 900 
   L   K   R   T   V   A   A   P   S   V   F   I   F   P   P   S   D   E   Q   L   K   S   G   T   A   S   V   V   C   L   L   N   N  
             810          820          830          840           850          860          870           880          890  
 
TTC TAT CCC AGA GAG GCC AAA GTA CAG TGG AAG GTG GAT AAC GCC CTC CAA TCG GGT AAC TCC CAG GAG AGT GTC ACA GAG CAG GAC AGC AAG GAC AGC A  < 1000 
 F   Y   P   R   E   A   K   V   Q   W   K   V   D   N   A   L   Q   S   G   N   S   Q   E   S   V   T   E   Q   D   S   K   D   S    
            910          920          930           940          950          960           970          980          990  
   
CC TAC AGC CTC AGC AGC ACC CTG ACG CTG AGC AAA GCA GAC TAC GAG AAA CAC AAA GTC TAC GCC TGC GAA GTC ACC CAT CAG GGC CTG AGC TCG CCC GT  < 1100 
T   Y   S   L   S   S   T   L   T   L   S   K   A   D   Y   E   K   H   K   V   Y   A   C   E   V   T   H   Q   G   L   S   S   P   V 
            1010         1020          1030         1040         1050          1060         1070         1080          1090  
   
C ACA AAG AGC TTC AAC AGG GGA GAG TGT GGA GGC GGT GGG TCA GGG GGC GGT GGA TCC GGG GGA GGC GGT TCA GGA GGC GGT GGG AGT GCC TCC ACC AAG  < 1200 
   T   K   S   F   N   R   G   E   C   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   G   G   G   G   S   A   S   T   K  
             1110         1120         1130         1140          1150         1160         1170          1180         1190  
   
GGC CCA TCG GTC TTC CCC CTG GCA CCC TCC TCC AAG AGC ACC TCT GGG GGC ACA GCG GCC CTG GGC TGC CTG GTC AAG GAC TAC TTC CCC GAA CCG GTG A  < 1300 
 G   P   S   V   F   P   L   A   P   S   S   K   S   T   S   G   G   T   A   A   L   G   C   L   V   K   D   Y   F   P   E   P   V    
            1210         1220         1230          1240         1250         1260          1270         1280         1290  
 
CG GTG TCG TGG AAC TCA GGC GCC CTG ACC AGC GGC GTG CAC ACC TTC CCG GCT GTC CTA CAG TCC TCA GGA CTC TAC TCC CTC AGC AGC GTG GTG ACC GT  < 1400 
T   V   S   W   N   S   G   A   L   T   S   G   V   H   T   F   P   A   V   L   Q   S   S   G   L   Y   S   L   S   S   V   V   T   V 
            1310         1320          1330         1340         1350          1360         1370         1380          1390  
   
G CCC TCC AGC AGC TTG GGC ACC CAG ACC TAC ATC TGC AAC GTG AAT CAC AAG CCC AGC AAC ACC AAG GTG GAC AAA CGC GTT GAG CCC AAA TCT TGT GCg  < 1500 
   P   S   S   S   L   G   T   Q   T   Y   I   C   N   V   N   H   K   P   S   N   T   K   V   D   K   R   V   E   P   K   S   C   A  
             1410         1420         1430         1440          1450         1460         1470          1480         1490  
 
gcc GCA GAC AAA ACT CAC ACA TGC CCA CCG TGC CCA GCA CCT GAA CTC CTG GGG GGA ... 
 A   A   D   K   T   H   T   C   P   P   C   P   A   P   E   L   L   G   G  ...    
            1510         1520         1530          1540         1550        
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